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Summary 
 
Acute lymphoblastic leukemia (ALL) is the most common cancer in childhood and 
occurs in the bone marrow and blood. Patients can be effectively cured with 
combinatorial chemotherapy in 80% of cases, but the high toxicity of the treatment 
and the frequency of relapses still are major obstacles and lead to high mortality. 
Based on current treatment protocols of one of the biggest study groups on childhood 
ALL, the BFM study group (named after Berlin-Frankfurt-Münster, to credit the 
founding members), a group of patients can be identified with particular bad 
outcome. The prognosis is given based on the measurement of minimal residual 
disease (MRD). This group of very high risk patients (VHR-ALL) is in need of novel 
treatment approaches. Due to the scarcity of primary material and the lack of in vitro 
models to study ALL biology we have established a xenograft model of VHR-ALL 
with the aim to model high-risk disease. Therefore, it is necessary to understand the 
effects of the selective pressures that are inherent to the xenograft model. Clonal 
evolution of the leukemogenic compartment could contribute to alter the response to 
chemotherapy in ALL. Thus, we have investigated the phenotypic and genetic 
composition of VHR-ALL cases before and after xenotransplantation.  
We found that the phenotypic properties remained unchanged, with concordant 
immunophenotypes after up to 5 passages in NOD/scidIL2RȖnull (NSG) mice and 
stable in vitro drug response profiles. Analysis of copy number alterations (CNA) 
showed that the xenografted leukemia, even when reconstituted from hundred ALL 
cells, remained highly related to the diagnostic sample, with minor changes in CNAs, 
emerging in most cases in the first passage into mice and occurring in recurrently 
detected loci in ALL. At the single cell level, the pattern of mono-and bi-allelic 
deletions of the CDKN2A locus revealed distinct leukemia subpopulations, which 
were reproducibly tracked in xenografts. Only in one case, the major clone of 
xenografts was different to diagnosis but could be backtracked. In most VHR-ALL 
cases, the predominant diagnostic clones were reconstituted in xenografts, as shown 
by multiplex PCR analysis of Ig/TCR loci. In other cases, the pattern in CNAs and 
Ig/TCR rearrangement was less concordant in xenografts, suggesting the outgrowth 
of subclones.  
In four of six VHR-ALL cases, the relative low number of 100 unsorted cells was 
enough to propagate leukemia in NSG mice and the resulting leukemias resembled 
in phenotype, genotype and clonal composition the diagnostic sample in the same 
way as leukemias generated from more cells. Thus, we have demonstrated the multi-
clonal composition of leukemia-propagating cells in VHR-ALL samples, making it 
likely that if here is a hierarchy in VHR-ALL it is a flat one  
Our xenograft model was successfully used as a preclinical model to evaluate new 
treatment rationales for chemosensitization for VHR-ALL patients. We proved that 
the small molecule obatoclax could effectively re-sensitize to chemotherapy in the 
xenograft model. This approach will be translated into a Phase-1 clinical trial. We 
also exploited the xenograft system as a renewable source of relevant patient 
material and thereby could contribute to the understanding of the importance of 
CRLF2 in the context of Down-Syndrome ALL. Taken together, we have established 
a xenograft model of VHR-ALL that enables to perform functional studies with 
relevant samples. It is likely that a larger proportion of ALL cells are leukemogenic 
and the nature of ALL cells is oligo- or even polyclonal, providing the basis for clonal 
selection and escape of treatment. Consequentially, future treatment approaches 
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need to consider the full diversity of ALL and targeting of all subpopulations must be 
reached.  
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Zusammenfassung 
 
Die häufigste Krebsart bei Kindern ist die akute lymphatische Leukämie (ALL), eine 
Erkrankung des Blutes und Knochenmarkes. 80% der Patienten können durch eine 
Kombinationstherapie geheilt werden. Dabei führen die hohe Toxizität der 
Behandlung und die häufigen Rezidive jedoch zu einer hohen Mortalitätsrate. 
Aufgrund von den derzeitigen Protokollen einer der grössten Studiengruppen der 
pädiatrischen ALL, der BFM-Studiengruppe (benannt nach den Gründungszentren in 
Berlin-Frankfurt-Münster), können Patienten mit einer ausgesprochen schlechten 
Prognose identifiziert werden. Die Prognose wird anhand der Messung der 
minimalen Resterkrankung (MRD) erstellt. Diese Patienten mit Hochrisiko-ALL (VHR-
ALL) brauchen neue Therapieansätze. 
Eine präklinische experimentelle Plattform ist wünschenswert, da diagnostisches 
Material sehr rar ist und es an in vitro Methoden zur Erforschung der ALL mangelt. 
Wir haben daher ein Xenograft-Modell der VHR-ALL etabliert. Um das Modell zur 
präklinischen Forschung zu nutzen, ist es notwendig den selektiven Druck genau zu 
charakterisieren, der durch das Xenograft auf die ALL Zellen wirkt. Die klonale 
Evolution der Leukämie erzeugenden Subpopulationen könnte das Ansprechen auf 
die Chemotherapie verändern. Daher haben wir die phänotypische und genetische 
Zusammensetzung der ALL vor und nach der Xenotransplantation in 
NOD/scidIL2RȖnull (NSG) Mäusen untersucht. Wir konnten zeigen, dass die 
phänotypischen Eigenschaften unverändert blieben. Im Einzelnen waren die 
Immunphänotypen und die in vitro Toxizitätsprofile bis zu fünf Passagen lang stabil. 
Die Analyse von Copy Number Abweichungen (CNA) der DNS zeigte, dass 
Xenograft-Proben den diagnostischen Proben sehr ähnlich waren, sogar wenn nur 
100 Zellen zur Transplantation des Xenografts benutzt wurden. Kleinere 
Veränderungen traten meistens schon in der ersten Passage auf. Und zwar in 
solchen Genen, die in der Leukämie schon zuvor als veränderlich bekannt waren. 
Auf Einzelzellebene wurden mono- und bi-allelische Deletionen des Gens CDKN2A 
angeschaut. Dabei zeigte sich, dass es verschiedene leukämische Subpopulationen 
gibt. Diese wurden reproduzierbar in mehreren Xenograft Proben detektiert. Nur in 
einem Fall war der vorherrschende Klon zwischen Diagnose und Xenograft 
unterschiedlich, konnte jedoch zurückverfolgt werden. In den meisten VHR-ALL 
Fällen wurden die in der Probe der Diagnose vorherrschenden Klone auch in den 
Xenograft-Proben nachvollzogen, wie wir mittels PCR Analyse der Ig/TCR-Loci 
feststellen konnten. In seltenen Fällen war das Muster der CNAs und Ig/TCR 
Rearrangements weniger konserviert, was auf eine Selektion von Subpopulationen 
schliessen lässt.  
In vier von sechs VHR-ALL Fällen waren 100 unsortierte Zellen ausreichend, um 
eine Leukämie in den NSG Mäusen zu erzeugen. Die daraus resultierenden 
Leukämien ähnelten in Phänotyp und Genotyp den diagnostischen Proben genauso 
stark wie Leukämien, die mit mehr Zellen erzeugt wurden. So konnten wir zeigen, 
dass die Leukämie erzeugenden Zellen von Hochrisiko Patienten eine multiklonale 
Zusammensetzung haben und dass diese Zusammensetzung während der 
Xenotransplantation in NSG Mäuse stabil erhalten bleibt.  
Unser Xenograft Modell wurde als präklinisches Modell zur Evaluierung neuer 
Behandlungsprinzipien zur Chemosensibilisierung von resistenten Patienten 
erfolgreich angewandt. Wir konnten im Xenograft Modell zeigen, dass das kleine 
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Molekül Obatoclax zur effektiven Resensibilisierung gegenüber der Chemotherapie 
geführt hat. Dieser Ansatz wird demnächst in einer klinischen Phase 1 Studie 
umgesetzt werden. Ausserdem nutzten wir das Xenograft Modell als erneuerbare 
Quelle für das seltene diagnostische Material und konnten so zu einer Studie über 
die Bedeutung von CRLF2 im Zusammenhang mit Leukämien von Down-Syndrom 
Patienten beitragen.  
Zusammengefasst haben wir ein Xenograft Modell der VHR-ALL etabliert, welches 
funktionale Studien mit relevanten Fällen ermöglicht. Da es wahrscheinlich ist, dass 
ein Grossteil der ALL-Zellen Leukämien induzieren kann und sie oligo- oder sogar 
polyklonal sind, ist anzunehmen, dass dies der Grund ist, weshalb es zur klonalen 
Selektion kommt und ein Entrinnen von der Therapie möglich ist. Neue 
Therapieansätze müssen daher konsequenterweise die Vielfalt der gesamten 
Leukämischen Population umfassen. 
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Introduction 
 
Childhood Acute Lymphoblastic Leukemia 
 
Leukemias are the most frequent cancers in childhood. Due to specific risk-directed 
treatment of patients, progress in the therapy has led to high cure rates (five-year 
survival) of 80% in acute lymphoblastic leukemia (ALL) and 60% in acute myeloid 
leukemia (AML). Nevertheless, the high toxicity of the treatment and occurrence of 
relapses are a major problem. Relapses are ranking under the top four most common 
diagnoses in pediatric oncology in the US and top five in Switzerland demonstrating 
the need for novel therapies (Stanulla 2009; Pui 2007; 2011; Bailey 2008; Einsiedel. 
2005). ALL is the most frequent type of leukemia in childhood (nearly 80%) in 
children. ALL derives from B- or T- lymphocyte progenitors, which are blocked in their 
maturation. The massive proliferation of these cells can overpower the normal 
hematopoietic differentiation and leads to accumulation of leukemic blasts in primary 
and secondary hematopoietic sites such as liver, spleen, lymph nodes and thymus 
(Pui 2007). Leukemic blasts show antigen expression profiles similar to the 
maturation stages of normal B- and T-cells (Figure 1). These maturation stages can 
be identified with cell-surface markers and leukemic blasts typically have aberrant 
patterns of immunoglobulin expression. Immunophenotyping performed at diagnosis 
allows to sub-classify cases according to the maturation stage at which they are 
blocked. Clinically important is the distinction of B-cell precursors and of mature B-
cells (Pui 2007). Also, different reports have shown that some markers do not remain 
stable under the early phases of treatment and observed down-modulation of CD10 
and CD34 and up-modulation of CD19 and CD20 in residual blasts (Gaipa 2008; 
Dworzak 2008; SzczepaĔski 2006). These differences can be helpful to create 
specific antibody-directed therapies. Moreover, the use of immunophenotyping is an 
important tool for monitoring minimal residual disease (Ratei 2009).  
 
 
Figure 1. Maturation stages of normal B cells and respective surface marker expression. 
Adapted from (Pui 2007). 
 
Treatment Response is the Most Important Prognostic Factor 
 
In childhood ALL a limited number of significant risk factors have been described with 
different clinical and biological characteristics that are used for prognosis and 
adaptation of the treatment. These include leukocyte count at diagnosis, 
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immunophenotype, age, chromosomal abnormalities and response to initial therapy 
(Bailey 2008) (Table 1). These factors are used to stratify patients into different 
treatment groups and optimize their individual treatment. Thereby patients with 
unfavorable factors receive more intense chemotherapy, whereas those with “good 
prognosis” receive less or modified versions of the intensive treatment elements.  
 
Factors commonly used for risk stratification 
Factor Favorable Adverse 
Age (years) 1-9 <1 or 10 
Leukocyte count (×10
9
/L) <50 >50 
Immunophenotype B-cell precursor T-cell 
Genotype 
Hyperdiploidy>50 chromosomes, 
TEL-AML1 (ETV6-RUNX1) 
Hypodiploidy<44 chromosomes, 
BCR-ABL1, MLL-AF4 
MRD after induction <0.01% 1% 
 
Table 1. Risk factors in childhood ALL. Adapted from (Pui 2010). 
 
Currently, the most powerful risk stratification criterion is the initial response to 
therapy. The European BFM study group (named after the founding centers in Berlin-
Frankfurt-München) has developed a powerful method to follow the disease 
regression over treatment time by measuring the minimal residual disease (MRD). 
This is a quantification of residual leukemic blasts in the bone marrow and peripheral 
blood of patients measured either by quantitative PCR of clone specific 
Immunoglobulin (Ig) and T-cell receptor (TCR) rearrangements and/or by flow 
cytometry of surface markers (van Dongen 1998; Schrappe 2004; Flohr 2008; Ratei 
2009). Multi-parameter flow cytometry uses the atypical expression of leukemia-
associated surface proteins to distinguish between normal and malignant cells. For 
example, CD10 is often expressed at a higher level in precursor B-ALL than in 
normal B precursor cells. For detection of MRD, proteins that are aberrantly co-
expressed on ALL cells, such as CD58 or CD9 for precursor-B ALL will be very useful 
to clearly distinguish a small population of blasts over the background of normal 
regenerating lymphoid cells. Other aberrantly expressed markers are cross-lineage 
expression of T-cell and myeloid cell markers including CD7, CD13 and CD33 
(SzczepaĔski 2006).  
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Figure 2. Expression of surface markers and antigen receptor rearrangement in correlation to 
B-cell development. Adapted from (van Zelm et al. 2005) 
 
The junctional regions of Ig and TCR gene rearrangements are suitable PCR targets 
as they represent unique sequences, which are created through deletions and 
random insertions of nucleotides during the rearrangement process of B- and T-cell 
receptors (Figure 2). Leukemic blasts, stalled in their maturation process have 
undergone the rearrangement process as normal lymphocytes, but often not until the 
complete V-D-J rearrangement. Unlike in healthy blood, where one detects multi-
clonal rearrangements, reflecting the diversity of B- and T-cells, leukemic blasts are 
more homogeneous and allow detecting strong signals of monoclonal 
rearrangements. Extensive studies have established the time points and cut offs for 
MRD levels that are most suitable to distinguish between patients with a high risk or 
low risk to relapse with their disease. Patients with persisting MRD levels above the 
determined cut off (10-3 leukemic cells per one normal cell) after 12 weeks of 
chemotherapy have a high risk of relapse (MRD-HR, Figure 3 left panel). These 
patients, as well as few additional cases identified based on cytogenetic risk criteria 
(cases with the translocations t(9;22) or t(4;11), see below and Table1) will qualify for 
more intensive treatment after this time point. An additional MRD time point at week 
22 during consolidation therapy further discriminates a subgroup of patients with very 
high risk of relapse (VHR-MRD) (Figure 3 right panel). About 50% of these patients 
also have no response to the steroid treatment, which is given in the first week of 
ALL treatment. 
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Figure 3. Value of MRD analysis for prognosis. Survival curves of the different MRD 
subgroups identified by qPCR of Ig/TCR rearrangements at measurements after 12 weeks 
(left) and 22 weeks (right). Adapted from (Schrauder 2007). 
 
Genetic Subtypes in ALL 
 
Cytogenetic characterization of ALL patients is commonly performed at diagnosis 
and several subtypes of leukemia can be distinguished based on cytogenetic 
analysis (Figure 4). Many abnormalities are known but most of them are not 
commonly used for clinical risk evaluation (Table 1). 
 
Cytogenetic Subtypes with Favorable Outcome 
 
The most common translocation found in childhood B-precursor ALL is the 
translocation t(12;21)(p13;q22) leading to the TEL-AML1 fusion product (also known 
as ETV6-RUNX1). It is found in around 25% of patients and is a robust prognostic 
factor for favorable outcome (McLean 1996). This group of patients represents a 
distinct biological subset as was shown by gene expression studies (Yeoh 2002). 
Moreover, it is likely that TEL-AML1 is the initiating event in this subtype as the 
presence of the translocation on neonatal blood spots demonstrated that the 
translocation is already present in blood years before the disease is overt (Greaves 
2003). Nevertheless, the mechanism of leukemogenesis of TEL-AML1 leukemias is 
not unraveled yet.  
The next common aberration is hyperdiploidy (more than 50 chromosomes), which 
also confers a favorable prognosis. It was also shown to be a distinct subset of ALL 
by microarray studies (Yeoh 2002). Around 5% of patients carry the t(1;19) 
rearrangement, leading to the fusion of the transactivation domain of the transcription 
factor E2A with the homeobox (HOX) gene PBX (Armstrong 2005). E2A transcription 
factors plays a role in lymphocyte development and as the translocation impairs one 
copy it is likely to contribute to leukemogenesis. HOX family genes are known for 
their role in leukemogenesis, and as PBX1 can alter the HOX regulated programs, it 
may contribute to leukemogenesis (Armstrong 2005).  
 
MRD < 10
-4
  
10
-3 
< MRD < 10
-4
  
MRD  10-3  
Resistance to induction chemotherapy 
MRD week5 and week12 ? high-risk patients 
Resistance to consolidation chemotherapy 
MRD week22 ? Very high-risk patients 
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Figure 4. Common genetic abnormalities in B-ALL and T-ALL. Aberrations only found in T-
ALL are shown in purple. Adapted from (Pui 2011). 
 
Cytogenetic Subtypes with High-Risk for Relapse 
 
In infant leukemias (age below 1 year), translocations involving MLL rearrangements 
on chromosome 11q23 are common. This risk factor defines a group of children that 
are expected to have a high risk of relapse (Biondi 2000). These rearrangements can 
occur in AML and ALL and some cases show both lymphocytic and monocytic 
involvement, which triggered the naming of mixed-lineage-leukemia (MLL) for the 
gene on 11q23. MLL is a DNA binding protein that is involved in hematopoiesis 
through the regulation of HOX-family genes and was shown to be a leukemia-
initiating event (Owens 2002). MLL has a variety of fusion partners, MLL-AF4 
(t(4;11)) was the first to be identified and is most common in ALL. Now more than 40 
partners are identified and as particular translocations are associated with particular 
immunophenotypes, the fusion partner might play a role (Krivtsov 2007; Armstrong 
2002). 
A poor prognosis is attributed to translocation t(17;19) (E2A-HLF) which occurs in 
around 1% of ALL patients. Like the t(1;19) rearrangement, t(17;19) contains the E2A 
transcription factor which plays a crucial role in lymphocyte development (Armstrong 
2005). The fusion protein has been shown to be sufficient to immortalize lymphocyte 
precursors (de Boer 2010) and to up-regulate the anti-apoptotic protein Survivin 
(Okuya 2010). Both mechanisms could explain the resistance to treatment.  
The translocation t(9;22), also called Philadelphia chromosome, is also associated 
with high risk. It results in the fusion of the BCR signaling protein to the tyrosine 
kinase ABL1 causing constitutive active kinase activity and interactions with other 
transforming elements such as RAS, which renders the kinase an interesting target 
for small molecule targeted therapy (Pui 2007). The BCR-ABL1 inhibitor imatinib is 
successfully used for the therapy of chronic myeloid leukemia (CML) where the 
majority of patients carry this translocation (Ren 2005).  
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Down-Syndrome and ALL 
 
Interestingly, children with Down-Syndrome (DS) have a higher risk of developing 
leukemias, both AMLs and ALLs, while they generally have a lower risk for 
developing solid tumors. In case of ALL, DS is associated with higher risk than non-
DS, and DS-ALL is a clinical and biological distinct subset from non-DS ALL patients 
(Hertzberg 2010; Zwaan 2010). Several groups have reported the presence of 
somatic activating mutations in the Janus kinase JAK2 in approximately 20% of DS-
ALLs (Bercovich 2008; Kearney. 2009; Mullighan 2009c). Similar mutations can also 
be found in approximately 10% of high-risk ALLs in non-DS children, corresponding 
to approximately 3% of unselected childhood ALLs (Mullighan 2009c). The mutations 
involve highly conserved residues of the kinase and pseudo-kinase domains and 
lead to constitutive-active JAK/STAT signaling and thus to immortalization of 
hematopoietic progenitors and cytokine-independent growth, as was shown in-vitro 
(Bercovich 2008; Mullighan 2009c).  
An additional molecular abnormality was found by gene expression profiling, which 
revealed that 60% of DS-ALLs overexpress the cytokine receptor CRLF2. This was 
associated with activating mutations in JAK2 or the receptor itself (manuscript 4) 
(Hertzberg 2010). In normal lymphoid development, CRLF2 plays a role in TSLP 
receptor (thymic stromal-derived lymphopoietin receptor) formation by dimerization 
with IL7RA (Fujio 2011; Pandey 2000). As IL7RA is expressed on leukemic blasts, 
CRLF2 could interact to form TSLPR on the leukemic cells in a similar fashion. On 
the other hand it was also demonstrated that CRLF2 cooperates with JAK2, in the 
absence of IL7RA, suggesting an independent activation through homodimerization. 
CRLF2 and mutated JAK2 led to a robust cytokine-independent growth, 
demonstrating that these two proteins cooperate in providing growth and survival 
advantage (Figure 5) (Hertzberg 2010). Finally, these data imply that therapeutically 
targeting of JAK/STAT signaling may be of potential benefit to the majority of DS-ALL 
patients, not limited only to those with mutated JAK2.  
 
 
Figure 5. A model of CRLF2 and JAK2 in Down-Syndrome ALL. High levels of CRLF2 as a 
cause of genomic aberrations are followed by activating mutations in CRLF2, JAK2 or other 
yet unidentified kinases, which contribute to the growth advantage of DS-ALL blasts. 
Adapted from (Hertzberg 2010) (manuscript 4).  
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The cooperation of mutated JAK2 and high levels of CRLF2 was also observed in 7% 
of non-DS ALL pre-B leukemias (Mullighan 2009a; Harvey 2010; Russell 2009). 
Overall, high-levels of CRLF2 were associated with poor event-free survival, but 
some studies showed that only the rearrangement of CRLF2 with P2RY8, but not the 
overexpression of CRLF2 alone was an independent predictor for high-risk of relapse 
for patients otherwise classified as standard risk (Cario 2010; Harvey 2010). 
Therefore, through the detection of CRLF2 rearrangements a group of patients can 
be identified in future which are in need of intensified treatment and are not 
recognized by MRD measurements. Additionally, the use of JAK/STAT inhibitors, 
also for non-DS ALL patients, needs to be evaluated. 
 
High-Resolution Genomic Profiling 
 
In the last years, a rapid progress has been made in high-throughput genomic 
technologies, not limiting the genetic analysis to cytogenetics but allowing more in-
depth studies. This has led to a very complex and heterogeneous picture of ALL 
genetics. Several groups have used high-resolution single nucleotide polymorphism 
(SNP) arrays of diagnostic ALL samples and detected recurrent genetic aberrations. 
Often these were small genetic lesions, mostly deletions but also chromosomal 
translocations were detected. With increasing numbers of studies performed, it 
becomes clearer which cellular pathways are the targets of DNA copy number 
aberrations (CNA). Most often aberrations were observed in master regulators of 
lymphoid development, such as PAX5, EBF and IKZF1. Other targets include 
regulators of the cell cycle (CDKN2A/B), tumor suppressor genes (PTEN, BF1, RB1) 
and regulators of apoptosis (BTG1) (Mullighan 2009; Mullighan 2009b; Mullighan 
2008a; Mullighan 2008; Mullighan 2007; Harvey 2010). In 60% of pre-B ALL cases a 
loss of genes that regulate B-lymphoid development is observed and it was shown in 
experimental models that this leads to an acceleration of leukemogenesis (Mullighan 
2008; Hu 2004; Ross 2003) and thus these aberrations could also contribute in 
human leukemogenesis.  
Overall, the average number of aberrations is limited to around six per case at 
diagnosis, demonstrating that there is no general chromosomal instability in ALL. On 
the other hand, the number of aberrations differs significantly between different 
subgroups of ALL (Mullighan 2008). MLL-rearranged leukemias carried up to one 
CNA, indicating that only a limited number of lesions are necessary for leukemia 
initiation. In BCR-ABL and TEL-AML1 rearranged leukemias more than 6 CNAs were 
found, suggesting that disruption of multiple pathways is required for leukemia 
initiation and progression. The most frequent deletion in this group was found in the 
IKFZ1 gene. It encodes the transcription factor Ikaros and was deleted in 76.2% of 
childhood BCR-ABL ALL and in 90.9% of adult BCR-ABL ALL cases. Further, PAX5, 
located on chromosome 9p, was frequently deleted (in 51% of samples), mostly 
occurring in cases also carrying the IKZF1 deletion (Mullighan 2008a). Also located 
on chromosome 9p are the cell cycle regulators CDKN2A and B, which were 
frequently deleted and the whole 9p chromosome arm was lost in many cases 
(Figure 6).  
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Figure 6. Frequent chromosome 9p aberrations. A heatmap of the full chromosome 9 of 
several B-ALL and T-ALL cases is depicted and the loci for PAX5 and CDKN2A/B are 
highlighted. Blue strips indicate lower copy numbers and red strips higher copy numbers. 
Adapted from (Mullighan 2009). 
 
More recently, a candidate gene sequencing approach has identified mutations in 
diagnostic and relapsed ALL. Some of them in genes known to be recurrent DNA 
CNA targets in ALL (e.g. PAX5, ETV6, JAK1, FBXW7) and many in novel ALL target 
genes, such as the transcription coactivators CREBBP and NCOR1 and the 
transcription factors ERG, SPI1, TCF4 and TCF7L2 (Mullighan 2011). In 18.3% of 
relapses CREBBP was mutated, which is a histone acetyltransferase binding protein 
acting as transcription coactivator. The mutation impaired the histone acetylation and 
transcription of target genes, which included glucocorticoid responsive genes. In 3 of 
4 cases the mutation of the relapse could be backtracked to minor clones at 
diagnosis and thus the mutation might confer treatment resistance to these cases 
(Mullighan 2011). 
In future, the combination of high-throughput genomic techniques, deep-sequencing 
of the leukemia genome and epigenetic profiling (for example methylation arrays for 
the detection of promoter and enhancer regions of candidate genes) will lead to the 
new identification of core lesions in ALL. It will be most important to link these data 
with biologic functions and clinical significance and it will require experimental 
platforms for functional investigation of the different lesions (Bonapace 2010).  
 
Cancer Stem Cells, Leukemia Initiating Cells and Clonal Evolution 
 
The concept of cancer stem cells (CSC) predicts that cancer cells are phenotypically 
and/or genetically heterogeneous and that only a subpopulation has the ability to 
propagate and maintain the disease. This subset of cells shares characteristics with 
their counterparts from normal tissue as the abilities to self-renew, to differentiate, to 
proliferate extensively and to resist to chemotherapeutics (Figure 7b) (Lobo 2007). 
This concept suggests that cells within a given cancer are hierarchically organized. 
The CSC concept puts the CSCs in the center for novel targeted therapies, as they 
are the main responsible elements for occurrence of relapses. In this concept, a pre-
cancerous cell or cell-of-origin is created through an oncogenic event. 
Transformation and tumor formation then occurs through additional supporting 
CDKN2A/B 
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genetic or epigenetic events. The CSC is the cell maintaining and propagating the 
tumor once it is established, but not necessary the cell-of-origin, which is the cell that 
is transformed in the “first hit” and might later evolve to be also the CSC (thus the 
CSC can also be termed tumor-propagating cell, or in case of leukemias, leukemia-
initiating cell). Treatment of tumors that follow the CSC model might eradicate most 
of the cells, but any CSC that is evading can differentiate again and cause a relapse 
(Bomken 2010). On the other hand, a treatment that targets tumor-propagating cells 
specifically and not the bulk of the tumor mass could disable the tumor to generate 
new cells and lead to tumor regression (Huntly 2005).  
Tumor-propagating cells are thought to share features with normal stem cells, which 
render them more resistant to chemotherapy. For example, both hematopoietic stem 
cells and tumor cells have increased levels of telomerase, which prevents them from 
replicative senescence and cell death (Morrison 1996; Gal 2006; Campbell 2006). In 
addition, although they have the potential to self-renew, they usually rest in the G0 
phase of the cell cycle. This means that conventional chemotherapeutic drugs, such 
as 5-fluorouracil, which act on cycling cells eradicate effectively the normal tumor 
mass but not the tumor-propagating cells, as was shown in AML (Ravandi 2006). The 
quiescent state of LICs could contribute to their resistance to treatment. Moreover, 
the multi-drug resistance of tumors is often associated with higher expression ABC-
transporters on tumor-propagating cells, which leads to increased drug efflux from 
the cells, and thus the drugs are ineffective (de Jonge-Peeters 2007). Therefore, the 
identification of targeted therapies to tumor-propagating cells could lead to improved 
outcomes for patients with drug-resistant disease.  
 
 
Figure 7. Concepts of tumor heterogeneity. (A) Variations result from intrinsic and extrinsic 
factors, right combinations thereof could trigger self-renewal. (B) A tumor shows a hierarchy 
similar to normal tissues with self-renewing cells at the top. (C) Ongoing clonal evolution with 
sequential genetic and epigenetic changes that result in a polyclonal population. Adapted 
from (Bomken 2010). 
 
To describe the first CSC it was necessary to sort the different subpopulations based 
on immunophenotype and to use immuno-compromised mice for evaluation of tumor 
initiating ability. The methodology of sorting cell subsets and then transplanting them 
at limiting numbers into immuno-compromised mice has set the gold-standard for the 
identification of self-renewing and tumor-propagating cells, after its first use for the 
identification of hematopoietic stem cells by Irving Weissman and colleagues (Clarke 
2006; McCune 1988). John Dick’s laboratory was the first to show for myeloid 
leukemia that a restricted subpopulation was able to propagate the entire original 
leukemia into NOD/scid mice over serial transplantations. Only the immature 
CD34+/CD38- cells but not more mature CD34+/CD38+ cells were able to self-renew 
and recapitulate the tumor using very low numbers of cells (Lapidot 1994; Bonnet 
1997). After that, CSCs were identified in solid tumors of the breast (Al-Hajj 2003), 
brain (Hemmati. 2003; Singh. 2004), and colon (O'Brien 2007; Ricci-Vitiani 2007). 
Obstacles still are the identification of suitable surface markers to enable sorting of 
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subpopulations, the scarcity of primary material and the different experimental set-
ups used by different groups. 
 
Another concept for heterogeneity of tumor cells within a tumor provides the 
stochastic model. According to that model, all tumor cells could be biologically 
equivalent and the heterogeneity derives from extrinsic or intrinsic influences, 
including niche interactions and intercellular signaling that result in random or 
stochastic responses (Figure 7a) (Dick 2008; Bomken 2010). The right combinations 
of these events could enable any cell of the tumor to self-renew and propagate 
disease. This is not necessarily contradicting to the CSC model, if one accepts that 
tumor-propagating cells need not be rare and that tumor cells either can evolve or be 
selected for to re-activate their stem-cell programs. Gupta et al (Gupta 2009) 
introduced the term bi-directional interconvertability to describe the plasticity of non-
CSCs to become CSCs.  
 
In childhood B-ALL, it is quite unclear at the moment if the traditional concept of 
CSCs is applicable. BCR-ABL positive ALL was described, similar to AML, to harbor 
the leukemia initiating cells (LICs) in immature CD34+/CD38- compartments, (Cox 
2005; Cobaleda 2000). Then two reports showed that the LICs reside in the more 
mature CD19+/CD34+/CD38dim populations in good-risk ALL (Castor 2005; Hong 
2008). And more recently a very immature phenotype, CD133+/CD19-, similar to the 
hematopoietic stem cell was described to exclusively harbor LIC activity (Cox 2009). 
These data propose that those leukemia subtypes associated with high-risk and 
resistance to treatment have more immature LICs resembling normal stem cells. 
Whereas in leukemias with favorable prognosis, the LICs reside in a more mature 
compartment. 
These studies were however contradicted by others, which showed that LICs could 
be found in both immature and mature compartments (le Viseur 2008; Kong 2008). In 
particular, both studies demonstrated that CD34+/CD19- , CD34+/CD19+ and CD34-
/CD19+ sorted populations initiated leukemias in NOD/scid-IL2RȖnull (NSG) mice. 
Importantly these leukemias reflected the complete original immunophenotype and 
were retransplantable in NSG mice, demonstrating that these populations had the 
ability to move forth and back between the different populations (le Viseur 2008). In 
addition, the groups of Andreas Strasser and Scott Armstrong demonstrated in 
syngeneic mouse models that the frequency of cells with repopulating ability was as 
high as 1:10 and 1:4, respectively and therefore LICs need not be rare (Kelly 2007; 
Krivtsov 2006). This was further underlined by work of three groups, including ours, 
that were able to show that the number of unsorted leukemic blasts needed for 
initiation of leukemia in the NSG mouse model was between 10-100 cells (see 
manuscript 1) (Morisot 2010; Rehe 2009; Schmitz 2009). These findings suggest that 
in B-ALL the LIC organization follows rather the stochastic than the hierarchic CSC 
model. 
 
Leukemic Clone Evolution and the Origin of Relapse 
 
The conclusion that LICs in B-ALL are not fixed populations, but evolve genetically, 
phenotypically and functionally must be drawn from the before-mentioned studies. 
Recently more support for the clonal evolution model was given. By using multi-
plexed fluorescence in-situ hybridization (FISH) analysis a complex, branched, not 
linear, clonal architecture with successive acquisition of CNAs was detected in TEL-
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AML1 positive ALL cases. Moreover, changes in the genetic composition at relapse 
or after xenograft transplantation could be backtracked to diagnosis (Anderson 
2010). These data illustrated that different clones constitute the leukemogenic 
compartment and that leukemias undergo changes in their composition with different 
dominant subclones at different points of disease (Figures 7c and 8). Similarly, it was 
shown in adult BCR-ABL positive ALL using SNP arrays that the leukemic 
compartment evolves during disease (Notta 2011). A correlation of patient survival 
with concordance of CNAs before and after xenograft was shown. Less survival was 
associated with stably detectable CNAs and better survival with discordant CNAs 
(Notta 2011). This could indicate that more aggressive types of clones had been 
selected in patients with worse outcome. Therefore, clonal evolution could contribute 
to disease progression and treatment resistance.  
 
 
Figure 8. Altered clonal composition at different time points of disease. Different clones 
(phenotypical and genetical) with altered propagating abilities are observed as the major 
clone throughout disease. Adapted from (Greaves 2010). 
 
Further evidence underlining the evolution of clones from disease initiation to disease 
maintenance was presented in twin studies. The pre-leukemic populations of 
identical twins with TEL-AML1 positive B-ALL were compared; less putative LICs 
were found in the twin with pre-leukemia compared to the twin with overt ALL. The 
phenotype and genotype of the pre-leukemic cells was distinct from the B-ALL cells 
(Hotfilder 2005). It is hypothesized that fusion transcripts (MLL-AF4, TEL-AML1, 
BCR-ABL) are established prenatally, already in-utero in the cell-of-origin (Vormoor 
2009). For TEL-AML1 it was shown in five pairs of monozygotic twins that the fusion 
gene formation occurred prenatally and was postnatally followed by acquisition of 
more genetic lesions (Bateman 2010; Hong 2008). Additionally, a mechanism was 
described that confers TEL-AML1 positive cells with a growth advantage. 
Transduction of normal cord blood precursor cells with TEL-AML1 increased a subset 
of cells with a “pre-B leukemia-phenotype”, CD34+/CD38-/CD19+, and these cells 
had higher self-renewal capacity and survival rates (Hong 2008; Ford 2009). This 
indicates that the fusion gene formation is the primary leukemogenic event and 
subsequently further clonal evolution and selection is ongoing until and after overt 
leukemia is established.  
 
Pre-leukemic, Cell-of-Origin 
Diagnosis 
Treatment or Transplantation 
Relapse or Xenograft 
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Figure 9. Genetic clonal evolution. Most of the cases at relapse show a clear relation to the 
diagnosis or to a common ancestral clone as suggested by CNA patterns. Adapted from 
(Mullighan 2008). 
 
Not only the relation between pre-leukemic clones and diagnosis but also the 
connection of clones at relapse and at diagnosis was shown. With genome-wide 
studies large cohorts of matched diagnostic and relapsed cases were analyzed 
(Mullighan 2008; van Delft 2011; Kuster 2011; Davidsson 2010). Relapse cases 
showed higher numbers of CNAs than diagnosis cases (mean 12.5 vs. 7.5 CNAs per 
case in TEL-AML1) (Kuster 2011), and interestingly the obtained CNAs often 
targeted known oncogenic loci, such as CDKN2A/B, IKZF1, RAG, PAX5 and NR3C1, 
speaking for a role in treatment resistance and selective advantage for these genes. 
Overall, in 90% of cases, there were different CNAs detected in diagnosis and 
relapse nevertheless most of the cases were highly related. Cells from the major 
subclones at relapse could most often be backtracked to minor subclones at 
diagnosis, suggesting that clonal selection occurred during treatment (Mullighan 
2011; Kuster 2011; van Delft 2011; Davidsson 2010). As most relapses lacked some 
of the CNAs from diagnosis, it is suggested that a common ancestral clone exists 
(Figure 9) (Mullighan 2008).  
The clonal variability at diagnosis might be the basis of treatment escape and origin 
of relapse. Thus, it will be crucial to identify the key lesions, which need to be 
targeted to prevent relapses.  
 
Xenografts and Genetic Mouse Models to Study High-Risk 
Leukemias 
 
Increasing data are available that characterize leukemia cells on genetic and 
phenotypic level. This provides the basis for the development of targeted therapies. 
To evaluate new treatment approaches preclinical models are needed. No cell lines 
are available that represent high-risk leukemias. And genetic mouse models have not 
been developed to a large extent as compared to the genetic complexity of ALL 
which was described above.  
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Genetic engineered mouse models mimic known genetic aberrations and allow 
investigating their importance for the biology of the tumor. In the field of leukemia, 
only a few models could be established. There is a model for BCR-ABL ALL, where 
the transduction of arf-null bone marrow progenitors with BCR-ABL was enough to 
induce lymphoblastic leukemia. These leukemias were highly tumorigenic in serial 
transplantations and resistant to imatinib in presence of cytokines (Williams 2007). 
There are also models for MLL-AF9 leukemias, which result in myeloid, but not 
lymphoid leukemias in mice (Krivtsov 2006; Somervaille 2006). Other models cover 
T-cell lymphomas, B-lymphomas, CML and AML (Kelly 2007; Adams 2008; Huntly 
2004; Deshpande 2006; Neering 2007), illustrating the variety of tumors that can be 
modeled but also showing the lack of a representative model for high-risk B-ALL. A 
general disadvantage of genetic models is that they investigate single genetic 
aberrations and not the full genetic complexity. Therefore, they represent only a 
minor fraction of patients. In future, it will be a challenge as it is time consuming, but 
necessary to generate more genetic mouse models for the characterization of 
relevant genetic aberrations and their role in tumorigenesis and drug resistance. 
For preclinical drug testing, xenografts have been more widely used. In that 
approach, primary patient material is transplanted into immunodeficient mice and is 
then recapitulating the original leukemia. The advantages of xenografts are – that the 
starting material is usually from advanced cancers, - that the tumors represent the 
original tumor in the patient, including the genetic complexity – and that you can test 
multiple drugs in different settings against the same set of cells or against different 
tumors from different patients (Politi 2011). Therefore, by using xenograft models all 
relevant patient groups can be modeled.  
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Subject of Investigation 
 
Functional investigations of human ALL are limited by the difficulty to establish 
representative cell culture systems in vitro. Xenotransplantation of human leukemia 
cells in immunodeficient mice provides a new and powerful tool to model disease, 
provided the consequences of the selective pressures that are inherent to this model 
are better understood. The composition of the leukemia-propagating (or initiating) 
compartment in ALL appears to be more complex than previously proposed. This has 
important implications for our understanding of disease progression and treatment 
resistance mechanisms. The major aim of my PhD Thesis was to: 
 x Establish a representative xenograft model of childhood precursor B-ALL 
(manuscript 1 and 2)  x Functionally investigate the clonal composition of the LIC compartment in ALL 
and understand the consequences of the murine microenvironment for the 
xenograft model (manuscript 1).  
 
Having established this system, I also contributed significantly to:  
 x Evaluate new treatment rationales for chemosensitization of de novo highly 
resistant cases using the xenograft model for in vitro and in vivo drug testing 
(manuscript 3) x Use the xenograft system as a renewable source of leukemic cells for the 
investigation of new ALL subtypes (manuscript 3 and 4) 
 
Manuscript 1: Xenografts of highly resistant leukemia recapitulate the clonal 
composition of the leukemogenic compartment (first author). 
Manuscript 2: Alternative technique for intrafemoral injection and bone marrow 
sampling in mouse transplantation models (first author). 
Manuscript 3: Induction of autophagy-dependent necroptosis is required for 
childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance 
(co-author). 
Manuscript 4: Down syndrome acute lymphoblastic leukemia, a highly 
heterogeneous disease in which aberrant expression of CRLF2 is associated with 
mutated JAK2: a report from the International BFM Study Group (co-author). 
 
Manuscript one constitutes the main part of my work and thus will be the essential 
part in the discussion section. 
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Results  
 
Xenografts of Highly Resistant Leukemia Recapitulate the Clonal Composition 
of the Leukemogenic Compartment 
 
Maike Schmitz, Petra Breithaupt, Nastassja Scheidegger, Gunnar Cario, Laura 
Bonapace, Barbara Meissner, Paulina Mirkowska, Joelle Tchinda, Felix K. Niggli, 
Martin Stanulla, Martin Schrappe, Andre Schrauder, Beat C. Bornhauser* and Jean-
Pierre Bourquin* 
* These authors contributed equally 
 
Blood (2011) doi: 10.1182/blood-2010-11-320309 
 
 
Abstract: 
Clonal evolution of the leukemogenic compartment may contribute to alter the 
therapeutic response in acute lymphoblastic leukemia (ALL). Using 
xenotransplantation of primary leukemia cells we evaluated the phenotypic and 
genetic composition of de novo resistant very high risk (VHR) precursor B-cell ALL, a 
subgroup defined by the persistence of minimal residual disease (MRD) despite 
intensive chemotherapy. Analysis of copy number alterations (CNA) showed that the 
xenografted leukemia, even when reconstituted from hundred cells, remained highly 
related to the diagnostic sample, with minor changes in CNAs, mostly deletions, 
emerging in most cases in the first passage into mice. At the single cell level, the 
pattern of mono-and bi-allelic deletions of the CDKN2A locus revealed distinct 
leukemia subpopulations, which were reproducibly tracked in xenografts. In most 
VHR-ALL cases, the predominant diagnostic clones were reconstituted in xenografts, 
as shown by multiplex PCR analysis of Ig/TCR loci. In other cases, the pattern in 
CNAs and Ig/TCR rearrangement was less concordant in xenografts, suggesting the 
outgrowth of subclones. These results unequivocally demonstrate the existence of 
clonally closely related but distinct subsets of leukemia initiating cells in ALL, which 
has important implications for drug development and preclinical disease modeling.  
 
For detailed information, see attached manuscript 1 
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Alternative Technique for Intrafemoral Injection and Bone Marrow Sampling in 
Mouse Transplantation Models 
 
Maike Schmitz, Jean-Pierre Bourquin, and Beat C. Bornhauser 
 
Leukemia & Lymphoma (2011) doi: 10.3109/10428194.2011.580023 
 
 
Letter to the editor: 
Bone marrow punctures are often required when modeling hematologic malignancies 
in mice. Orthotopic intrabone injection resulted in superior engraftment of human 
hematopoietic stem cells or of human leukemia cells in immunodeficient mice. 
Similarly, between 10-100 cells from patients with acute lymphoblastic leukemia were 
sufficient to reconstitute leukemia in immunodeficient NOD/scidIL2RȖnull (NSG) mice 
after intrafemoral injections. Current protocols for bone marrow procedures in mice 
involve a two-step process that requires to perforate the cortical bone with a first 
needle and to retrieve the orifice subsequently with a needle with smaller gauge for 
injection or aspiration of cells. As alternative, we used a small needle with a stylet in 
analogy to bone marrow aspiration needles that are used in the clinic. Here we show 
that a pediatric spinal tap needle (also called atraucan needle) can be used efficiently 
and conveniently for bone marrow transplantation and sampling procedures in mice. 
This one step injection procedure (Figure 1) resulted in highly reproducible 
engraftment with primary human ALL cells (Table-1). 44 out of 45 xenograft ALL 
samples repopulated secondary recipients. This technique was used to establish an 
in vivo model of highly resistant leukemia. Furthermore, in serial dilution experiments 
100 ALL cells were sufficient for engraftment in 4 different ALL cases, demonstrating 
that the injections can be performed with minimal losses due to dead volume with this 
needle. Bone marrow aspiration through the atraucan needle did not damage the 
bone marrow cells, as shown with 7-AAD stainings for cell viability by flow cytometry 
(Figure 1b). A homogeneous, viable population of CD19 and CD10 double positive 
human leukemia cells was detected in the bone marrow at 8 weeks after 
transplantation. The analysis of engraftment in the peripheral blood showed lower, 
although detectable, presence of human leukemia cells. By aspirating the femur 
contralateral to the injection site we collected up to 15’000 lymphocytes in 10 ȝl bone 
marrow aspirate without requirement for subsequent erythrolysis. By tail vein 
bleeding, we collected 50 ȝl of blood that was enough to detect at least the same 
number of lymphocytes.  
Taken together, the use of the pediatric atraucan needle very effectively eliminates 
the need to perform two punctures of the cortical bone in order to inject into or 
sample cells from the bone marrow cavity. We are convinced that this simple 
modification will be of great interest for many investigators as xenograft models with 
human normal or malignant hematopoietic cells are increasingly applied.  
 
For detailed information, see attached manuscript 2 
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Induction of Autophagy-Dependent Necroptosis is Required for Childhood 
Acute Lymphoblastic Leukemia Cells to Overcome Glucocorticoid Resistance 
 
Laura Bonapace*, Beat C. Bornhauser*, Maike Schmitz, Gunnar Cario, Urs Ziegler, 
Felix K. Niggli, Beat W. Schäfer, Martin Schrappe, Martin Stanulla, and Jean-Pierre 
Bourquin 
* These authors contributed equally 
 
J Clin Invest. 2010;120(4):1310–1323.  
 
 
Abstract: 
In vivo resistance to first-line chemotherapy, including to glucocorticoids, is a strong 
predictor of poor out- come in children with acute lymphoblastic leukemia (ALL). 
Modulation of cell death regulators represents an attractive strategy for subverting 
such drug resistance. Here we report complete resensitization of multi- drug-resistant 
childhood ALL cells to glucocorticoids and other cytotoxic agents with subcytotoxic 
concentrations of obatoclax, a putative antagonist of BCL-2 family members. The 
reversal of glucocorticoid resistance occurred through rapid activation of autophagy-
dependent necroptosis, which bypassed the block in mitochondrial apoptosis. This 
effect was associated with dissociation of the autophagy inducer beclin-1 from the 
antiapoptotic BCL-2 family member myeloid cell leukemia sequence 1 (MCL-1) and 
with a marked decrease in mammalian target of rapamycin (mTOR) activity. 
Consistent with a protective role for mTOR in glucocorticoid resistance in childhood 
ALL, combination of rapamycin with the glucocorticoid dexamethasone triggered 
autophagy-dependent cell death, with characteristic features of necroptosis. 
Execution of cell death, but not induction of autophagy, was strictly dependent on 
expression of receptor-interacting protein (RIP-1) kinase and cylindromatosis (turban 
tumor syndrome) (CYLD), two key regulators of necroptosis. Accordingly, both 
inhibition of RIP-1 and interference with CYLD restored glucocorticoid resistance 
completely. Together with evidence for a chemosensitizing activity of obatoclax in 
vivo, our data provide a compelling rationale for clinical translation of this 
pharmacological approach into treatments for patients with refractory ALL. 
 
For detailed information, see attached manuscript 3   
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Down Syndrome Acute Lymphoblastic Leukemia, a Highly Heterogeneous 
Disease in which Aberrant Expression of CRLF2 is Associated With Mutated 
JAK2: a Report from the International BFM Study Group 
 
*Libi Hertzberg, *Elena Vendramini, *Ithamar Ganmore, Gianni Cazzaniga, Maike 
Schmitz, Jane Chalker, Ruth Shiloh, Ilaria Iacobucci, Chen Shochat, Sharon 
Zeligson, Gunnar Cario, Martin Stanulla, Sabine Strehl, Lisa J. Russell, Christine J. 
Harrison, Beat Bornhauser, Akinori Yoda, Gideon Rechavi, Dani Bercovich, Arndt 
Borkhardt, Helena Kempski, †Geertruy te Kronnie, †Jean-Pierre Bourquin, †Eytan 
Domany, and †Shai Izraeli 
*† these authors contributed equally 
 
Blood. 2010;115:1006-1017 
 
 
Abstract: 
We report gene expression and other analyses to elucidate the molecular 
characteristics of acute lymphoblastic leukemia (ALL) in children with Down 
syndrome (DS). We find that by gene expression DS-ALL is a highly heterogeneous 
disease not definable as a unique entity. Nevertheless, 62% (33/53) of the DS-ALL 
samples analyzed were characterized by high expression of the type I cytokine 
receptor CRLF2 caused by either immunoglobulin heavy locus (IgH@) translocations 
or by interstitial deletions creating chimeric transcripts P2RY8-CRLF2. In 3 of these 
33 patients, a novel activating somatic mutation, F232C in CRLF2, was identified. 
Consistent with our previous research, mutations in R683 of JAK2 were identified in 
10 specimens (19% of the patients) and, interestingly, all 10 had high CRLF2 
expression. Cytokine receptor-like factor 2 (CRLF2) and mutated Janus kinase 2 
(Jak2) cooperated in conferring cytokine-independent growth to BaF3 pro-B cells. 
Intriguingly, the gene expression signature of DS-ALL is enriched with DNA damage 
and BCL6 responsive genes, suggesting the possibility of B-cell lymphocytic genomic 
instability. Thus, DS confers increased risk for genetically highly diverse ALLs with 
frequent overexpression of CRLF2, associated with activating mutations in the 
receptor itself or in JAK2. Our data also suggest that the majority of DS children with 
ALL may benefit from therapy blocking the CRLF2/JAK2 pathways.  
 
For detailed information, see attached manuscript 4 
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Discussion 
 
In this thesis, I describe the establishment of a xenograft model for the study of highly 
resistant childhood acute lymphoblastic leukemia (ALL) with primary material, the 
validation as preclinical model of high risk disease and the application to investigate 
the nature of the leukemia propagating cell compartment.  
 
The functional investigation of the biology of acute leukemias has been hampered by 
the facts - that diagnostic material is scarce, - that cell lines can only be established 
for a minority of cases and not necessarily represent the original leukemias, - that in 
vitro culturing of primary leukemic cells is difficult – and that due to the genetic 
complexity transgenic mouse models for high-risk subtypes of B-ALL are missing. 
Therefore, xenografting primary patient material in immunodeficient mice provides an 
interesting alternative to model disease. Scarce primary material can hereby be 
repeatedly amplified (on average around 500x of initial cell numbers) creating a bank 
of primary material for in vitro and in vivo experiments.  
However, the consequences of the selective pressure that the xenogenic 
environment imposes on the leukemic cells must be understood. We therefore 
established a xenograft model of high risk ALL and evaluated the consequences of 
xenotransplantation on the genotype and phenotype of leukemia cells. 
The leukemia initiating cell (LIC) compartment has been set in the focus for the 
development of novel treatment approaches and it is crucial to know its composition 
to be able to understand progression of leukemia and treatment resistance. For that 
reason, we investigated the clonal composition of LICs in the context of the xenograft 
model. 
 
Set-Up of the Xenograft Model 
 
The European BFM study group (named after the founding centers in Berlin-
Frankfurt-München) has pioneered risk stratification protocols based on measuring 
minimal residual disease (MRD). This is a quantification of residual leukemic blasts in 
the bone marrow and peripheral blood of patients (Schrappe 2004; Flohr 2008; 
Conter 2010). The BFM study group has large banks of primary diagnostic material 
with clearly defined clinical and genetic characterization. Each year around 1000 de-
novo resistant cases and around 300 relapse cases are included. As an integrated 
part of the BFM we have established the preclinical xenograft model. We picked 
samples from patients with very poor prognosis (VHR-ALL) and from those with very 
good prognosis (SR-ALL), according to the BFM MRD classification. For the studies 
described in this work in total 17 VHR-ALL, 15 SR-ALL, 4 HR-ALL and 8 samples 
from patients with Down-Syndrome ALL were used. As illustrated in Figure 10, the 
xenograft model represents the basis of several preclinical research projects. 
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Figure 10. Overview of the BFM xenograft consortium and the current research projects. 
 
For the xenograft model we used the highly immunocompromised mouse strain 
NOD/scidIL2RȖnull (NSG), that was demonstrated to have superior engrafting 
potential compared to the NOD/scid mouse strain (McDermott 2010; Agliano 2008). 
The additional deletion of the Ȗ-chain of the IL2 receptor renders the natural-killer 
cells of the mouse dysfunctional and thus prevents an immune response towards the 
transplanted human leukemic cells. And indeed we found that more than 75% of all 
our patient samples engrafted in NSG mice. If multiple mice were transplanted of one 
patient with known engraftment potential, the efficiency was close to 100%. 
Therefore, non-engrafting cells potentially have intrinsic differences rendering them 
incompatible to engraft in mice (personal communication, D. Bonnet). More 
refinement of the transplantation efficiency was achieved by using intra-femoral (IF) 
rather than intra-venous (IV) transplantation. The superiority of IF over IV was 
demonstrated by limiting dilution experiments, where we saw engraftment at the 
limiting dose of 100 cells only in the group of mice transplanted via IF route and 
never if IV route was applied (Schmitz 2009), and was also reported by others for 
leukemic and normal hematopoietic samples (le Viseur 2008; Mazurier 2003). The 
reason for that may be a faster and more efficient homing to the bone marrow after 
transplantation. To facilitate the IF transplantation technique we used an atraucan 
spinal tap needle usually applied in the clinics for bone marrow aspirations in 
children. This needle has a stylet, which allows performing the transplantation in one 
step, and therefore facilitates the procedure also adding to the high engraftment rates 
(manuscript 2).  
 
Xenografts Mirror the Phenotype of Original Human ALL Cells 
 
To answer the question if xenotransplantation is selecting for certain subpopulations 
of leukemic cells, for example favoring engraftment of immature subpopulations over 
differentiated ones, we have investigated the immunophenotype and the functional 
drug response of cells before and after transplantation. We looked at a panel of 
eleven different cell-surface markers, which is also used for diagnosis, covering the 
whole diversity of markers from immature to differentiation to cross-expression, in 16 
patients and xenografts thereof and found the phenotypes to be very similar. In five 
cases we could perform measurements from matched diagnosis and xenograft 
samples ourselves on the same instrument and had concordant results in 46 of 51 
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measurements. For the eleven other cases we could not perform analysis of 
diagnostic material ourselves and therefore compared our data to the data from the 
BFM reference lab. There we observed changes in 15 of 99 measurements, and 
changes occurred in different surface markers (CD34, CD20, CD13, CD33, and 
CD7). Therefore, the changes we observed might reflect a minor selection in NSG 
mice in the context of the xenogenic environment.  
We further investigated whether serial xenotransplantation changed the drug 
responses to four common chemotherapeutic compounds (namely, Dexamethasone, 
Vincristine, Cytarabine and Daunorubicine) in vitro. As expected, xenograft cells from 
the VHR samples were highly resistant and xenograft cells from SR patients were 
sensitive to these compounds. Moreover, the drug response profiles did not change 
with higher serial passages used. These data suggest that it is rather an adaptation 
to the mouse environment and not a selection of ALL cells that are intrinsically more 
resistant to chemotherapeutic agents, which is responsible for the acceleration of 
engraftment in secondary transplantation of SR-ALL cells. 
This conservation of drug response features upon xenografting enabled us to 
investigate the mechanisms of treatment resistance in VHR-ALL patients (manuscript 
3). We evaluated the new compound obatoclax, a pan-BCL-2 inhibitor to act as a 
chemosensitizer. Using the xenograft model, we demonstrated that obatoclax has a 
strong chemosensitization effect in VHR-ALL samples in vivo (Bonapace 2010). 
Indeed, mice that were engrafted with leukemia and then treated for two weeks with 
a combination of obatoclax and dexamethasone had significant better survival than 
the control groups. With in vitro experiments using xenograft material we then found 
that unexpectedly, resensitization to glucocorticoids resulted from activation of 
autophagy-dependent necroptosis, an alternative cell death pathway, which 
bypasses the apoptotic blockade in glucocorticoid resistant cells. 
Based on these observations it seems to be justified to go on using 
xenotransplantation as a way to expand the limited number of cells present at 
diagnosis and to use this assay as a tool to filter out relevant mechanisms of high risk 
leukemia biology.  
 
Can Engraftment Kinetics Predict Patient Outcome? 
 
A question often raised in the field is whether the engraftment in mice can reflect the 
course of disease in patients. In our work we found that the VHR-ALL group of 
patients had significant faster engraftment times (median 8 weeks) than the SR-ALL 
patients (median 13 weeks). Concordant with this, it was shown in NOD/scid mice 
that samples, which engrafted rapidly, were from patients with early relapses (Meyer 
2011). One can carefully propose that VHR-ALL samples with very unfavorable 
leukemia biology have been selected with genetic or epigenetic features that favor 
proliferation and engraftment in the xenograft model. On the one hand, extrinsic 
factors like the mouse environment, homing and different cytokines accessible, could 
force the selection. On the other hand, intrinsic factors to the patients’ more 
aggressive leukemia could be responsible for the faster engraftment. Interestingly, 
we observed an acceleration of the engraftment kinetics in the SR-ALL group of 
patients upon secondary transplantation. Secondary engraftment of these cases 
occurred with similar kinetics than for VHR-ALL samples (median 7 weeks), as VHR-
ALL secondary engraftments were not further accelerated. Remarkably, in three of 
five cases this acceleration correlated with the emergence of readily detectable new 
Ig/TCR gene rearrangements in the xenografts. It is possible that in VHR-ALL 
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dominant clones with higher proliferating abilities have already been selected and 
stably propagate in the mice whereas in SR-ALL higher degrees of clonal selection 
occur upon xenografting due to the absence of a dominant clone. Similar 
observations were made in BCR-ABL ALL xenografts where it was shown that the 
pattern of CNAs was more concordant in cases from fast engrafting patients and that 
these patients had a trend to shorter survival times (Notta 2011). 
 
Are Leukemia-Initiating Cells Rare? 
 
There is an ongoing debate whether ALL is following a hierarchic cancer stem cell 
model or rather a stochastic model. Our data (manuscript 1) and that of others 
(Rehe. 2009; Morisot 2010; Anderson 2010) challenge the hierarchic model which 
proposes that the leukemia is maintained from a subset of immature stem cells (Cox 
2009; Cobaleda 2000). We found that in four of six cases hundred VHR-ALL cells 
were sufficient to reconstitute leukemia in the NSG mouse strain, which suggests that 
the LIC compartment is not limited to a rare subpopulation of cells. However, in two 
cases of SR-ALL 100 cells were never sufficient. Similar LIC frequencies have been 
demonstrated by other groups for different subtypes of ALL (Morisot 2010; Rehe 
2009; Chiu 2010). Likewise, ALL cells from different maturation stages were shown 
to reconstitute the full leukemic phenotype in NSG mice. Thus, LIC activity is not 
limited to one certain subset of cells (le Viseur 2008). In addition, Strasser et al 
demonstrated in syngeneic mouse models that the frequency of leukemia cells with 
repopulating ability was as high as 1:10 and therefore LICs need not be rare (Kelly. 
2007). However, contradicting data comes from other groups who could show in 
different high-risk subtypes of ALL that LICs reside only in defined rare and immature 
subpopulations, like the hematopoietic stem cell-like CD133+ compartment or the 
CD34+/CD38- compartment (Cox 2009; Cox 2005; Cobaleda 2000). And for SR-ALL 
more mature CD19-positive compartments were proposed to contain the LIC activity 
(Castor 2005; Hong 2008). In future it will be interesting to see whether leukemias 
with a favorable outcome are associated with lower frequencies of LICs coming from 
more mature compartments.  
Some of these contradicting results might be attributed to the technical limitations of 
the xenografts system as was described above. More examples for differing results 
as a consequence of different experimental set-up come from melanoma, T-ALL and 
AML. The melanoma stem cell was at first described as a very rare cell, with a 
frequency of 1 in 106 using NOD/scid mice (Fang 2005; Dou 2007), but later 
Quintana et al showed that the frequency dropped to 1 in 4 using the more 
immunocompromised NSG mice (Quintana 2008). Also for T-ALL the influence of the 
model system was shown, as only T-ALL xenograft cells that were negative for the 
thymic maturation marker CD1a engrafted NOD/scid mice. Repeating this experiment 
in NSG mice, T-ALL engraftment was more efficient, with evidence also for 
engraftment of sorted CD1a positive T-ALL cells (Chiu 2010). And in AML the initially 
non-LIC population CD34+/CD38+ was indeed also able to initiate leukemia (Taussig 
2008). In the initial study the use of a certain anti-CD38 antibody led to clearance of 
the labeled cells in the mice and therefore led to the different interpretation of the 
results (Taussig 2008). These effects of residual immunologic functions and the 
xenogenic environment highlight the importance of the many factors contributing to 
successful transplantation assays. And it raises awareness for the fact that with 
xenotransplantation assays we are only looking at the reconstitution capacity in the 
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model chosen, but the situation for cancer stem cells in situ might be much more 
complex than that (e.g. interactions with microenvironment, trafficking to niche). 
We performed serial dilution analysis with unsorted samples as in most ALL cases, 
even extensive multicolor FACS strategies often do not result in the visualization of 
distinct subpopulations based on lineage maturation or stem cell markers, which 
limits the identification of an underlying hematopoietic hierarchy based on surface 
markers. Similarly, difficulties in finding markers that can discriminate subpopulations 
were observed in a study about melanoma propagating cells (Quintana 2008). 
Moreover, antibodies used for cell sorting experiments can increase clearance of 
sorted cells even in immunodeficient mice (Taussig 2008). An alternative could be 
the use functional markers of stemness, such as Aldehyde dehydrogenase (ALDH) 
activity. In our set of samples, we did not identify a consistent ALDH positive 
compartment and positivity did not correlate with a high frequency of LICs in the 
xenograft system. Also, we did not detect differences in NSG repopulation capacity 
when sorting cells based on ALDH activity (data not shown). In AML high ALDH 
activity has been proposed to be a stem cells marker in the CD34+CD38- 
compartment (Pearce 2005), but for normal mouse hematopoietic stem cell function 
ALDH activity was shown to be dispensable (Levi 2009). Taken together, we think 
that in VHR-ALL propagating cells are relatively frequent from the manifestation of 
the disease on and therefore VHR-ALL is intrinsically difficult to eradicate.  
 
Do Xenografts Filter for Resistant Subpopulations? 
 
To explore whether high-risk leukemias are intrinsically resistant or acquire 
resistance through mechanisms of clonal evolution or selection we investigated the 
genetic composition of VHR- and SR-ALL cases before and after xenografting. 
Overall, we observed a pattern reflecting the propagation of highly related clones.  
We performed SNP array analysis of six matched diagnostic, remission and 
xenograft samples. Only few, up to 8, copy number alterations (CNAs) were 
observed per sample, as is typical for ALL and was reported before in other datasets 
(Mullighan 2008a; Mullighan 2007; Mullighan 2008b), with the exception of one high-
hyperdiploid case which had more than 30 whole chromosome amplifications. Most 
of the aberrations were reported before in larger studies and only up to 4 changes 
were observed per matched diagnosis and xenograft sample (max. 2 new deletions, 
3 lost deletions, 2 new amplifications, 1 lost amplifications). These CNA changes 
occurred at loci recurrently detected in ALL and usually appeared already in the first 
amplification in the mice (Mullighan 2008a; 2007; Mullighan 2009). This 
demonstrates that changes in CNAs are most likely neither due to increased genetic 
instability in the xenograft system nor due to selective pressure from the xenogenic 
environment.  
Among the CNA changes occurring in xenografts, the p-arm of chromosome 9 was a 
recurrent target. In five of the six samples analyzed aberrations did occur. Deletions 
occurring on 9p are frequently detected in childhood ALL (Mullighan 2007; Novara 
2009; Heerema 2004; Mullighan 2008a). The genes involved are the B-cell 
development and cell-cycle regulators CDKN2A and CDKN2B, which seem to play a 
role in ALL pathogenesis, but their association to relapse is inconsistently described 
(Heerema 2004; Novara 2009). A study in adult BCR-ABL ALL showed that 
appearance of CDKN2A CNAs in xenografts was associated with a trend towards 
shorter survival times of the corresponding patients (Notta 2011). On the other hand, 
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in our cohort and other studies (Sherborne 2010; Sulong 2009) CDKN2A aberrations 
were found in samples from both high-risk and standard-risk subtypes of ALL.  
As the number of cases in xenograft studies is understandingly small and as there is 
a high heterogeneity in ALL subgroups with respect to their genetic features we 
cannot make a final conclusion of the importance of this finding for pathogenesis. 
Moreover, a change in CNA after xenografting could simply reflect a growth 
advantage in the xenogenic environment rather than the relevant mechanism to 
escape chemotherapy treatment. Nevertheless, with higher numbers and 
comparative studies including relapse samples the xenograft system could be used 
in future to filter out the driving events that lead to chemotherapy resistance and 
disease progression and to evaluate the effect of recurrent mutations especially with 
respect to clonal selection and drug resistance. 
 
Clonal Stability or Selection in Treatment Resistance? 
 
With further analysis of CDKN2A copy numbers on the single-cell level by 
fluorescence in-situ hybridization (FISH) we observed that the leukemogenic 
compartment is composed of several distinct clones rather than just one clone. We 
found nearly half of all patients with aberrations and most patients had various types 
of aberrations in distinct cells, speaking for clonal diversity within each patient. 
Sometimes we detected changes in the frequency of clones between diagnosis and 
xenografts (i.e. a different major clone at diagnosis and xenograft), indicating minor 
selection of subpopulations. And the analysis of clonal Ig/TCR rearrangements 
revealed loss of less prominent markers suggesting that most changes involve the 
loss of minor ALL subclones. Markedly, replica and serial xenografts and also 
xenografts from limiting dilution appeared almost the same regarding their genetic 
clonal composition, signifying that selection occurred during the first passage into 
mice and subsequent stability of the xenograft model.  
Other studies further underline our observation that the LIC compartment is 
oligoclonal. An in-depth study of the clonal composition in TEL-AML1 ALL by 
multicolor FISH with analysis of up to five genetic loci per cell found a complex 
genetic architecture with up to 14 distinct clones per leukemia (Anderson 2010). In 
addition, SNP analysis demonstrated the clonal diversity of adult BCR-ABL ALL 
(Notta 2011). Together, this data suggests that clonal selection may occur to a 
certain degree in the xenograft model, usually at the first passage in mice already, 
and that the overall similarity of the xenografted samples to the original diagnosis 
samples is high. The multi-clonal appearance of ALL may constitute the ground for 
clonal selection or evolution and treatment escape. In future, it will be interesting to 
investigate the clonal complexity during disease course to detect those clones that 
escape the chemotherapy treatment. 
 
Summary 
 
Collectively, the work performed in this thesis contributes to the understanding of the 
leukemogenic compartment of high risk ALL. We have established a leukemia 
xenograft model that enables to perform functional studies with samples that are 
relevant for translational research. Our findings and those of others demonstrated 
that LICs are relatively frequent and consist of a heterogeneous population. It 
appears unlikely to identify one unique subpopulation with repopulating potential and 
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thus we believe that ALL has, if at all, a flat hierarchy and the LIC compartment is 
oligoclonal. In the xenograft model, ALL samples were propagated as a dynamic 
multi-clonal population with highly conserved features after xenotransplantation. The 
limitations of the xenograft model are the reflections of multiple factors that influence 
engraftment, for example the homing capability, the self-renewal capacity and the 
interactions with the murine microenvironment.  
The multi-clonal appearance of ALL may constitute the ground for clonal selection or 
evolution and treatment escape. In future, it will be interesting to investigate the 
clonal complexity during disease course. Two approaches could be applied, the 
modeling of the MRD phase in the NSG mice by mild, non-curative treatment of 
transplanted animals or the engraftment of patient bone marrow samples from MRD 
measurements. To understand if the outgrowth of minor clones leads to relapses and 
if this can be modeled in the xenograft system we will need to study matched relapse 
and diagnostic material from patients that were initially classified in the standard risk 
group. 
The mouse xenograft system will enable to investigate the consequences of different 
types of interventions on the clonal composition of the disease. With the xenograft 
system we were able to show the effectiveness of a novel compound, obatoclax, to 
overcome the apoptotic blockade in glucocorticoid resistant ALL.  
Clearly, development of new therapeutic approaches will have to take into account 
that the whole leukemia population has to be eradicated to prevent the escape of 
single clones that might generate a relapse. These considerations also reinforce the 
importance of combination therapy, which is supported by decades of clinical 
research in oncology. The development of xenograft models of distinct clinical and 
genetic entities will greatly improve our capability to evaluate new treatment 
rationales. Based on the availability of the renewable source of relevant patient 
material that we generated, combinatorial treatment studies that take the clonal 
complexity of the disease in consideration can be conducted in future. 
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Xenografts of highly resistant leukemia recapitulate the clonal composition of the
leukemogenic compartment
Maike Schmitz,1 Petra Breithaupt,2 Nastassja Scheidegger,1 Gunnar Cario,2 Laura Bonapace,1 Barbara Meissner,2
Paulina Mirkowska,1 Joelle Tchinda,1 Felix K. Niggli,1 Martin Stanulla,2 Martin Schrappe,2 Andre Schrauder,2
*Beat C. Bornhauser,1 and *Jean-Pierre Bourquin1
1Division of Oncology and Children’s Research Center, University Children’s Hospital, University of Zurich, Zurich, Switzerland; and 2Department of Pediatrics,
University Hospital Schleswig Holstein, Kiel, Germany
Clonal evolution of the leukemogenic
compartment may contribute to alter the
therapeutic response in acute lympho-
blastic leukemia (ALL). Using xenotrans-
plantation of primary leukemia cells, we
evaluated the phenotypic and genetic
composition of de novo resistant very
high risk precursor B-cell ALL, a sub-
group defined by the persistence of mini-
mal residual disease despite intensive
chemotherapy. Analysis of copy number
alterations (CNAs) showed that the xeno-
grafted leukemia, even when reconsti-
tuted from 100 cells, remained highly
related to the diagnostic sample, with
minor changes in CNAs, mostly dele-
tions, emerging in most cases in the first
passage into mice. At the single-cell level,
the pattern of monoallelic and biallelic
deletions of the CDKN2A locus revealed
distinct leukemia subpopulations, which
were reproducibly tracked in xenografts.
In most very high risk ALL cases, the
predominant diagnostic clones were re-
constituted in xenografts, as shown by
multiplex polymerase chain reaction anal-
ysis of immunoglobulin and T-cell recep-
tor loci. In other cases, the pattern in
CNAs and immunoglobulin and T-cell re-
ceptor rearrangement was less concor-
dant in xenografts, suggesting the out-
growth of subclones. These results
unequivocally demonstrate the existence
of clonally closely related but distinct
subsets of leukemia initiating cells in
ALL, which has important implications
for drug development and preclinical dis-
ease modeling. (Blood. 2011;118(7):
1854-1864)
Introduction
For children with precursor B acute lymphoblastic leukemia (ALL)
that relapse on current intensive chemotherapy regimens, second-
line therapy is challenging.1 Diagnostic markers that are predictive
of poor treatment response are scarce, and modern treatment
protocols base risk stratification mostly on in vivo response to
treatment by monitoring persistence of minimal residual disease
(MRD) after induction chemotherapy.2 Using xenotransplantation
in mice, which provides new opportunities for functional investiga-
tion in ALL,3-7 we established a preclinical model of a subgroup of
patients with very high risk for relapse (VHR-ALL),8 as identified
by MRD.9,10
The genetic basis of resistant disease is ill defined. Single
nucleotide polymorphism (SNP) array analyses revealed that the
number of focal copy number alterations (CNAs) is limited to 6 to
8 CNAs per case in ALL.11 Studies in twins provide insight in the
possible sequence of events that are associated with progression to
overt disease from a common ancestral clone.7,12 The most frequent
CNAs in ALL involve master transcription factors regulating
lymphoid development, such as Ikaros family and tumor suppres-
sor genes of the INK4A/CDKN2A/B locus that may represent tumor
driving events. Surprisingly, only a limited number of additional
changes were detected at relapse, often related to a minor subpopu-
lation in the matched diagnostic sample.13,14 A candidate gene
sequencing approach has identified mutations in several genes in
relapsed ALL, mostly detectable in matched diagnosis samples
already, sometimes only in minor subpopulations.15 Thus, leukemia
progression does not appear to be associated with a high degree of
ongoing genetic instability in ALL but rather with clonal evolution
and selection of a limited number of genetic lesions.
Several reports based on xenotransplantation of ALL in NOD/
SCID mice have led to the hypothesis that ALL may be maintained
from a rare subpopulation of leukemia initiating cells (LICs).4,16
This concept has been challenged by observations in syngeneic
mouse models that indicated a much higher frequency of ALL cells
with repopulation capacity17-19 and by the observation that both
sorted leukemia cells from immature (CD19/CD34) and from
mature (CD19/CD34) ALL compartments exhibited comparable
leukemia repopulating capacity in NOD/scidIL2Rnull (NSG)
mice.5,18,19 Furthermore, 2 most recent studies provide clear
evidence for a dynamic pattern of clonal diversity of the LIC
compartment in TEL/AML1-positive ALL20 and BCR/ABL-
positive leukemias.21 Clonal evolution of the leukemogenic com-
partment may contribute to disease progression and resistance to
therapy.
Here we provide important new functional and genetic data to
support the notion that the LIC in ALL consists of highly related
subclones that evolve with distinctive additional genetic lesions
and that the clonal composition of bulk VHR-ALL samples can be
stably propagated by xenotransplantation to constitute a renewable
source of leukemia cells, closely related to the original sample. Our
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results justify the use of unsorted samples to model disease in this
system and provide new avenues to investigate the consequences of
therapy on the composition of the LIC compartment and disease
progression.
Methods
Details can be found in supplemental Methods (available on the Blood Web
site; see the Supplemental Materials link at the top of the online article).
Patient samples
ALL cells were recovered from cryopreserved anonymized bone marrow
aspirates from patients enrolled in the ongoing ALL-BFM 2000 study and
had given informed consent in accordance with the Declaration of Helsinki.
Approval was obtained from the Institutional Review Board of the Medical
School Hannover and the local Institutional Review Board for all participat-
ing centers in the trial ALL-BFM 2000. Samples were anonymized with
labels that refer to the clinical risk stratification. Depending on the MRD
result during induction therapy (MRD1  2) and during consolidation
therapy (MRD3), patients are defined here as: standard risk (SR) if
MRD1  2 was negative, high risk (HR) if MRD1  2 was positive less
than or equal to 103, and VHR if HR patients were still positive for MRD3
(supplemental Table 1). Cases are anonymized with a label according to the
risk group and with a unique number.
Xenograft model
Primary ALL cells were recovered from cryopreserved presentation samples
by scraping the required amount of cells with a sterile scalpel from the
cryotube kept on dry ice, washed in phosphate-buffered saline, and
transplanted intrafemorally into NSG mice. Unless stated otherwise,
1 million viable cells were transplanted (as assessed by trypan blue
exclusion, supplemental Table 2). Engraftment was followed every 3 to
4 weeks (supplemental Table 2) by flow cytometry in the peripheral blood
of transplanted animals, using mouse-specific, anti-CD45 combined with
human-specific anti-CD45 and anti-CD19 antibodies. Xenografts are
labeled with identifiers corresponding to the anonymized patient sample.
This labeling system is used consistently for publication. For each
xenograft sample, information about the transplantation and identification
of the mouse is recorded in our database for later reference.
Flow cytometry
Immunophenotype analyses of primary ALL samples at diagnosis and of
xenograft samples were performed as described.22
Affymetrix Genome-Wide Human SNP Version 6.0 microarrays
DNA from paired primary leukemic and remission samples as well as
matching DNA from xenografts were hybridized on Affymetrix Genome-
Wide Human SNP Version 6.0 microarrays according to the manufacturer’s
protocols (performed by Atlas Biolabs).
Raw intensity data were analyzed using Affymetrix Genotyping Con-
sole for quality control and generation of genotype calls. Paired DNA copy
number and paired loss of heterozygosity (LOH) were analyzed using the
Partek Genomics Suite software (Partek Incorporated).
Fluorescence in situ hybridization
Cryopreserved cells were thawed and fixed with methanol/acetic acid (3:1).
A total of 2000 cells were dropped per slide for fluorescence in situ
hybridization (FISH) with the LSI CDKN2A Spectrum Orange/CEP9
Spectrum Green FISH Probe Kit (Vysis/Abbott). The LSI CDKN2A probe
hybridizes to the 9p21 locus, including CDKN2A/B. Slides were hybridized
and evaluated as described.23
Analysis of clonal Ig/TCR rearrangements
Detection of patient-specific junctional regions of Ig and TCR genes was
performed following the protocol established for the clinical follow-up
analyses of MRD, which has been established and validated by an
international study group and is reported in several publications (supplemen-
tal Table 3), summarized by van der Velden et al.24
Results
Reconstitution of de novo resistant ALL is faster than SR ALL
in NSG mice
To model the relevant risk groups that emerge from in vivo
response to treatment,9 samples from 17 cases with de novo
resistant VHR disease (VHR-ALL by MRD) and from 15 cases
with SR ALL (SR-ALL, control group) were selected from the
repository of the ALL-BFM-2000 study25 and transplanted into
NSG mice (supplemental Table 1), extending our initial series.8 We
also included 4 cases with HR ALL. Using orthotopic intrafemoral
transplantation without conditioning, engraftment rates of  70%
were observed. A total of 1 million viable cells, as determined by
trypan blue staining and microscopy, were injected unless stated
otherwise at first passage in NSG mice (supplemental Table 2). In
3 cases, less cells were available (0.3-0.7 million). In these cases,
engraftment was not delayed compared with the median time of the
respective risk group. Subsequent passages were performed consis-
tently with injection of 1 million cells. Reconstitution of the
leukemia occurred faster in mice transplanted with VHR-ALL
cases (median of  75% of patients engrafted at 8 weeks) than in
animals transplanted with SR-ALL cells (median of  75% of
patients engrafted at 20 weeks, P  .05; Figure 1A). All leukemias
that were retransplanted (24 of 28 samples, supplemental Table 2)
repopulated secondary recipient animals with high engraftment
levels in bone marrow and spleen, demonstrating conserved NSG
repopulating capacity. Strikingly, the time to engraftment was
decreased in the second passage in NSG mice for most cases with
SR-ALL (median engraftment time, 13.25 weeks for primary
transplants vs 6.5 weeks for secondary transplants, P  .01),
whereas it was unchanged for VHR-ALL cases, suggesting that
leukemia cells from de novo drug-resistant cases are more adapted
to overcome the xenograft barrier compared with SR-ALL (Figure
1A-B). Xenografted VHR-ALL cells were serially passaged up to
6 times in mice with reconstitution of the full phenotype in mice
(Figure 1B; supplemental Table 2). Very high yields of ALL cells
were recovered from spleens (Figure 1C). Clinical symptoms of
central nervous system disease (eg, palsy or exophthalmoses) were
not detected (data not shown). As supported also by others,3,5,18
these data indicate that xenotransplantation can serve to amplify
normally rare primary ALL cells and as model to study resistant
disease, provided the consequences of selective pressure from the
xenograft barrier are better understood.
ALL xenografts retain phenotypic properties of the
diagnostic samples
Alteration of the microenvironment has been shown to influence
the leukemia phenotype in a model of MLL rearranged leukemia.26
Because passage in NSG mice could influence the pattern of
leukemia-associated cell surface markers with respect to matura-
tion and differentiation stage, we compared the immunophenotype
of xenografts after successive passages in NSG mice to the
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diagnostic sample using the same panel of antibodies for 5 cases for
which sufficient material was available (Figure 2; supplemental
Table 4A). In addition, we compared the immunophenotypes of
11 additional cases from xenografts to the diagnostic data from the
reference laboratory of the BFM study (supplemental Table 4B). In
general, the expression of the lineage-associated cell surface
markers CD45, CD19, CD10, CD20, CD22, CD38, and CD34, and
the pattern of CD7, CD13, CD33, and CD117 coexpression were
very similar. Discrepancies were detected in single xenografts in
some cases for the markers CD33 (6 of 16), CD20 (3 of 16), CD34
(3 of 16), CD22 (3 of 15), CD13 (2 of 15), CD117 (1 of 14), CD7
(1 of 15), and CD45 (1 of 16). We may slightly overestimate
discrepancies in the 11 cases where direct comparison based on the
same antibody panel was not available. These changes may reflect
minor differences after selection in NSG mice in the context of a
xenogenic environment. Based on these observations, it appears
justified to continue to immunophenotype xenografts as part of the
validation of this preclinical model system.
Because VHR-ALL patients are identified based on persistence
of significant MRD loads in vivo and given an earlier study
correlating in vitro drug resistance patterns to outcome for ALL,27
we hypothesized that a major phenotypic feature of VHR-ALL
would be resistance to multiple chemotherapeutic agents in vitro.
To better reflect the protective bone marrow niche, which contrib-
utes to drug resistance in different models,28,29 we assayed drug
response profiles of xenograft cells cocultured on immortalized
human mesenchymal stroma cells.8,30 Xenografts of SR-ALL cells
were sensitive to chemotherapeutic agents used for induction
chemotherapy (daunorubicine, vincristine and cytarabine), with
one exception (SR-02 was not responsive to cytarabine). In
contrast, VHR-ALL cells were at least 10-fold less sensitive to
these 4 drugs, and resistance to dexamethasone correlated with
poor response to prednisone in vivo (Figure 3; supplemental
Table 2).8 Drug response profiles remained mostly unchanged over
up to 2 passages in NSG mice for SR-ALL cells and up to
4 passages for VHR-ALL cells (Figure 3; supplemental Table 2).
These results extend findings from our earlier study,8 where some
of these samples were used to test for obatoclax-induced steroid
resensitization of VHR-ALL samples. In addition, we show that the
drug response profiles remain stable over serial transplantation.
Our results indicate that an adaptation to the mouse environment
rather than a selection of ALL cells that are intrinsically more
resistant to chemotherapeutic agents might be responsible for the
acceleration of engraftment in cells from SR patients.
LICs are frequent in xenografts of VHR-ALL samples
For many applications of the ALL xenograft model, it will be
important to better understand the hierarchy in the malignant
hematopoietic tissue with respect to its LIC compartment. Indeed,
in analogy to other forms of leukemia,31 it is conceivable that a
restricted compartment of LIC could constitute a reservoir of
resistant cells. To functionally evaluate the LIC compartment, we
performed serial dilution experiments by intrafemoral injection of
ALL cells in NSG mice. In 4 of 6 VHR-ALL cases, 100 xenograft
cells were sufficient to fully reconstitute the leukemia without
conditioning the mice (Table 1; supplemental Table 5). Flow
cytometry analyses of the leukemia-associated cell surface markers
revealed complete conservation of the immunophenotype of the
leukemia cells resulting from transplantation with 100 cells (supple-
mental Figure 1). Our results are in line with similar observations
by others for precursor B-ALL32 and T-ALL.33 We included
samples from SR-ALL patients and cryopreserved primary ALL
cells whenever available. Overall, 10 000 xenograft VHR-ALL
cells were enough to repopulate leukemia in all cases, despite the
xenograft barrier (Table 1; supplemental Table 5). Together with
other reports,32-34 our data suggest that the LIC frequency could be
higher than initially anticipated in ALL.
Xenografted ALL cells are clonally highly related to the
corresponding diagnostic sample
Given the occurrence of multiple genetic aberrations in ALL and
the evidence for a prenatal origin for certain genetic subtypes of
ALL with the acquisition of additional CNAs, even before the
leukemia becomes clinically apparent,7 it is possible that leukemia
samples will be constituted by a pool of related subclones.
Extensive studies have established that in most ALL cases a limited
number of in part recurrent CNAs can be identified.11,14 Concor-
dance of genetic aberrations detected by SNP analysis in xenograft
samples compared with diagnostic samples was suggested to
Figure 1. Engraftment characteristics over serial
transplantation of primary ALL cells in NSG mice.
Cryopreserved diagnostic material was thawed, and
1 million cells were transplanted by intrafemoral injection
into NSG mice 6 to 10 weeks of age. Mice were checked
every 4 weeks by flow cytometry for human engraftment.
Positive engraftment was defined as  1% human CD19/
CD45-positive and mouse CD45-negative cells in the
peripheral blood. (A) Analysis of the time to engraftment
for 9 VHR-ALL (black) and 13 SR-ALL (gray) patients.
The time to engraftment in weeks is plotted for primary
(solid lines) and secondary (dashed lines) transplanta-
tions. Statistical evaluation was performed with the log-
rank test and indicates significant differences for the time
to engraftment between VHR-ALL and SR-ALL (P  .05)
and between primary and secondary transplantation for
SR-ALL (P  .01). (B) Time to engraftment was analyzed
for 7 VHR-ALL patients with up to 6 rounds of serial
passages. (C) Number of cells harvested from spleens
per mouse at death, when the percentage of human cells
in the peripheral blood reached 70%. The mean value
was 500 million for VHR-ALL and 650 million cells for
SR-ALL xenografts (indicated as horizontal line).
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correlate to some extent with poor survival in BCR/ABL-positive
ALL.21 To get insight into the genetic stability of xenografts on
serial passage in NSG mice, we performed genome-wide copy
number and LOH analysis using Affymetrix SNP Version 6.0 arrays.
We compared diagnostic and remission samples of 6 ALL patients
with the corresponding samples after serial transplantation in NSG
mice (Figure 4; supplemental Table 6). As expected, a low number
of focal CNAs ( 100  1000 kb) and whole arm or total chromo-
some abnormalities were detected in the diagnostic samples, most
of them previously reported in larger studies. In all cases, CNAs
corresponding to expected Ig and TCR gene rearrangements were
stably detectable over serial transplantation. Only in one case
(VHR-04), an additional CNA corresponding to an incomplete
rearrangement of the Ig  (IgL) occurred (Table 2; supplemental
Table 6).
We found up to 8 CNAs (deletions and amplifications) and
copy neutral LOHs (cnLOH) ranging in size from single gene
aberrations to chromosome whole arm deletions/amplifications
at diagnosis, with the exception of one high-hyperdiploid patient
who had 30 whole chromosome amplifications. On passage into
Figure 2. Primary human ALL cells are phenotypically stable in serial xenotransplantation. The immunophenotype of 2 representative cases was determined in the
same experiment on cryopreserved diagnostic cells and cells from multiple serial passage in NSG mice. Xenografts from 5 passages were analyzed for case VHR-03 (A) and
2 passages for case SR-09 (B). At least 10 000 viable cells were gated based on forward-side scatter properties, and histograms representing number of events versus signal
intensity are shown.
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NSG mice, all but 6 lesions found in the diagnostic samples
were maintained (Table 2). In one case (VHR-02), a deletion of
the FBXW7 gene at 4q31.3 was lost after transplantation;
whereas in VHR-03, deletions at 1q42, the whole 9p arm, and
14q12, which were detected in the diagnostic sample, were not
found in corresponding xenografts. Analysis of copy number
Figure 3. Drug response profiles of xenografts remain stable. Xenograft cells from up to 4 passages from 3 VHR-ALL (A) and 4 SR-ALL (B) were cocultured on
hTERT-immortalized mesenchymal stroma cells and treated for 3 days with increasing concentrations of chemotherapeutic agents. Drug concentrations (in nanomolar) are
given on the x-axis in a log scale. Measurement of ALL cell survival using 7-AAD and flow cytometry and compared with vehicle-treated controls revealed conserved resistance
profiles. DEX indicates dexamethasone; VCR, vincristine; DNR, daunorubicin; andAraC, cytarabine. Experiments were performed twice, and one representative example is shown.
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ratios indicated that subclones were present in the diagnostic
samples harboring these deletions, which were lost in the first
round of transplantation. Two amplifications, one in sample
SR-02 that involves 7p21 with no known gene detected in the
diagnostic sample and one in sample HR-03 at 9p, present in a
subclone at diagnosis, were not detected in xenografts.
In addition to that, only few lesions occurred in xenograft
samples that were not detected in the corresponding diagnostic
sample, namely, up to 2 deletions and up to 2 amplifications per
sample (Table 2; Figure 4; supplemental Table 6). Deletions at
9p loci are frequent in childhood ALL11,35,36 and proposed to be
associated with poor risk. In 3 of the 4 analyzed VHR cases,
additional deletions detected in xenograft but not in diagnostic
samples occurred at 9p, involving genes that control B-cell
development, such as CDKN2A and CDKN2B. Xenografts of
VHR-01 had a deletion of the whole 9p chromosome arm; whereas
in VHR-02, 2 focal deletions only deleted CDKN2A and B, along
with the C9orf53-gene at 9p21.3, and the ZCCHC7 gene at 9p13.2,
respectively. Last, a homozygous deletion at 9p21 and LOH over
the whole 9p arm was present in xenografts of VHR-03 also present
Figure 4. Genetic lesions remain stable in xenograft cells. A copy number heat map was produced from log2 ratio Affymetrix SNP Version 6.0 analyses of 6 ALL patients and
their corresponding xenografts of up to 3 subsequent amplification rounds.All CNAs of  100 kb in size were included, also showing Ig/TCR gene rearrangements. Dx indicates diagnostic
sample; and 1st, 2nd, and 3rd indicates first, second, and third amplification round, respectively. *The xenografts were obtained from transplantations with 100 cells.
Table 1. Serial dilution of 4 VHR-ALL xenografts by intrafemoral and
intravenous transplantation
Patient
Round of
transplantation
Cell
dilution
Intrafemoral
engrafted/
total
Intravenous
engrafted/
total
Mean
engraftment
in bone
marrow, %
VHR-01 Second 1 000 000
10 000
100*
2/4
3/3
2/3*
3/3
3/3*
0/3
88
86
96
VHR-02 Third 1 000 000
10 000
100*
1/2
3/3
2/3*
2/3
1/3*
0/3
94
97
90
VHR-03 Third 1 000 000
10 000
100*
2/2
2/2
1/2*
2/2
2/2*
0/2
94
97
77
VHR-04 Second 1 000 000
10 000
100*
2/2
1/3
1/3*
2/3
2/3*
0/3
99
99
99
Four VHR-ALL patients from different amplification rounds were transplanted
intrafemorally and intravenously. Engraftment was considered positive when 1% of
human CD19/CD45 mouse CD45 cells were detected in peripheral blood by flow
cytometry, and spleens and bone marrows were engrafted at harvest.
*Lowest dilution that resulted in engraftment.
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as subclone in the diagnostic sample. However, a complete deletion
of the whole 9p arm was detected in a fraction of the cells at
diagnosis as suggested by the analysis of copy number ratios
(Table 2; Figure 4; supplemental Table 6).
Other CNAs emerging in xenografts were detected for VHR-01
at 12p13 (cnLOH, including ETV6) and at 22q (whole arm
amplification), for VHR-03 at 7q22 deleting the gene for PIK3CG,
for VHR-04 at 22q11 the locus of the IgL rearrangement including
VPREB1, and for SR-02 at 1q23 (genes for F11R and ITLN2). In
xenografts of SR-02, amplifications at 3q22 (ALG1L2) and 1p36
(genes for CROCCL1, ESPNP, MST1P2, MST1P9, and NBPF1)
were also found. Interestingly, xenografts that were derived from
an HR patient with BCR-ABL positive and high-hyperdiploid
leukemia were remarkably stable but showed an additional amplifi-
cation of the BCR-ABL fusion gene. With the exception of the
abnormalities at 20p and 14q12, these have been described11,14 to
occur in ALL samples, suggesting that these abnormalities are not
selected for randomly in NSG mice (Table 2; Figure 4; supplemen-
tal Table 6).
To evaluate the genetic stability from passage to passage in the
mice, we looked at cells from 2 passages in duplicates and
transplanted at limiting dilution with only 100 cells. Interestingly,
we observed that differences between diagnostic and xenografted
material were present in all mice of all passages and in serial
dilution cases with the exception of 2 mice from VHR-03 where the
deletion at 7q22 was not detectable (Figure 4; supplemental
Table 6). Taken together, these observations suggested that clonal
selection may occur to some degree, mostly during the first
xenotransplantation already, but that overall the xenograft samples
are highly related to the original diagnostic samples.
Persistence of dominant subclones with deletions at the
CDKN2A/B locus in xenografts
Given the frequent occurrence of CNAs on chromosome 9p and
evidence for the acquisition of additional lesions in this region
in xenografts, we performed FISH to assess the clonal heteroge-
neity with respect to deletions in 9p21 (including the gene for
CDKN2A and CDKN2B) at the single-cell level. We detected
9p21 deletions in subclones in most of the xenograft cases, and
these subclones were predominant in 10 of 24 cases (supplemen-
tal Table 7). To assess differences between primary samples and
xenograft cells, we included matched diagnostic samples from
9 ALL cases, including those from which SNP data were
available (Figure 5; supplemental Table 7) and those that
showed 9p21 deletions in the xenograft sample. As expected, we
detected the existence of subpopulations with respect to their
heterozygous or homozygous 9p21 deletion status. In all but one
case, the major subclone was maintained in xenografts, although
with relative changes in the distribution of respective subclones
in some instances. As exception, xenografts of VHR-01 selected
for heterozygous deletion of 9p, which was present as minor
subclone at diagnosis. In 3 samples (VHR-01, SR-09, and
SR-11) clones with heterozygous 9p21 deletions became pre-
dominant, indicating selection for heterozygous events. In
addition, SR-11 xenografts further showed a gradual shift
toward heterozygous and homozygous clones on serial transplan-
tation (Figure 5). The existence of subclones with differences at
the 9p21 locus have been described in cytogenetic reports but, to
our knowledge, has not been evaluated carefully with respect to
its importance in the evaluation of the clonal compartment in
ALL.23,37 Our data show that xenotransplantation results in only
Table 2. Changes in CNA between diagnosis and xenograft
Sample Gain or loss of CNA Cytoband
Copy
number Overlapping genes
Overlapping
miRNAs
Lesions detected only in xenografts,
not in matched diagnostic samples
VHR-01 Gain
Gain
Gain
9p
12p13
22q
Deletion
cnLOH
Amplification
Many
Many, including ETV6
Many
7
4
26
VHR-02 Gain
Gain
9p21.3
9p13.2
Deletion
Deletion
C9orf53, CDKN2A,
CDKN2BAS, CDKN2B
Intron of ZCCHC7
None
None
VHR-03 Gain 7q22.3 Deletion PIK3CG None
VHR-04 Gain 22q11.22 Deletion VPREB1, IgL hsa-miR649
SR-02 Gain
Gain
Gain
1p36.13
1q23.3
3q22.1
Amplification
Deletion
Amplification
CROCCL1, ESPNP, MST1P2,
MST1P9, NBPF1
F11R, ITLN2
ALG1L2, LOC729375
None
None
None
HR-03 Gain
Gain
9q34.11; 22q11.23
1q
Amplification
Amplification
BCR-ABL1, many
Many
13
45
Lesions not detected in xenografts,
only in matched diagnostic samples
VHR-02 Loss 4q31.3 Deletion 20.34% of FBXW7 hsa-miR3140
VHR-03 Loss of CNA in subclone
Loss of CNA in subclone
Loss of CNA in subclone
1q42.11-1q42.13
9p
14q12
Deletion
Deletion
Deletion
Many
Many
AP4S1, C14orf126, COCH,
HEATR5A, HECTD1,
MIR624, STRN3
3
7
None
SR-02 Loss 7p21.3 Amplification None None
HR-03 Loss of CNA in subclone 9p Amplification Many 7
CNAs that changed from diagnosis to xenograft material (additional/lost deletions, amplifications, and cnLOH) are presented. If  10 genes or 3 miRNAs were in one CNA,
it was noted as many or the number was listed.
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limited changes overall; however, shifts in the distribution of
subclones with respect to particular lesions do occur, indicating
that selection of preexisting subclones does occur.
A dominant pattern of Ig/TCR rearrangements is propagated in
VHR-ALL xenografts
To detect significant changes in the clonal distribution in ALL, we
took advantage of the standardized polymerase chain reaction
(PCR)-based methodology to detect clonal specific rearrangements
of the Ig and TCR genes in ALL xenografts.25 In 10 of 14 patient
samples analyzed, composing primary up to quaternary xenografts
of VHR- and SR-ALL samples, the 2 markers that were used for
MRD follow-up in the patients remained stable in the xenografted
samples (supplemental Table 8). In 4 cases, one or both of these
MRD markers could not be detected after transplantation. This is
reminiscent of a large clinical study that reported the loss of both
diagnostic MRD markers at relapse in 11% of patients.38 We then
screened 10 cases (5 VHR-ALL and 5 SR-ALL) systematically for
the presence of 23 clonal specific Ig/TCR rearrangements in the
diagnostic and corresponding xenografts, looking at replica from
the same passage number and at serially passaged xenografts
(Figure 6). We sequenced all detected bands of the expected size to
verify accuracy of the PCR on xenograft material at least once. Two
representative examples are shown in Figure 6A, and a summary of
all data is represented in a schematic form (Figure 6B; supplemen-
tal Figure 2). Overall, the pattern of expected Ig/TCR rearrange-
ments was remarkably stable. In a representative VHR-ALL
sample (Figure 6A), 5 markers were stably detected in both the
diagnostic and in xenograft samples (boxed in orange in Figure 6A),
whereas 4 markers were lost in at least one of the xenograft samples
(boxed in red in Figure 6A). In general, a similar pattern of
dominant markers could be detected in all xenograft passages,
whereas additional markers were lost to a variable degree in
xenografts (Figure 6B). Interestingly, in 3 of 5 SR-ALL samples,
1 or 2 new Ig/TCR rearrangements emerged in xenograft samples
(Figure 6B). For instance, in SR-9, one new rearrangement was
detected as a strong PCR fragment in primary and secondary
xenografts, but not in the diagnostic sample (Figure 6A). Interest-
ingly, samples with the appearance of new Ig/TCR rearrangements
(SR-9, SR-12, and SR-13) showed the greatest acceleration in
engraftment from primary to secondary passage (11 vs 4 weeks,
14 vs 3 weeks, and 28 vs 5 weeks; supplemental Table 2). Whether
these rearrangements preexisted in minor subclones at diagnosis or
occurred during propagation of the disease in mice cannot be
determined based on these data. The Ig/TCR patterns detected in
leukemia reconstituted from 100 unsorted cells (VHR01-04) were
comparable to the patterns obtained from bulk transplanted samples
(Figure 6B). This analysis reinforces the notion that the LIC
compartment contains related but distinct clonal subpopulations
with a dominant pattern selected in NSG mice.
Taken together, our results indicate that the LIC compartment in
ALL is large and consists of a mixed population of related
subclones. Expansion in NSG mice is associated with clonal
evolution to some extent, as there were corresponding subclones
present in the diagnostic samples from which xenografts were
derived. In many instances, selection appears to occur with the first
passage and the patterns of genetic markers remain sufficiently
stable to use the xenograft system to model disease.
Discussion
Understanding the nature of the leukemia propagating cell compart-
ment in resistant ALL will greatly impact on the design and
Figure 5. Interphase FISH analysis of 9p21 (CDKN2A) lesions
reveals the existence of genetically distinct subclones. The
clonal composition of ALL samples was analyzed using dual-color
FISH probes against 9p21 (CDKN2A, red) and the centromer of
chromosome 9 (CEN9, green) as control in samples from diagno-
sis and corresponding xenografts. (A) Representative images are
shown, indicating wild-type cells with no deletion in the 9p21 locus
(left), a heterozygous deletion (middle), and a homozygous
deletion (right). (B) The clonal distribution was analyzed in
samples from up to 6 rounds of serial transplantation. A total of
200 cells were counted in each sample. The original data are
reported in supplemental Table 7. ALL cells with germline,
heterozygous deletion, and homozygous deletions are repre-
sented by colored dots of size proportional to the percentage of
cells in each category in relation to the total cell number as
indicated in the legend. One case, VHR-01, shows clonal selec-
tion toward additional deletions at this locus, whereas the 4 other
cases analyzed are more stable with respect to the clonal
composition based on this genetic feature. Original magnifica-
tions 40 (Leica LX Widefield Microscope DMI6000B with the
DFC 350 FX R2 camera).
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experimental evaluation of new treatment rationales. We estab-
lished a xenograft model with diagnostic samples from patients
with highly resistant disease based on in vivo response to treat-
ment, which remains the strongest predictor of poor outcome in
ALL.9 Here we provide compelling evidence to propose that both
chemoresistant and chemosensitive ALL consist of highly related,
albeit genetically diverse, clonal subpopulations. These results
corroborate with contemporary studies of ETV6-RUNX1–positive
ALL20 and BCR-ABL–positive ALL21 and imply that ALL can be
propagated as dynamic multiclonal populations of LICs. Function-
ally, the analysis of both serial and replica xenografts from several
independent diagnostic samples reveals that genetically distinct
subclones have different NSG repopulation capacity, suggesting
selection of properties conferring selective advantages in NSG
mice. In many instances, a pattern reflecting the propagation of
highly related clonal populations was detected. Only minimal
changes in CNAs occurred, mostly in chromosomal regions that
were previously reported in ALL, which indicates that these change
are neither the result of increased genetic instability, nor specifi-
cally the result of selective pressure from the xenogenic environ-
ment. The analysis of clonal Ig/TCR rearrangements revealed loss
of less predominant markers, suggesting that most changes may be
inferred to the loss of minor ALL subclones.
Some differences emerge between highly resistant VHR-ALL
and chemosensitive SR-ALL cases. Most notable is the accelera-
tion of the engraftment kinetics with the second passage into mice,
which correlates in 3 of 5 cases with the emergence of readily
detectable new Ig/TCR rearrangements. It is tempting to speculate
that, in VHR-ALL patients with a very unfavorable leukemia
biology, ALL clones have been selected with genetic or epigenetic
features that favor engraftment and proliferation in a xenogenic
environment. This could explain the propagation of dominant
subclones of leukemia cells for VHR-ALL in NSG mice. Similarly,
in selected cases of BCR-ABL ALL xenografts, the pattern of
genetic lesions was more concordant in cases that engrafted mice
readily, which was associated with a trend toward shorter survival
times in patients.21 Strikingly, this was strictly associated with
additional deletions in the CDKN2A/B locus in BCR-ABL ALL
xenografts. In our series, the occurrence of additional deletions at
this locus was also observed but occurred both in SR-ALL and
VHR-ALL cases. Although genome-wide association studies clearly
implicate the CDKN2A/B locus in the pathogenesis of ALL,39 the
prognostic value of deletions of this locus in ALL is less clear, as
the association with relapse is inconsistent.40 Given that the number
of cases included in such xenograft studies is necessarily small and
the ALL subgroups compared heterogeneous with respect to their
underlying genetic features, we remain cautious with the interpreta-
tion of these results. Moreover, the relevant mechanisms to escape
the selective pressure of chemotherapy may not necessarily overlap
with factors that favor engraftment in a xenogenic environment.
Indeed, knowing that in many cases the pattern of clonal-specific
genetic markers are dominant over several passage in NSG mice, it
will be possible to study the consequences of selective pressure by
therapeutic agents or interference with microenvironmental factors
with the xenograft system in vivo. As such, this model may be
useful to functionally identify driving events that lead to disease
progression and resistance to treatment. In particular, the xenograft
model may provide the means to evaluate the effect of recurrent
Figure 6. Analysis of Ig/TCR rearrangements reflects
the evolution of the clonal compartment in xeno-
grafts. The Ig/TCR rearrangement pattern of diagnostic
samples and matched xenografts was determined in
5 VHR- and in 5 SR-ALL samples by PCR using
standardized sets of primers that are validated for MRD
analysis. (A) Representative examples for a VHR-ALL
(left panel) and an SR-ALL (right panel) sample, which
showed a marked acceleration from primary to second-
ary passage. All positive bands of the correct size were
sequenced once for verification. Stable rearrangements
are framed with an orange line; and bands framed in red
represent markers that disappeared in xenografts. In
this SR sample, one new Ig/TCR rearrangement ap-
peared (framed in green). (B) Overview of Ig/TCR
rearrangements detected. Detected Ig/TCR rearrange-
ments are highlighted in blue. Loss of such a marker in a
given xenograft is highlighted in red. Newly detected
markers in xenografts are highlighted in green.
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mutations that are more frequently detected at relapse in ALL with
respect to clonal selection and drug resistance.15
Our data, together with recently published evidence20,21 show-
ing that the leukemogenic compartment is composed of genetically
distinct albeit related clones, challenge the hierarchic model, which
proposed that the leukemia is maintained from a subset of
immature stem cells.16 Our findings that 100 VHR-ALL cells are
sufficient to reconstitute leukemia in NSG mice, a strain that is
more permissive for lymphoid cells,41 suggests that leukemia
propagating cells are not restricted to a rare subset of cells. Similar
LIC frequencies were reported for other ALL subtypes.20,21,33
Likewise, the fact that sorted ALL cells reconstitute immunodefi-
cient mice efficiently independent of their immuno-differentiation
status5,20 supports this notion. In the absence of markers to enrich
for NSG repopulating capacity, definitive conclusions with respect
to the hierarchy of LIC in ALL have to be deferred. Our limiting
dilution experiments indicate that primary diagnostic samples
engraft at a lower frequency than samples that were previously
established in NSG. These results may be influenced by differences
in cell viability in the stored primary patient samples. However, the
trend to accelerated engraftment that we observed with samples
from chemosensitive patients on the second passage in NSG
suggests that selection for better NSG repopulating capacity occurs
in some cases. But the xenograft assay is a reflection of combined
functions, which include self-renewal capacity, but also homing
and protective interactions with the recipient microenvironment.
Further improvements of humanized immunodeficient mouse strains
may contribute to clarifying this issue.42 Given 2 other reports that
imply an association between NSG repopulation kinetics and
adverse outcome,21,43 prospective and detailed investigation is
warranted to understand whether leukemia with a more favorable
biology is associated with lower frequencies of LIC and to dissect
the nature of the selective advantages in HR leukemias. Studies of
relapses cases from patients that were classified in the SR group at
initial presentation using the xenograft system will be needed to
understand whether outgrowth of minor subclones may be clini-
cally relevant in this setting.
Taken together, our results demonstrate that the clonal composi-
tion of leukemia samples from patients with highly resistant
disease remains remarkably stable on serial passage in NSG mice.
Based on available data, it is probable that a larger proportion of
ALL cells are leukemogenic. The oligoclonal or even polyclonal
nature of ALL may confer the ground for clonal selection/
progression to escape chemotherapy. The mouse xenograft system
will enable to investigate the consequences of different types of
interventions on the clonal composition of the disease. Clearly,
development of new therapeutic approaches will have to take into
account that the whole leukemia population has to be eradicated for
successful treatment. These considerations also reinforce the
importance of combination therapy, which is supported by decades
of clinical research in oncology. The development of xenograft
models of distinct clinical and genetic entities will greatly improve
our capability to evaluate new treatment rationales. With this
renewable source of relevant samples, combinatorial studies can be
performed taking the clonal complexity of the disease into
consideration.
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Supplementary methods 
 
 
Reagents 
FITC-labeled anti-human CD7, FITC-labeled anti-human CD20, FITC-labeled anti-human CD34, PE 
and PE-AlexaFluor750-labeled anti-human CD19, Alexa 647-labelled anti-mouse CD45, and RPE-
Alexa 750-labelled anti-human CD45 antibodies were from AbD Serotec. APC-labeled anti-human 
CD22, APC-labeled anti-human CD38, PerCP-Cy5.5-labeled anti-human CD34, APC-H7-labeled 
anti-human CD20, FITC-labeled anti-human CD33 and PE-labeled anti-human CD13 were from BD 
Biosciences. FITC-labeled anti-human CD45, PE-labeled anti-human CD7 and 7- Amino-
actinomycin D (7-AAD) were from eBioscience. FITC-labeled anti-human CD117 was from Abcam. 
FITC-labeled anti-human CD38 and APC-labeled anti-human CD10 were from Biolegend. Pacific 
orange-labeled anti-human CD45 was from Invitrogen. 
 
Flow cytometry 
Immunophenotype analysis of xenograft material was performed from cryopreserved material. 1 
million of cells were thawed and stained in phosphate buffered saline (PBS) containing 0.5% fetal 
calf serum (FCS). Either 4 or 7 antibodies per tube were combined. 7-AAD was used for 
discriminating live and dead cells. Fluorescence-minus-one-controls were used for determining 
background signals. Measurements were carried out on a BD Bioscience FACS Canto II flow 
cytometer and analyzed using FlowJo software (TreeStar Inc.).  
 
Xenograft model 
Xenografted ALL cells were recovered from the spleen by mechanical disruption and filtering (45 
µM cell strainer, BD Biosciences) and from bone marrow by flushing dissected femurs and tibias 
with PBS using a 25 gauge needle, yielding more than 95% human CD45 and CD19 positive cells 
per harvest as verified by flow cytometry. 
For serial dilution experiments 102, 104 and 106 ALL cells recovered from a first or second 
xenotransplantation in NSG mice were injected intrafemorally or intravenously into cohorts of NSG 
mice. Leukemia progression was assessed by flow cytometry of the mouse peripheral blood. 1% 
human cells detectable in peripheral blood was scored as engrafted leukemia. At more than 75% of 
human cells in the peripheral blood or if signs of sickness were apparent, animals were euthanized 
and cells harvested as described. Time to engraftment was calculated as time from transplantation 
until >1 % of human leukemia cells were detected in the peripheral blood of transplanted animals; 
statistical evaluation was performed using the log rank test (GraphPad prism).  
 
Cell culture – Coculture 
Primary patient samples were co-cultured on hTERT-immortalized human mesenchymal 
stroma cells (MSC), and drug response curves were generated after incubation with 
indicated drugs. The following concentrations were used: Dexamethasone was used at 100, 
1000 and 7600 nM, vincristine at 3, 10 and 100 nM, daunorubicine at 10, 100 and 1000 nM 
and cytarabine at 10, 100 and 1000 nM. Cell viability was analyzed with flow cytometry using 
7-AAD8. Human hTERT-immortalized primary bone marrow MSCs21 were provided by D. 
Campana (St Jude Children's Research Hospital).  
 
Affymetrix Genome-Wide Human SNP 6.0 microarrays 
Copy number aberrations were scored with the segmentation approach available within the Partek 
software package. Deleted and amplified segments were filtered to be at least 100 kbp long. 
Segments of sizes between 100kbp and 1000kbp were regarded as focal deletions. Regions of 
special interest, for example 9p21 and regions of Immunoglobulin rearrangements and T-cell 
receptors, were investigated separately and exceptions from the >100 kbp-rule were made in these 
cases. All segments were visually inspected and aberrations that were already present in the 
matched remission samples were excluded from further analysis. 
 
Fluorescence in situ hybridization 
A Leica LX Widefield Microscope DMI6000B with the DFC 350 FX R2 camera was used for the 
analysis. The A4 filter cube was used for detection of DAPI (UV, Exc: BP 360/40), a L5 filter cube 
for spectrum green (blue, Exc: BP 480/40) and a TX2 filter cube for spectrum orange. (green, Exc: 
BP 515/40). 200 intact single cells were scored at 40x original magnification. Peripheral blood 
mononuclear cells of healthy donors were used to determine cut off values, which were set to 15 of 
200 scored cells for all subsets. 
 
Analysis of clonal Ig/TCR rearrangements. 
The following immunoglobuline and T cell receptor genes were analyzed: (IGVH[1-5])-JH), ț-
deleting element (IGVțI-IV-Kde), T-cell receptor Ȗ (TCRVȖI-IV-JȖ), and T-cell receptor į (TCRVį[1-
3]-Jį1; Vį2-Dį3; Dį2-Dį3; Dį2-Jį1). Each positive marker was sequenced using standard 
methodology.  
 
Supplemental Table 1. Patient characteristics 
 
Part A: Very High Risk patients 
 
Patient Risk MRD TP3 additional Information Relapse Survival Age Sex Immunology 
Leukocyte 
count 
Blasts 
periph % 
VHR-01 VHR positive Early, relapse, T(17;19) yes 2x no 14.1 m Common-ALL 6300 13 
VHR-02 VHR positive  yes yes 12.8 f Common-ALL 79600 68 
VHR-03 VHR positive TRM no no 17.1 m Common-ALL 20100 78 
VHR-04 VHR positive  no yes 5.7 f Common-ALL 45700 97 
VHR-06 VHR positive 
E2A-PBX1, TEL-AML, 
complex karyotype yes no 17.6 m Pre-B-ALL 8000 73 
VHR-07 VHR positive MLL-AF4 no yes 11.6 m Pro-B-ALL 100000 99 
VHR-10 VHR positive  no yes 14.4 f Common-ALL 150000 89 
VHR-11 VHR positive DS yes no 3.1 m Pre-B-ALL 16000 na 
VHR-12 VHR positive  no yes 15.3 f Pre-B-ALL 7410 92 
VHR-15 VHR positive Deletion 9p no yes 13.2 m Pre-B-ALL 2900 60 
VHR-16 VHR positive  no yes 10.4 m Common-ALL 151800 93 
VHR-17 VHR positive DS yes no 16.1 m Common-ALL 220000 95 
VHR-18 VHR positive T(17;19), MLL-AF9+ENL yes no 3.4 m Common-ALL 36000 na 
VHR-19 VHR positive  no yes 16.1 m Common-ALL 31700 65 
VHR-20 VHR positive  yes yes 8.2 m Common-ALL 27400 42 
VHR-21 VHR nd Early relapse yes no 8.8 f Pre-B-ALL 197200 na 
VHR-22 VHR positive  yes no 11 m Common-ALL 16700 23 
 
Part B: Standard and High Risk patients 
 
Patient Risk MRD TP3 additional Information Relapse Survival Age Sex Immunology 
Leukocyte 
count 
Blasts 
periph %
SR-01 SR negative  no yes 10.5 m Pre-B-ALL 18300 39 
SR-02 SR negative Amplification AML1 no yes 12.1 m Pre-B-ALL 447000 94 
SR-03 SR negative  no yes 3.4 f Pre-B-ALL 10600 42 
SR-04 SR negative E2A-PBX1 no yes 3.6 f Common-ALL 19000 55 
SR-05 SR negative HHD no yes 1.7 m Common-ALL 21600 79 
SR-06 SR negative HHD yes no 3.3 f Common-ALL 4400 43 
SR-07 SR negative CNS no yes 6.8 m Pre-B-ALL 46230 72 
SR-08 SR negative E2A-PBX1 no yes 12.8 f Pre-B-ALL 14600 66 
SR-09 SR negative  yes yes 5.5 f Common-ALL 317400 na 
SR-10 SR negative  no yes 7.3 m Common-ALL 17050 65 
SR-11 SR negative CNS yes yes 6.1 m Common-ALL 66600 87 
SR-12 SR negative E2A-PBX1 no yes 10.4 m Common-ALL 88500 na 
SR-13 SR negative  no yes 4.1 f Common-ALL 21000 na 
SR-14 SR negative ETV6-RUNX1 no yes 5.8 m Pre-B-ALL 124000 44 
SR-16 SR negative CNS yes yes 9.2 f Common-ALL 92900 14 
HR-13 HR negative BCR-ABL no yes 9.8 m Common-ALL 3500 3 
HR-03 HR negative CNS, BCR-ABL, HHD no  yes 16.9 f Common-ALL 13300 78 
HR-08* HR negative MLL no yes 0.3 f Infant-ALL 446000 na 
HR-10* HR nd Early relapse, MLL yes no 0.1 m Infant-ALL 250000 66 
 
 
MRD-TP3, time point 3 of minimal residual disease measurements by qPCR (according to the ESG-MRD-ALL study group), positive, detectable above threshold 
of 10-8, negative, not detectable; * denotes patients with infant-ALL that were treated according to the “interfant-ALL” protocol; CNS, disease spread into central 
nervous system; HHD, high hyperdiploid; DS, Down-Syndrome; na, not available; nd, not determined. 
 
 
Supplemental Table 2. Xenograft samples characteristics 
 
successful engraftment                             
Patient 
Pred 
response
Risk 
group
Passages 
in NSG 
Mean 
yield 
(spleen) 
Mean 
spleen%
Mean 
bone 
marrow%
Mean 
blood%
Weeks to 
engraftment 
1/2/3/4/5/6 
passages 
EC 50 
obatoclax
EC 50 
ABT-737 DEX DNR VCR araC
% 
CD34
# of viable 
cells 
injected 
passage 1 
(millions) 
VHR-01 PPR VHR 3 4.64E+08 91-99 74-99 10-55 8 / 14 / 8 700nM 6nM PPR R R R 0 1 
VHR-02 PPR VHR 6 6.82E+08 98-99 75-99 14-91 8 / 7 / 14 / 12 / 8 / 8 2uM 7nM PPR R R R 69 5 
VHR-03 PPR VHR 6 7.18E+08 93-99 63-99 11-91 6 / 9 / 8 / 7 / 5 / 4 600nM 50nM PPR R R R 11 1 
VHR-04 PGR VHR 3 7.02E+08 97-99 98-99 14-50 11 / 12 / 14 350nM 6nM PGR R R R 79 5 
VHR-06 PGR VHR 3 3.33E+08 85-99 84-98 5-87 8 / 4 / 4 800nM 80nM PGR R R R 1 1.3 
VHR-07 PPR VHR 3 2.22E+08 90-99 97-99 36-75 7 / 6 / 4 1.3uM 50nM PPR R R R 16 1 
VHR-10 PPR VHR 2 3.08E+08 87-99 74-99 25-76 11 / 8 900nM 200nM PPR R R R 81 1 
VHR-11 PGR VHR 2 2.12E+08 45-94 95-98 10-40 8 / 5 nd nd nd nd nd nd 38 1 
VHR-12 PPR VHR 2 7.08E+08 70-99 96-99 44-82 4 / <4 80nM 95nM PPR R S R nd 1 
VHR-15 PPR VHR 2 6.08E+08 95-99 85-99 15-50 6 / 4 500nM 50nM PPR R R R 92 0.7 
SR-01 PGR SR 1 1.16E+09 98-99 98-99 64-76 7 200nM 10nM PGR S S S 0 1 
SR-02 PGR SR 3 7.50E+08 96-99 89-99 41-87 5 / 7 / 6 550nM 60nM PGR S S R 0 1 
SR-03 PGR SR 2 5.89E+08 99 nd 54-73 14 / 7 800nM 10nM PGR S S S 77 1 
SR-04 PGR SR 2 4.94E+08 97-99 97-99 7-75 18 / 5 nd nd nd nd nd nd 0 1 
SR-05 PGR SR 3 4.34E+08 95-99 97-99 23-74 30 / 12 / 17 nd nd nd nd nd nd 79 1 
SR-06 PGR SR 1 9.50E+08 96-99 99 65-75 13 nd nd nd nd nd nd 44 1 
SR-07 PGR SR 2 7.53E+08 95 - 99 74-92 12-51 28 / 16 nd nd nd nd nd nd 7 1 
SR-08 PGR SR 2 3.67E+08 96-99 86-99 14-88 7 / <4 nd nd PGR S S S 0 2 
SR-09 PGR SR 2 2.06E+08 94-99 98-99 70-83 11 / 4 150nM 50nM  PGR M S S 96 1 
SR-10 PGR SR 2 1.34E+09 99 99 20-96 32 / 10 90nM 10nM PGR S S S 57 1 
SR-11 PGR SR 2 1.11E+09 98-99 91-99 53-66 12 / 9 100nM 20nM PPR S S S 3 0.6 
SR-12 PGR SR 2 4.67E+08 98-99 96-99 53-84 14 / <4 nd nd nd nd nd nd 57 1.3 
SR-13 PGR SR 2 1.30E+09 99 99 19-78 28 / 5 nd nd nd nd nd nd 14 3.5 
SR-14 PPR SR 2 7.85E+08 94-100 55-93 31-84 10 / 8 300nM 10nM PPR M M R 61 1 
HR-13 PGR HR 2 4.99E+08 90-99 80-99 52-76 5 / <4 nd nd nd nd nd nd 55 1 
HR-10 PPR HR 1 1.85E+08 98 96 57-92 <4 nd nd nd nd nd nd 89 1 
HR-03 PGR HR 5 3.82E+08 86-99 70-99 11-95 8 / 9 / 6 / 4 / 4 560nM nd PGR R R R 22 1 
HR-08 PPR HR 1 3.08E+08 99 98 30-34 <4 80nM 60nM PPR S S M 96 0.3 
 
 not engrafted  
Patient 
Pred 
response
Risk 
group 
# of viable cells 
injected passage 1 
(millions) 
VHR-16 PPR VHR 1 
VHR-17 PPR VHR 1 
VHR-18 PGR VHR 1 
VHR-19 PGR VHR 1 
VHR-20 PPR VHR 1 
VHR-21 PPR VHR 1 
VHR-22 PGR VHR 1 
SR-16 PGR SR 1 
 
Characteristics of all engrafted and not-engrafted SR-, HR- and VHR-patients are shown. Clinical parameters at diagnosis and engraftment characteristics are 
given (yield, time to engraftment, percentage of human cells, % of CD34 positive cells, drug response). PPR, Prednisone poor response; PGR, Prednisone good 
response; DEX, dexamethasone; DNR, daunorubicine; VCR, vincristine; araC, Cytarabine; R, resistant; M, intermediate response; S, sensitive; nd, not 
determined. 
 
 
Supplemental Table 3. Layout and primers for Ig and TCR gene rearrangement PCR 
 
 Forward Reverse Rearrangement 
lane 1 VH1/7 JH 
lane 2 VH2 JH 
lane 3 VH3 JH 
lane 4 VH4/6 JH 
lane 5 VH5 JH 
IgH VH-JH 
lane 6 Vd2 and Dd2 Dd3 
lane 7 Vd2 and Dd2 Jd1 
lane 8 Vd1 Jd1 
TCRD 
lane 9 VK1 and RS-3 Kde 
lane 10 VK2 Kde 
lane 11 VK3 Kde 
lane 12 VK4 Kde 
IGK 
lane 13 Vg2 and Vg3 Jg1.3/2.3 
lane 14 Vg4 Jg1.3/2.3 and Jg1.1/2.1 
lane 15 Vg1 Jg1.1/2.1 and Jg1.3/2.3 
TCRG 
lane 16 Vd2 Ja29 TCRD/A 
lane 17 Vb (23x) Jb1.1 and Jb1.2 TCRB Vb-Jb 
 
For primer sequences see: van der Velden VH, van Dongen JJ. MRD detection in acute lymphoblastic 
leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR. 
Methods Mol Biol. 2009;538(115-150). 
 
 
Supplemental Table 4. Stability of immunophenotypes over serial passages. 
 
Part A: Measurements from diagnostic and xenografted samples carried out on the same flow 
cytometer. 
 
Patient CD7 CD19 CD20 CD22 CD10 CD34 CD45 CD13 CD33 CD117 CD38 
VHR-01 - ++ - ++ ++ - ++ + ++ - ++ 
1 - + - + ++ - ++ + ++ - nd 
2 - ++ - ++ ++ - ++ + ++ - nd 
2* - ++ - + ++ - ++ + ++ + nd 
3 - ++ + nd ++ - ++ + ++ nd ++ 
VHR-03 - ++ - ++ + + ++ + + - ++ 
2 - ++ + + + + ++ + + - nd 
2 - ++ - nd ++ + ++ + - nd ++ 
3 - ++ - nd ++ + ++ nd - nd ++ 
3* - ++ - ++ ++ + ++ + - - ++ 
3* - ++ - ++ ++ + ++ + - - ++ 
4 - ++ + ++ ++ + ++ + ++ - nd 
4 - ++ - nd ++ + ++ + - nd ++ 
5 - ++ - nd + + ++ + - nd ++ 
6 - ++ - nd + + ++ + - nd ++ 
VHR-10 nd ++ + + ++ + ++ - - nd + 
1 - ++ ++ + ++ ++ ++ - - - nd 
1 - ++ + + ++ + ++ - - nd nd 
2 - ++ + nd ++ + ++ - - nd + 
2 - ++ + nd ++ + ++ - - nd + 
SR-09 - ++ - ++ ++ ++ ++ - - - ++ 
1 - ++ - nd ++ ++ ++ - - nd ++ 
1 - ++ - ++ ++ ++ ++ - - - nd 
2 - ++ - nd ++ ++ ++ - - nd ++ 
SR-11 - ++ - nd ++ - - + - nd ++ 
1 - ++ - nd ++ ++ - + - nd ++ 
2 - ++ - nd ++ ++ - + - nd ++ 
 
 Part B: Measurements from diagnostic samples carried out in the ALL-BFM reference laboratories, 
and xenograft samples analyzed in Zurich laboratories. 
 
Patient CD7 CD19 CD20 CD22 CD10 CD34 CD45 CD13 CD33 CD117 CD38 
VHR-04 + ++ + ++ ++ ++ ++ + + - ++ 
1 + ++ + ++ ++ ++ ++ - - - nd 
1 + ++ + nd ++ ++ ++ + nd nd ++ 
2* + ++ + nd ++ ++ ++ + nd nd ++ 
2 + ++ + nd ++ ++ ++ + nd nd ++ 
3 + ++ + nd ++ ++ ++ + nd nd ++ 
VHR-06 - ++ - ++ ++ - ++ - + - nd 
1 - ++ - ++ ++ - ++ - + - nd 
VHR-07 - ++ - + - - ++ - - - nd 
1 - ++ - ++ - - ++ - - - nd 
HR-03 - ++ + ++ ++ + ++ + - - nd 
1 - ++ ++ - ++ ++ ++ - + - nd 
1 - ++ + - + ++ ++ - - - nd 
SR-01 - ++ - - ++ - ++ - - - nd 
1 - ++ - - ++ - ++ - - - nd 
1 - ++ - - ++ - ++ - - - nd 
SR-02 - ++ + + ++ - ++ - - - nd 
1 - ++ + + ++ + ++ - - - nd 
1 - ++ - - + + ++ - - nd nd 
SR-03 + ++ ++ ++ ++ ++ ++ nd - - nd 
1 - ++ + + ++ ++ ++ nd + - nd 
SR-04 - ++ + ++ ++ - ++ - - - nd 
2 - ++ ++ + ++ - ++ - + - nd 
SR-08 - ++ - ++ ++ - ++ - - - nd 
1 - ++ - + ++ + ++ -  - - nd 
SR-10 - ++ ++ ++ ++ ++ ++ - - - nd 
1 - ++ ++ - ++ ++ ++ - - - nd 
SR-12 - ++ ++ ++ ++ + - - - - nd 
1 - ++ ++ ++ ++ + + - ++ - nd 
 
 
Expression of surface markers measured by flow cytometry. First rows show diagnostic 
measurements (in bold) and following rows show measurements of xenografted material (1-first round, 
2-2nd round etc). In part A data are shown with measurements carried out on the same flow cytometer, 
in part B data from diagnostic measurements carried out at the ALL-BFM reference lab in Berlin are 
given, together with measurements of xenograft samples performed in Zurich. * depicts sample after 
100 cell transplantation; nd, not determined; -, no expression; +, weak expression up to 20%; ++, 
strong expression in more than 20% of all cells. 
Supplemental Table 5. Engraftment of VHR- and SR-ALL in NSG mice after serial dilution. 
 
Patient Round of 
amplification Cell dilution
if 
engrafted/total
iv 
engrafted/total 
weeks to 
engraftment 
1000000 2/2 nd 8 
10000 2/2 nd 20 VHR-01 diagnostic 
100 0/3 nd - 
1000000 2/4 3/3 14 / 16 
10000 3/3 3/3 8 / 14 VHR-01 2nd 
100 2/3 0/3 14 
1000000 1/2 2/3 10 / 10 
10000 3/3 1/3 12 / 12 VHR-02 3rd 
100 2/3 0/3 26 / - 
1000000 2/2 2/2 9 / 8 
10000 2/2 2/2 5 / 12 VHR-03 3rd 
100 1/2 0/2 14 / - 
1000000 2/2 2/3 12 / 10 
10000 1/3 2/3 12 / 10 VHR-04 2nd 
100 1/3 0/3 18 / - 
1000000 2/2 nd 4 
10000 3/3 nd 7 VHR-06 diagnostic 
1000 0/3 nd - 
1000000 2/2 nd 4 
10000 3/3 nd 7 
1000 1/3 nd 28 VHR-06 2nd 
100 0/5 nd - 
1000000 2/2 nd 8 
10000 0/3 nd - VHR-07 diagnostic 
100 0/5 nd - 
1000000 3/3 nd 5 
10000 3/3 nd 5 VHR-07 2nd 
100 0/5 nd - 
80000 2/2 nd 8 
10000 0/2 nd - SR-02 diagnostic 
100 0/5 nd - 
1000000 2/2 nd 4 
10000 2/2 nd 8 SR-02 2nd 
100 0/5 nd - 
500000 2/2 nd 10 
10000 0/2 nd - SR-08 diagnostic 
100 0/5 nd - 
1000000 2/2 nd 4 
10000 1/2 nd 6 SR-08 2nd 
100 0/5 nd - 
1000000 2/2 3/3 9 / 6 
10000 0/3 3/3 0 / 6 HR-03 3rd 
100 0/3 0/3 - 
 
VHR-, SR- and one HR-ALL patients from different amplification rounds were transplanted intrafemoral 
or intravenous. Engraftment was considered as positive when 1% of humanCD19/CD45 positive 
mouseCD45 negative cells were detected in peripheral blood by flow cytometry and spleens and bone 
marrows were engrafted at harvest. if, intra femoral; iv, intra venous; nd, not done. 
 
Supplemental Table 6. Regions of CNAs in diagnostic and xenograft samples. 
 
Sample Cytoband CNA CNA 
average Overlapping Genes Near Genes Rearrangement 
VHR-02: all 2p11.2 Deletion 0.8  FLJ40330 IgK 
VHR-02: all 7q34 Deletion 1.1 PRSS1, PRSS2  TCRb 
VHR-02: all 7p14.1 Deletion 0.8  TARP TCRg 
VHR-02: 2 
mice 14q11.2 Deletion 0.3  DAD1 TCRab 
VHR-02: 3 
mice 14q11.2 Deletion 0.8  DAD1 TCRab 
VHR-02: all 14q32.33 Deletion 1.0 KIAA0125, ADAM6, LOC100133469  IgH 
VHR-02: all 22q11.22 Deletion 1.2 VPREB1  IgL 
VHR-02: 
diagnostic 4q31.3 Deletion 1.2 
overlaps with 20.34% of 
FBXW7 FBXW7  
VHR-02: all 7p12.2 Deletion 1.0 parts of IKZF1 IKZF1  
VHR-02: all 
mice 9p21.3 Deletion 1.0 
C9orf53, CDKN2A, 
CDKN2BAS, CDKN2B   
VHR-02: all 
mice 9p13.2 Deletion 1.1 intron of ZCCHC7 ZCCHC7  
VHR-03: all 2p11.2 Deletion 0.9  FLJ40330 IgK 
VHR-03: all 7p14.1 Deletion 1.1 TARP  TCRg 
VHR-03: all 14q11.2 Deletion 0.5  DAD1 TCRab 
VHR-03: all 14q32.33 Deletion 1.4 KIAA0125  IgH 
VHR-03: 
diagnostic 
subclone 
1q42.11 - 
1q42.13 Deletion 1.6 many   
VHR-03: 3/5 
mice 7q22.3 Deletion 1.1 PIK3CG   
VHR-03: all 9p cnLOH 2.0 many   
VHR-03: all 9p21.3 Deletion 0.4 many, incl. CDKN2A/B   
VHR-03: 
diagnostic 
subclone 
9p Deletion 0.6 many   
VHR-03: 
diagnostic 
subclone 
14q12 Deletion 1.7 
AP4S1, C14orf126, 
COCH, HEATR5A, 
HECTD1, MIR624, 
STRN3 
NUBPL, SCFD1  
VHR-03: all 20p13 - 20p11.23 Amplification 2.9 many   
VHR-03: all 20q cnLOH 2.0 many   
VHR-04: all 2p11.2 Deletion 1.0  FLJ40330 IgK 
VHR-04: all 14q11.2 Deletion 1.0  DAD1 TCRab 
VHR-04: all 14q32.33 Deletion 0.7 KIAA0125, ADAM6, LOC100133146  IgH 
VHR-04: all 
mice 22q11.22 Deletion 1.2 VPREB1  IgL 
SR-02: all 14q32.33 Deletion 1.0 KIAA0125, ADAM6  IgH 
SR-02: all 
mice 1p36.13 Amplification 3.4 
CROCCL1, ESPNP, 
MST1P2, MST1P9, 
NBPF1 
  
SR-02: all 
mice 1q23.3 Deletion 1.6 F11R, ITLN2   
SR-02: all 1q Amplification 3.1 many   
SR-02: all 
mice 3q22.1 Amplification 3.3 ALG1L2, LOC729375   
SR-02: 
diagnostic 7p21.3 Amplification 2.5  ARL4A  
SR-02: all 9p Deletion 1.1 many   
SR-02: all 9q Amplification 3.1 many   
SR-02: all 19p Deletion 1.2 many   
VHR-01: all 2p11.2 Deletion 0.5 none  Ig K 
VHR-01: all 14q11.2 Deletion 0.9 none  TCRab 
VHR-01: all 14q32.33 Deletion 1.2 KIAA0125, ADAM6  IgH 
VHR-01: all 22q11.22 Deletion 1.3 
VPREB1, LOC96610, 
ZNF280A,B, PRAME, 
LOC648691, 
POM121L1P, GGTLC2, 
 IgL 
VHR-01: all 
mice 9p Deletion 1.1 many   
VHR-01: all 12p13 cnLOH 2.0 many   
VHR-01: all 
mice 22q Amplification 3.0 many   
HR-03: all 2p11.2 Deletion 1.0 none  IgK 
HR-03: all 7p14.1 Deletion 0.3 TARP  TCR g 
HR-03: all 7q34 Deletion 0.7 MGAM  TCR b 
HR-03: all 14q32.33 Deletion 0.8 KIAA0125, ADAM6, LOC100133146  IgH 
HR-03: 
diagnostic 
subclone, all 
mice 
1 Amplification 
mice 2.89, 
diagnostic 
2.44 
many   
HR-03: all 2 Amplification 2.8 many   
HR-03: all 3 Amplification 2.8 many   
HR-03: all 4 Amplification 3.7 many   
HR-03: all 5 Amplification 2.8 many   
HR-03: all 6 Amplification 3.8 many   
HR-03: all 7 cnLOH 2.0 many   
HR-03: all 8 Amplification 3.7 many   
HR-03: all 9p21.3 Deletion 0.5 MTAP, CDKN2A, CDKN2BAS, C9orf53   
HR-03: all 9 cnLOH 2.0 many   
HR-03: 
diagnostic 
subclone 
9p Amplification 3.5 many   
HR-03: 
diagnostic 
subclone, all 
mice 
9q Amplification 2.9 to 3.68 ABL1, many   
HR-03: all 10 Amplification 2.9 many   
HR-03: all 11 Amplification 2.9 many   
HR-03: all 12 Amplification 2.9 many   
HR-03: all 13 Amplification 2.9 many   
HR-03: all 14 Amplification 2.9 many   
HR-03: all 15 Amplification 3.8 many   
HR-03: all 16 Amplification 2.9 many   
HR-03: all 17 Amplification 2.9 many   
HR-03: all 18 Amplification 2.9 many   
HR-03: all 19 Amplification 2.9 many   
HR-03: all 20 Amplification 3.7 many   
HR-03: all 20p Amplification 3.8 many   
HR-03: all 20 cnLOH 2.0 none   
HR-03: all 20q Amplification 2.8 PTPN1, many   
HR-03: all 21 Amplification 3.7 many   
HR-03: all 22 Amplification 2.9 many   
HR-03: all 
mice 22q Amplification 3.8 BCR, many   
HR-03: all X Amplification 2.9 many   
 Results are shown for six patients and the corresponding xenograft material (between one to five 
mice) available. CNAs of sizes ranging from at least 100kb to whole chromosomes are shown. CNA 
average is the mean of the measured copy number over the length of the abnormality. Where no 
genes were affected by the abnormality the nearest genes are mentioned. Ig or TCR gene 
rearrangements are mentioned where applicable. 
 
Supplemental Table 7. FISH analysis of chromosome 9p21 abnormalities 
 
 4/4 4/1 4/0 3/5 3/3 3/2 3/1 3/0 2/4 2/3 2/2 2/1 2/0 1/2 1/1 1/0
VHR ?01           169 22 1  7 1
P1           13 73 80  14 20
P2           4 184 4  7 1
P2           25 145 3  27 
P2           8 158 5  29 
P2           12 40 128  8 12
P2          1 22 115 41  14 7
P3
 
         3 172 6  19 
P3          1 2 162 6  29 
VHR ?02                
P2           31 63 94  6 6
P2           125 56 7  10 2
P3           134 45 11  8 2
P3           174 19   7 
P3           171 19   8 2
P3           136 55 7  2 
P3           156 31 5  8 
VHR ?03           5 2 171   22
P1             185   15
P2          1 2 3 175   19
P2   1          187   12
P3           2 4 152  2 39
P3           1 4 185   10
P3   1         2 164   34
P4      3     3 7 167  3 17
P4      8     16 14 157   5
P5        2    1 189   8
P6        1    1 190   8
VHR ?04                
P1     1     1 162 20 1  14 
P2          2 163 19 3  13 
P3     6      162 16   16 
VHR ?06                
P1          1 28 144 10  14 3
VHR ?07                
P1      1 1   2 161 14 9  11 1
VHR ?10           110 41 24 13 8 4
P2    1  2  1  25 80 35 45  8 3
P2           111 40 36  4 3
P2         1 4 34 37 119  2 7
P2 1          134 31 21  6 1
P2     1    1 6 113 37 42  6 2
VHR ?11                
P1     13 3   1 3 163 3   11 
VHR ?12                
P1           153 29 8  9 1
 
 
 
 
 
 
 4/4 4/1 4/0 3/5 3/3 3/2 3/1 3/0 2/4 2/3 2/2 2/1 2/0 1/2 1/1 1/0
SR ?01                
P1      1 1    155 14 7  20 1
SR ?02           51 123 17  8 1
P1       2 1   21 149 16  9 2
SR ?03                
P1     7 1     185    7 
SR ?04                
P2          4 179 2   15 
SR ?05           56 50 88  4 2
P1           2  177   21
SR ?07                
P1          5 49 58 75  6 7
P1     2      155 22 1  20 
SR ?08                
P1     5 2     179 8   8 6
SR ?09           80 90 5  23 2
P1           8 132 34  23 3
P2       1    29 130 5  34 1
P2           93 86 5  16 
P2      1     4 166 4  25 
SR ?10                
P1     1 1     171 9   9 3
SR ?11           133 35 13  15 4
P1           74 54 67  4 1
P2           86 66 28  15 5
P2  1        1 57 57 48  21 15
SR ?12                
P1     7      151 33 4  5 
 
 4/4 4/1 4/0 3/5 3/3 3/2 3/1 3/0 2/4 2/3 2/2 2/1 2/0 1/2 1/1 1/0
HR ?03                
P1     3 98 21 11   20 33 9  4 
HR ?08                
P1      1    1 191 3   3 
P1      2    2 190 6    
HR ?09                
P1         1 1 178 11 1  18 
HR ?13           22 12 158  2 6
P1     1 1  1   2 3 184   8
 
9p21 copy abnormalities were measured in 9 VHR-, 11 SR- and 4 HR-ALL samples (diagnostic and/or 
xenograft material). In the top row, the different configurations with respect to copies detected with the 
centromer chromosome 9 and the 9p21 (CDKN2A) probe, respectively. 200 cells were counted, and in 
yellow, the numbers of positive cells for a given configuration above the threshold (15 positive cells per 
200 counted) are given. 
 
Supplemental Table 8. Stable detection of diagnostic MRD markers after serial transplantation. 
 
Patient Round of 
amplification 
Marker 
detected/total
VHR-01 1st 2/2 
 2nd 2/2 
VHR-02 2nd 2/2 
 3rd 2/2 
 after 100 cells 2/2 
VHR-03 1st 2/2 
 2nd 2/2 
 3rd 2/2 
 after 100 cells 2/2 
 4th 2/2 
VHR-04 1st 0/1 
 2nd 0/1 
HR-03 1st 2/2 
 2nd 2/2 
 3rd 1/2 
 4th 1/2 
VHR-06 1st 2/2 
VHR-07 1st 0/2 
HR-05 1st 2/2 
HR-06 1st 2/2 
SR-01 1st 2/2 
SR-02 1st 2/2 
 2nd 2/2 
SR-04 1st 2/2 
SR-08 1st 1/1 
SR-09 1st 1/2 
 
MRD markers of clonal Ig and TCR gene rearrangements were established at diagnosis of each 
patient and used for detection by qPCR in the amplified material of different rounds of transplantation. 
 
Supplemental Figure 1: Phenotypic stability of ALL cells after serial dilution
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Supplemental Figure 1: Phenotypic stability of ALL cells after serial dilution. Flow 
cytometry analysis of VHR-03 (A) and VHR-04 (B). Multicolor flow cytometry analyses of 
primograft cells and secondary transplants thereof performed with 100 cells show preservation of 
immunophenotype. 
Supplemental Figure 2: Analysis of Ig/TCR rearrangements reflects the evolution of the clonal compartment in 
xenografts.
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Supplemental Figure S1: Analysis of Ig/TCR rearrangements reflects the evolution of the clonal 
compartment in xenografts. The Ig/TCR rearrangement pattern of diagnostic samples and matched 
xenografts was determined in 5 VHR- and in 5 SR-ALL samples by PCR using standardized sets of 
primers that are validated for MRD analysis. Representative gels for all analyzed VHR-ALL and 4 SR-ALL 
samples (SR-09 in Figure 6) are provided. All positive bands of the correct size were sequenced once for 
verification. Stable rearrangements are framed with an orange line, while bands framed in red represent 
markers that disappeared and green frames represent bands gained in xenografts. 
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Bone marrow punctures are often required when
modeling hematologic malignancies in mice. Ortho-
topic intrabone injection resulted in superior en-
graftment of human hematopoietic stem cells [1] or
of human leukemia cells [2,3] in immunodeficient
mice. Similarly, between 10 and 100 cells from
patients with acute lymphoblastic leukemia were
sufficient to reconstitute leukemia in immunodefi-
cient NOD/scidIL2Rgnull (NSG) mice after intrafe-
moral injections [4,5]. Current protocols for bone
marrow procedures in mice involve a two-step
process that requires perforation of the cortical
bone with a first needle and retrieval of the orifice
subsequently with a needle with a smaller gauge for
injection or aspiration of cells. As an alternative, we
have used a small needle with a stylet in analogy to
bone marrow aspiration needles that are used in
the clinic. Here we show that a pediatric spinal tap
needle (also called atraucan needle) can be used
efficiently and conveniently for bone marrow trans-
plant and sampling procedures in mice. This one-
step injection procedure [Figure 1(A)] resulted in
highly reproducible engraftment with primary human
acute lymphocytic leukemia (ALL) cells (Table I).
Forty-four out of 45 xenograft ALL samples repo-
pulated secondary recipients. This technique was
used to establish an in vivo model of highly resistant
leukemia [6]. Furthermore, in serial dilution experi-
ments, 100 ALL cells were sufficient for engraftment
in four different cases of ALL [5], demonstrating
that the injections can be performed with minimal
losses due to dead volume with this needle. Bone
marrow aspiration through the atraucan needle did
not damage the bone marrow cells, as shown with
7-aminoactinomycin D (7-AAD) stainings for cell
viability by flow cytometry [Figure 1(B)]. A homo-
geneous, viable population of CD19 and CD10
double-positive human leukemia cells was detected
in the bone marrow at 8 weeks after transplant. The
analysis of engraftment in the peripheral blood
showed a lower, although detectable, presence of
human leukemia cells. By aspirating the femur
contralateral to the injection site we collected up to
15 000 lymphocytes in 10 mL bone marrow aspirate
without requirement for subsequent erythrolysis.
By tail vein bleeding, we collected 50 mL of blood
that was enough to detect at least the same number of
lymphocytes.
Taken together, the use of the pediatric atraucan
needle very effectively eliminates the need to perform
two punctures of the cortical bone in order to inject
into or sample cells from the bone marrow cavity.
We are convinced that this simple modification will
be of great interest to many investigators as xenograft
models with human normal or malignant hemato-
poietic cells are increasingly applied.
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Figure 1. Bone marrow procedures were performed on NSG mice under inhalation anesthesia and analgesia with subcutaneous injections of
0.1 mg/kg temgesic. (A) After removal of the fur, the knee was held in the folded position, with the femur perpendicular to the table surface.
The femur head was punctured with a pediatric atraucan 26G needle containing a stylet (B. Braun Medical, Switzerland; left panel). For
intrafemoral injections, the stylet of the atraucan needle was removed and the 29G needle of an insulin syringe (BD Micro-fine; BD
Biosciences, USA) was inserted directly in the lumen of the atraucan needle (middle and right panels). The use of a needle instead of the
direct connection of a syringe to the atraucan needle minimizes the dead volume after injection. Cells, resuspended in a total volume of 30 mL
phosphate buffered saline (PBS), were then injected, and the atraucan needle was removed together with the insulin syringe. For bone
marrow aspirates, the needle of an insulin syringe containing 30 mL of PBS was inserted into the lumen of the atraucan needle, and bone
marrow was sampled by drawing the lever up and down several times. (B) Flow cytometry analysis of bone marrow aspirations and tail vein
bleedings of transplanted animals reveals efficient sampling. Bone marrow aspirates (upper panel) and peripheral blood samples from tail vein
bleedings (lower panel) were directly used for flow cytometry without erythrolysis. Representative plots of engraftment at 8 weeks after
transplant are shown. Cell viability and engraftment of human cells was analyzed by flow cytometry with the following probes and antibodies:
7-AAD for cell viability, PE-Alexa750-labeled anti-human CD19, and APC-labeled anti-human CD10. Gates were set using appropriate
control stainings. Numbers refer to respective percentages of cells in the gates. The mean percentage of dead cells was 2.70 + 0.54% for
bone marrow aspirates and 2.74 + 1.32% for tail vein bleedings. Data analysis was performed with FlowJo V7.6 (TreeStar).
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enrolled in the ALL-BFM 2000 study who had given
informed consent in accordance with the Declaration
of Helsinki. Approval was obtained from the Institu-
tional Review Board (IRB) of the Medical School
Hannover and the local IRB for all participating
centers in the trial ALL-BFM 2000. This study
was supported by the Swiss National Science
foundation (grant no 310030-118392), by the
Novartis Foundation for biomedical research, and
by the Vontobel-Stiftung.
Potential conflict of interest: Disclosure forms
provided by the authors are available with the full text
of this article at www.informahealthcare.com/lal.
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Table I. Efficiency of intrafemoral transplant* using the atraucan
spinal tap needle.
Patient ID Patient characteristic
No. of engrafted
mice/transplanted mice
VHR-03 Precursor B ALL 6/6
HR-03 Precursor B ALL 4/5
SR-02 Precursor B ALL 5/5
VHR-02 Precursor B ALL 15/15
SR-04 Precursor B ALL 2/2
VHR-06 Precursor B ALL 2/2
VHR-07 Precursor B ALL 2/2
SR13 Precursor B ALL 2/2
SR-05 Precursor B ALL 2/2
VHR-10 Precursor B ALL 2/2
SR-17 Precursor B ALL 2/2
*Primary transplants were done intrafemorally using the herein
described method. Engraftment efficiency was 98% with samples
that were known to engraft NOD/scidIL2Rgnull (NSG) mice.
ALL, acute lymphocytic leukemia; VHR, very high risk; HR, high
risk; SR, standard risk, as described [6].
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In vivo resistance to first-line chemotherapy, including to glucocorticoids, is a strong predictor of poor out-
come in children with acute lymphoblastic leukemia (ALL). Modulation of cell death regulators represents 
an attractive strategy for subverting such drug resistance. Here we report complete resensitization of multi-
drug-resistant childhood ALL cells to glucocorticoids and other cytotoxic agents with subcytotoxic concentra-
tions of obatoclax, a putative antagonist of BCL-2 family members. The reversal of glucocorticoid resistance 
occurred through rapid activation of autophagy-dependent necroptosis, which bypassed the block in mito-
chondrial apoptosis. This effect was associated with dissociation of the autophagy inducer beclin-1 from the 
antiapoptotic BCL-2 family member myeloid cell leukemia sequence 1 (MCL-1) and with a marked decrease in 
mammalian target of rapamycin (mTOR) activity. Consistent with a protective role for mTOR in glucocorti-
coid resistance in childhood ALL, combination of rapamycin with the glucocorticoid dexamethasone triggered 
autophagy-dependent cell death, with characteristic features of necroptosis. Execution of cell death, but not 
induction of autophagy, was strictly dependent on expression of receptor-interacting protein (RIP-1) kinase 
and cylindromatosis (turban tumor syndrome) (CYLD), two key regulators of necroptosis. Accordingly, both 
inhibition of RIP-1 and interference with CYLD restored glucocorticoid resistance completely. Together with 
evidence for a chemosensitizing activity of obatoclax in vivo, our data provide a compelling rationale for clini-
cal translation of this pharmacological approach into treatments for patients with refractory ALL.
*OUSPEVDUJPO
Resistance to the initial phase of chemotherapy, in particular 
poor response to glucocorticoids (GCs), is a strong predictor 
of adverse outcome for childhood acute lymphoblastic leuke-
mia (ALL) (1, 2). During the last decade, the cooperative Ber-
lin-Frankfurt-Muenster (BFM) study group has validated an 
effective risk stratification approach, which is based on the 
assessment of the in vivo response to chemotherapy by leuke-
mia-specific quantitative PCR. A group of patients at very high 
risk for relapse (VHR-ALL) can be identified based on persistence 
of minimal residual disease (MRD) (3). Because this is likely to 
reflect de novo resistance to multiple conventional antileukemic 
agents, combination treatment with new agents that modulate 
regulators of cell death represents an attractive approach to 
improve treatment response.
In GC-resistant ALL, the mechanisms underlying defective 
induction of mitochondrial apoptosis are still not understood. 
Increased expression of antiapoptotic myeloid cell leukemia 
sequence 1 (MCL-1) was a predominant feature of the gene expres-
sion signature of GC resistance (4). A bioinformatic screen of drug-
associated signatures identified rapamycin as a sensitizer to GC 
drugs in GC-resistant ALL. The GC-sensitizing effect of rapamycin 
was attributed to a decrease in MCL-1 levels, which was proposed 
to decrease the threshold to apoptotic stimuli by GC drugs (5).
Based on these considerations, we sought to evaluate the poten-
tial of the small molecule obatoclax (GX15-070) for combination 
therapy in refractory childhood ALL. This agent was proposed to 
act as a BCL-2 family antagonist and to disrupt the interaction 
between MCL-1 and its proapoptotic counterparts at cytotoxic 
concentrations (6, 7). Obatoclax was shown to trigger apoptosis 
at concentrations that resulted in disruption of Bak from MCL-1 
and cytochrome c release. However, obatoclax was also cytotoxic 
in cells that are deficient for the apoptosis effectors BAX and BAK, 
and lower concentrations of compound were sufficient to inhibit 
clonogenic growth of AML cells, suggesting the existence of addi-
tional target mechanisms (8). A recommended phase II dose has 
been established for adult patients with hematologic malignancies 
with an acceptable toxicity profile (9, 10), which constitutes the 
basis for further evaluation of obatoclax in pediatric trials.
In the context of defective apoptosis, an alternative cell death 
pathway has been identified that is dependent on macroau-
tophagy (11, 12), a major form of autophagy, in which parts of 
the cytoplasm and intracellular organelles are sequestered within 
characteristic double-membraned or multi-membraned autopha-
gic vacuoles (hereafter referred to as autophagy) (13). Autophagy 
is usually triggered to respond to increased metabolic require-
ments at times of cellular stress. Selected antiapoptotic BCL-2 
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family members can engage in cross-talk between the apoptotic 
and autophagic pathways, as they were show to associate with the 
autophagy regulator beclin-1 (11, 14, 15). When caspase-depen-
dent apoptosis was blocked, a cell death mechanism that required 
autophagy was mediated via the receptor-interacting protein 1 
(RIP-1) (12). RIP-1 is a central kinase that is associated with death 
receptor–induced signalling complexes to modulate the switch 
between survival and death under stress conditions (16). Under 
defective apoptotic conditions, RIP-1 kinase activity was shown 
to mediate an alternative cell death pathway that may represent 
a form of programmed necrosis, also called necroptosis (17, 18). 
Kinase activity of RIP-1 was shown to be dispensable for induc-
tion of cell survival signalling via NF-kB activation or death recep-
tor–mediated apoptosis (17, 19).
Here we show that a subcytotoxic concentration of obatoclax 
effectively restored the response to dexamethasone in GC-resistant 
ALL by triggering a nonapoptotic cell death pathway. Subcytotoxic 
concentrations of obatoclax induced disruption of beclin-1 from 
MCL-1 and the combination of dexamethasone with obatoclax 
was associated with inhibition of mammalian target of rapamycin 
(mTOR) activity, providing a possible mechanism for autophagy 
induction. Obatoclax also conferred clinically relevant broad che-
mosensitization in multidrug-resistant primary cells from VHR-
ALL patients. We provide genetic and pharmacologic evidence to 
show that sensitization to dexamethasone occurs via autophagy-
dependent necroptotic cell death, while sensitization to other cyto-
toxic agents was dependent on apoptosis. In a xenograft model, 
using GC-resistant cells from refractory ALL patients, combina-
tion treatment with dexamethasone and obatoclax reduced leu-
kemia progression significantly. Collectively, our data provide a 
strong rationale for a rapid clinical translation of this approach.
3FTVMUT
Obatoclax resensitizes GC-resistant ALL to dexamethasone. Because 
MCL-1 has been proposed to act as a central modulator of steroid 
resistance in ALL (4, 5), we first compared the effects of 2 small 
molecules with different selectivity toward MCL-1, ABT-737, 
and obatoclax in GC-resistant ALL cell lines. ABT-737 is a small 
molecule BH3 mimetic with selectivity for BCL-2 and BCL-XL 
(20). Resistance to ABT-737 has been attributed to its inabil-
ity to target MCL-1 (21–23). While both compounds displayed 
strong cytotoxicity across a panel of ALL cell lines (Supplemental 
Table 1; supplemental material available online with this article; 
doi:10.1172/JCI39987DS1), subcytotoxic doses of obatoclax but 
not ABT-737 resensitized GC-resistant cell lines to dexamethasone 
(Figure 1A and Supplemental Figure 1). We confirmed single-agent 
activity for obatoclax in VHR-ALL cells (Supplemental Table 2). 
Low-dose obatoclax restored sensitivity to dexamethasone in 
cells from all 7 poor-prednisone-responder (PPR) VHR-ALL 
patients tested (Figure 1B and Supplemental Figure 2). In con-
trast, no effect on steroid sensitivity using low doses of ABT-737 
or obatoclax was evident in steroid-sensitive cells (Figure 1A). 
Unexpectedly, the pan-caspase inhibitor zVAD.fmk did not inter-
fere with the steroid-sensitizing effect of obatoclax in GC-resis-
tant cells (Figure 2A), whereas zVAD.fmk blocked the cytotoxic 
effect of dexamethasone with or without obatoclax in GC-sensi-
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tive cells and in control experiments when cell death was induced 
by staurosporine (STS). Using clonogenic assays, we confirmed 
that obatoclax was equally effective in ALL cells that are devoid 
of caspase-9 or BAX and BAK, when compared with parental cell 
lines (Figure 2B and Supplemental Figure 3). Furthermore, obato-
clax-mediated GC sensitization resulted in neither the restoration 
of mitochondrial membrane depolarization (Figure 2C) nor an 
increase in cytochrome c release when compared with the effect 
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of dexamethasone in GC-sensitive cells (Figure 2D). In line with 
these findings, caspase-9 was not activated and caspase-3 was 
only marginally activated in steroid-resistant cells treated with 
the combination of obatoclax and dexamethasone (Supplemental 
Figure 4). Collectively, our results indicate that the combination 
of obatoclax and dexamethasone triggers a cell death mechanism 
that is independent of the apoptotic function of caspases in ste-
roid-resistant leukemia.
Induction of autophagy is essential for steroid sensitization in ALL cells. 
Because an autophagy-dependent cell death pathway has been 
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described in cell line models in which apoptosis is prevented (11, 24), 
we evaluated next whether autophagy was required for GC sensitiza-
tion by obatoclax. Indeed, autophagosome formation was evident in 
GC-resistant cells after 4 hours of exposure to low-dose obatoclax 
in combination with dexamethasone, which correlated with genera-
tion of endogenous LC3-II (Figure 3, A–C). Because rapamycin is 
known to be an inducer of autophagy (25), we asked whether the 
GC-sensitizing effect reported recently for rapamycin (5) could also 
be dependent on autophagy. As we expected, steroid sensitization by 
rapamycin was associated with hyperautophagic features (Figure 3, 
A and B). Obatoclax or rapamycin alone only marginally induced 
autophagosome formation and generation of LC3-II (Figure 3, A–C). 
Preincubation with the autophagy inhibitor 3-methyladenine (3-MA) 
abolished autophagosome formation, generation of LC3-II, and GC 
resensitization by obatoclax and rapamycin (Figure 3, B–D). Both 
bafilomycin, a late-stage inhibitor of autophagolysosome formation 
(25), and downregulation of the essential autophagy genes beclin-1 
(BECN1) and ATG-7 (ATG7) by RNA interference blocked GC-resen-
sitization by obatoclax and rapamycin (Figure 3, D–G). These results 
were confirmed in an independent cell line (Supplemental Figure 5). 
Clonogenic assays demonstrate that both addition of 3-MA and 
downregulation of beclin-1 prevented the cytotoxic effect of low-
dose obatoclax combined with dexamethasone, since clonogenic 
growth was comparable to that in untreated controls (Figure 3, 
F and G). In GC-sensitive ALL cells, inhibition of autophagy by 3-MA 
only marginally restored GC resistance, despite small amounts of 
detectable LC3 lipidation (Supplemental Figure 6). These findings 
implicate autophagy as part of a common mechanism for GC resen-
sitization by obatoclax and rapamycin.
To determine whether obatoclax triggers the autophagy path-
way as a general response to blockade of mitochondrial apoptosis, 
we studied the drug’s effects on Bax–/–Bak–/– mouse embryo fibro-
blasts (MEFs), which exhibit resistance to a broad range of apop-
totic stimuli (26). Like rapamycin, obatoclax induced autophagy in 
Bax–/–Bak–/– MEFs (Figure 4, A–C), as reflected by autophagosome 
formation (Figure 4, A and B) and generation of LC3-II (Figure 4C). 
Obatoclax was cytotoxic to WT and Bax–/–Bak–/– MEFs, whereas 
ABT-737’s activity was restricted to WT MEFs (Figure 4D). The 
death response was blocked by 3-MA (Figure 4E) and downregu-
lation of beclin-1 or ATG-7 (Figure 4, F and G). Taken together, 
these results indicate that the cytotoxic effects of obatoclax and 
rapamycin derive from induction of autophagy when mitochon-
drial apoptosis is blocked.
Modulation of the GC response by obatoclax is associated with inhibition of 
mTOR. A key regulator of cell fate decisions, including regulation of 
autophagy, is the kinase mTOR (27). Inhibition of mTOR by rapa-
mycin resensitizes steroid-resistant ALL cells to dexamethasone (5), 
but the role of autophagy has not been investigated in this study. 
Since dexamethasone has been shown to inhibit mTOR in other cel-
lular systems (28), we investigated the effect of dexamethasone and 
obatoclax treatment on mTOR activity. Alone dexamethasone slight-
ly induced a decrease of S6 protein phosphorylation (Figure 5A). 
Treatment with obatoclax or rapamycin and dexamethasone resulted 
in a sharp decrease of the phosphorylation of the mTOR targets S6 
protein and 4EB-P1 (Figure 5A). Interestingly, rapamycin but not 
obatoclax, either alone or in combination with dexamethasone, 
induced dephosphorylation of AKT at Ser473 (Figure 5A). Combina-
tion of obatoclax or rapamycin and dexamethasone also resulted in 
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dephosphorylation of S6 protein in primary ALL cells from steroid-
resistant high risk ALL patients (Figure 5B, left). In contrast, cells 
from steroid-sensitive patients did not show dephosphorylation 
of S6 protein after treatment with obatoclax and dexamethasone 
(Figure 5B, right). Our experiments suggest that in the context of GC 
resistance, exposure to dexamethasone could cooperate with expo-
sure to obatoclax to decrease mTOR activity. This finding will be 
exploited to develop correlative markers of biological response to in 
vivo treatment, for example, using phospho-flow cytometry to moni-
tor the phosphorylation status of S6 protein in leukemia cells.
Obatoclax disrupts a complex between beclin-1 and MCL-1. The anti-
apoptotic BCL-2 family member MCL-1 was proposed to act as 
a modulator of GC resistance (5). Because the autophagy regula-
tor beclin-1 was described to interact with antiapoptotic BCL-2 
family members, including MCL-1 (11, 14, 15), we next tested the 
effect of obatoclax on the interaction of beclin-1 with MCL-1. 
Subcytotoxic concentrations of obatoclax resulted in a markedly 
decreased detection of MCL-1 that coimmunoprecipitated with 
overexpressed, epitope-tagged beclin-1 in 293T cells (Figure 6A). 
We confirmed this result by performing coimmunoprecipita-
tion experiments of endogenously expressed proteins in ALL cells 
(Figure 6B). Again, in presence of subcytotoxic concentrations of 
obatoclax, less beclin-1 was shown to coimmunoprecipitate with 
MCL-1, and inversely, less MCL-1 was pulled down together with 
beclin-1. Obatoclax did not modify interactions between beclin-1 
and BCL-2. Interestingly, incubation with rapamycin or ABT-737 
did not affect the complex between beclin-1 and MCL-1. As expect-
ed from the reported MCL-1 interaction spectrum (29, 30), BIM 
was detectable by coimmunoprecipitation from steroid-resistant 
ALL cells, but binding of BIM to MCL-1 was not altered by treat-
ment with low-dose obatoclax. The BH3-only protein NOXA, 
which was shown to interact preferentially with MCL-1, did not 
bind to MCL-1 in this experimental setting (Figure 6B).
Since MCL-1 can be subjected to a high protein turnover (31), we eval-
uated the effect of combination treatment with obatoclax and dexa-
methasone on MCL-1 protein levels. In the presence of cycloheximide, 
MCL-1 levels rapidly decreased after 45 minutes of incubation, inde-
pendent of the presence of obatoclax and dexamethasone (Figure 6C). 
Absence of proapoptotic BIM induction by dexamethasone has been 
described in selected cases of steroid-resistant ALL (32). We did not 
detect any changes in BIM expression levels to correlate with the 
restored response to dexamethasone in combination with obatoclax 
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in GC-resistant ALL cells (Figure 6D). Interestingly, induction of BIM 
was not detectable consistently in steroid-sensitive cells (Figure 6D). 
While in RS4;11 cells, BIM was readily induced by dexamethasone, 
neither 697 cells nor primary ALL cell samples from steroid-resistant 
patients showed induction of this proapoptotic BH3-only protein 
after dexamethasone treatment (Figure 6D). In cells from steroid 
sensitive patients, a small increase in the BIM-L and BIM-S but not 
BIM-EL isoforms was detectable. These data indicate that steroid 
resensitization by obatoclax is not due to induction of BIM.
To obtain further insight into the role of MCL-1 for the mecha-
nism of action of obatoclax, we modulated MCL-1 expression 
using RNA interference. A reduction of MCL-1 protein levels 
resulted in partial resensitization to dexamethasone but, surpris-
ingly, prevented any additional chemosensitization by the combi-
nation with obatoclax (Supplemental Results and Supplemental 
Figure 7). Partial resensitization to dexamethasone was mediated 
via induction of apoptosis, which was blocked using the pan-cas-
pase inhibitor zVAD.fmk. Inhibition of autophagy with 3-MA did 
not affect the resensitization effect of MCL-1 knockdown to dexa-
methasone, even in presence of obatoclax. Instead, caspase-9 acti-
vation was detected, which correlated with a caspase-dependent 
decrease of beclin-1. Thus, it is possible that induction of apopto-
sis overrides induction of autophagy when MCL-1 is downregu-
lated, which limits the interpretation of these experiments. Taken 
together, our data indicate that disruption of the beclin–MCL-1 
interaction is part of the mechanism triggered by obatoclax and 
suggest an involvement of MCL-1 in the regulation of an autoph-
agy-dependent cell death pathway, in addition to its role as anti-
apoptotic regulator in leukemia cells.
Combination of obatoclax and dexamethasone triggers RIP-1 kinase–
dependent necroptosis in GC-resistant ALL. To better assess the nature 
of cell death occurring with obatoclax and dexamethasone, we pro-
ceeded with imaging by transmission electron microscopy. Indeed, 
autophagosome formation was evident after treatment with oba-
toclax and dexamethasone, which was completely inhibited by 
incubation with 3-MA (Figure 7, A and B). Cells displayed features 
consistent with a nonapoptotic cell death mechanism after expo-
sure to obatoclax and dexamethasone. Condensation of chromatin, 
a hallmark of classical apoptosis, was incomplete (Figure 7A, top 
row), which contrasts with the marked chromatin condensation 
after treatment with TRAIL, which induces death receptor–depen-
dent apoptosis in ALL cells (33). A characteristic feature of dead cells 
was the disintegration of the plasma membrane (Figure 7B), which 
is a hallmark of necroptosis (34). Increasing evidence suggests that 
a programmed necrotic cell death pathway can be triggered in the 
context of impaired apoptotic effectors, and this is dependent on 
RIP-1 kinase activity (12, 17). RIP-1 functions at the intersection of 
cell survival and cell death signalling (35, 36). Therefore, we test-
ed whether inhibition of RIP-1 with necrostatin-1 (nec-1; ref. 17) 
would interfere with steroid sensitization by obatoclax. Indeed, ste-
roid-resistant ALL cells treated with nec-1 were refractory to oba-
toclax-induced dexamethasone resensitization (Figure 7C). Nec-1 
also reduced the cytotoxic response to dexamethasone, alone or in 
combination with low-dose obatoclax in steroid-sensitive ALL cells 
(Figure 7C). Interestingly, nec-1 inhibited induction of BIM in ste-
roid-sensitive cells that showed BIM induction after dexamethasone 
(Supplemental Figure 8). Consistent with a central role for RIP-1 for 
the response to GC drugs, RIP-1–deficient ALL cells (37) were resis-
tant to obatoclax-mediated GC resensitization (Figure 7D).
The deubiquitinase cylindromatosis (turban tumor syndrome) 
(CYLD) is a direct regulator of RIP-1 kinase activity (38). Knocking 
down CYLD expression showed that CYLD is required for RIP-1–
dependent cell death induction by combination of dexamethasone 
and obatoclax (Figure 7E). Our results are consistent with the cur-
rent model, which proposes that the deubiquinated form of RIP-1 
is mediating cell death signals (35). An important finding is that 
induction of autophagy could be detected early, within 4 hours 
of treatment, and that generation of LC3-II was neither inhibited 
in RIP-1–deficient ALL cells (Figure 7F) nor in nec-1–treated ALL 
cells (Figure 7G). Taken together, these results demonstrate that 
the combination of obatoclax and dexamethasone triggers a non-
apoptotic cell death pathway, which shares the central features of 
necroptosis, including the characteristic morphology of cell death 
shown by electron microscopy, and a strict dependence on RIP-1 
kinase activity and RIP-1 deubiquitinase CYLD. Moreover, our 
data indicate that the autophagic process is triggered upstream of 
RIP-1 and does not occur as a consequence of necroptosis.
Obatoclax is a broad chemosensitizer in multidrug-resistant primary ALL 
cells, but activation of autophagy-dependent cell death is specific to the com-
bination with dexamethasone. To validate our results in primary cells, 
we tested pretreatment samples from PPR patients with precursor 
B cell ALL, who were further characterized by the molecular persis-
tence of leukemic cells under intensified conventional multiagent 
chemotherapeutic treatment and predicted to have a very high risk 
of relapse based on their poor in vivo response to chemotherapy 
(Supplemental Table 2). Indeed, low-dose obatoclax resensitized 
GC-resistant ALL cells to dexamethasone in mesenchymal stroma 
cell (MSC) cocultures, which was completely abolished using 3-MA, 
implicating autophagy as an essential mechanism in primary 
refractory ALL cells also (Figure 8A). At this dosage, obatoclax alone 
induces less than 5% cell death. Importantly, 3-MA did not interfere 
with the cytotoxic effect of treatment with dexamethasone, alone or 
combined with obatoclax, on primary ALL cells from GC-sensitive 
patients (Figure 8A), indicating that autophagy was not required 
for the death response to GC drugs in GC-sensitive cells. Consistent 
with our results in ALL cell lines, nec-1 abolished the GC-sensitiz-
ing activity of combination treatment in steroid-resistant primary 
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VHR-ALL cells. In contrast, blocking caspases with zVAD.fmk did 
not inhibit steroid resensitization in primary GC-resistant ALL 
cells, while the response to dexamethasone was inhibited by zVAD.
fmk treatment in cells from steroid-sensitive ALL patients.
Current treatment protocols include a steroid window followed 
by multidrug chemotherapy, including cytotoxic agents such as 
daunorubicin, vincristine, and cytarabine. Low-dose obatoclax 
resensitized primary refractory ALL cells to all 3 drugs, while the 
sensitivity of cells from sensitive patients was not increased fur-
ther. Interestingly, 3-MA did not restore resistance to these cyto-
toxic agents, indicating that induction of autophagy after treat-
ment with obatoclax is specific for GC resensitization (Figure 8B). 
In contrast, blocking caspases using zVAD.fmk completely inhib-
ited the resensitizing effect of low-dose obatoclax in combinations 
with daunorubicin, vincristine, and cytarabine, both in cells from 
very high risk and from standard risk patients. These results sup-
port the notion that autophagy-dependent necroptosis is specifi-
cally triggered with GCs in a GC-resistant context. Moreover, oba-
toclax could serve as a chemosensitizer for established multidrug 
regimens for ALL treatment, given its broad potential to restore 
the apoptotic response with non-GC antileukemic drugs.
Combination of obatoclax and dexamethasone is effective in a leukemia 
xenograft model, using cells from refractory ALL patients. To test the in 
vivo efficacy of obatoclax in GC resensitization, we transplanted 
primary ALL cells from 2 VHR-PPR patients into NOD/SCID/
IL2ranull (NSG) mice (39). When 1% human leukemic cells were 
detected in mouse peripheral blood, we treated mouse cohorts 
with vehicle, obatoclax (5 mg/kg/d), dexamethasone (5 +g/kg/d), 
or both for 3 weeks. In vehicle-treated animals, progression to leu-
kemia (>10% peripheral blasts) was observed in a median time of 11 
weeks for animals xenografted with cells from patient VHR-02 and 
1 week for animals xenografted with cells from patient VHR-01. All 
mice xenografted with cells from patient VHR-02 and treated with 
single-agent dexamethasone or obatoclax had to be sacrificed due 
to leukemia progression, while only 2 out of 8 animals treated with 
the combination of obatoclax and dexamethasone progressed to 
leukemia over the 50-week observation period. A significant delay 
in leukemia progression was achieved by combination treatment 
with dexamethasone and obatoclax when cells from VHR-01 were 
used (P < 0.02 for combination treatment versus vehicle or single 
agent treatment). This patient showed the recurrent translocation 
t(17;19)(q22;p13), which is virtually always associated with early 
relapse (40) (Figure 8C). This result suggests that GC sensitization 
of VHR-PPR ALL cells can be achieved in vivo, providing a strong 
rationale to explore the therapeutic potential of combined dexa-
methasone and obatoclax clinically.
%JTDVTTJPO
Here we describe a pharmacological approach that we believe to 
be new to specifically bypass the apoptotic blockade to chemo-
therapy in multidrug-resistant ALL. Subcytotoxic concentrations 
of the BCL-2 antagonist obatoclax restored the response to dexa-
methasone by inducing a nonapoptotic cell death pathway. The 
activation of autophagy-dependent cell death in cells that are 
resistant to the apoptotic stimuli by dexamethasone is reminis-
cent of observations that were reported using experimental sys-
tems with defined genetic defects of key regulators of the intrinsic 
and extrinsic apoptotic response. In Bax–/–Bak–/– MEFs and BCL-2– 
overexpressing MEFs, cell death triggered by etoposide or STS was 
dependent on autophagy genes beclin-1 and ATG-5 (11). As also 
reported by others (6, 8), obatoclax was cytotoxic for Bax–/–Bak–/– 
cell lines, which we demonstrate to be critically dependent on the 
autophagy pathway. Similarly, genetic or pharmacologic inter-
ference with caspase 8 or death receptor signalling can result in 
autophagy-dependent cell death with necroptotic features (12, 18, 
41). In lymphoid cells, this may constitute an alternative mecha-
nism to control abnormal cellular proliferation in the absence of a 
normal apoptotic response. In activated T cells from mice with cas-
pase-8 or FADD deficiency, autophagic signalling was required to 
induce RIP-1–dependent necroptotic cell death (41). We here show 
that this mechanism of cell death can be activated in GC-resistant 
leukemia to restore the response to dexamethasone.
Autophagy has been recognized as an important regulatory 
mechanism of cell fate decisions. While it is clear that autophagy 
can have a protective function at times of cellular stress, the contri-
bution of autophagy to the execution of programmed cell death is 
a subject of controversy (13). Our data demonstrate that autopha-
gic signalling is an integral part of the cell death mechanism when 
the response to dexamethasone is restored with obatoclax or rapa-
mycin. Both inhibitors that interfere early (3-MA) or late (bafilo-
mycin) with the autophagic process and knockdown of genes that 
are essential for autophagy, BECN1 and ATG7, prevented resensiti-
zation to dexamethasone completely. Combination of dexametha-
sone and obatoclax inhibited clonogenic growth of GC-resistant 
ALL cells, and electron microscopy imaging unequivocally showed 
rapid induction of necrotic cell death with autophagic features. 
There is clear evidence that in cancer, autophagy is not necessarily 
a protective feature. For example, BECN1 was shown to act as a 
haploinsufficient tumor suppressor gene (42, 43), with increased 
frequency of spontaneous neoplasia, including lymphomas in 
beclin-1–haploinsufficient mice. The genes that are essential for 
the autophagic machinery are highly conserved and required in 
several autophagy-dependent cellular processes (44). Several stud-
ies link autophagy genes to programmed cell death. In the central 
nervous system for example, ATG7 deficiency protected neurons 
from caspase-dependent and caspase-independent cell death 
after hypoxic/ischemic brain injury (45). In human glioblastoma, 
knockdown of the autophagy genes ATG1 or ATG5 prevented 
the cytotoxic effect of cannabinoids, which induce autophagy-
dependent cell death via an mTORC1-dependent pathway (46). 
Autophagy was also shown to regulate programmed cell death 
during development. The steroid hormone ecdysone triggered 
autophagy-dependent cell death during morphogenesis of sali-
vary glands from the larval stage to the adult stage in Drosophila. 
This cell death pathway was independent of caspase activity (47), 
providing compelling evidence for the modulation of an autopha-
gic cell death pathway via steroid hormone signalling in normal 
development. Similarly, autophagy is required for programmed 
cell death in the midgut during Drosophila metamorphosis, which 
provides additional evidence for specific regulation of cell death by 
autophagy, even in presence of an intact apoptotic machinery (48). 
Combination treatment of obatoclax with GC drugs but not with 
other cytotoxic agents induced autophagy-dependent cell death in 
resistant ALL. This raises the question of whether autophagy is also 
required for the effect of dexamethasone in GC-sensitive ALL. A 
recent report described increased autophagy after dexamethasone 
treatment in GC-sensitive ALL cell lines, but cell death was associ-
ated with apoptotic features and knockdown of beclin-1 resulted 
only in partial rescue of this effect (49). We also observed a partial 
reduction of dexamethasone cytotoxicity using 3-MA (Supplemen-
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tal Figure 6) or nec-1 (Figure 7C) in a subset of GC-sensitive cell 
lines. We could, however, not detect an effect of 3-MA in primary 
ALL cells, in which caspase-dependent cell death prevailed. Our 
results identify autophagy as an early and limiting step to steroid 
sensitization by obatoclax in GC-resistant cells and underscore the 
importance of understanding the cellular context when designing 
strategies to target autophagy for cancer treatment.
There is clear evidence for hyperactivation of AKT (50) and 
mTOR (5) in GC-resistant ALL. Because mTOR is implicated in 
the control of autophagy in different settings (27), hyperactive 
AKT-mTOR signalling could prevent induction of autophagy in 
resistant disease. We hypothesized that GC-resistant ALL cells 
could therefore be primed for mTOR-controled autophagy. Con-
sistent with this idea, we found that induction of autophagic cell 
death by the combination of dexamethasone and obatoclax result-
ed in marked reduction in phosphorylation of the mTOR target 
S6 protein in resistant cells. The mechanisms by which obatoclax 
or rapamycin potentiate the effect of dexamethasone on mTOR 
appear to be different. Indeed combination of dexamethasone 
with rapamycin, but not with obatoclax, resulted in a marked 
decrease in phosphorylation of AKT on Ser473, consistent with 
recent finding showing that mTOR can also act upstream of AKT 
(51). Modulation of mTOR target phosphorylation was only seen 
when obatoclax was combined with dexamethasone, but not with 
other cytotoxic agents, suggesting that dexamethasone exposure 
contributes to inhibition of mTOR. Indeed, exposure to dexa-
methasone was reported to be associated with repression of mTOR 
signalling in myoblast cell lines and lymphoid cells (28, 52). The 
importance of mTOR for the control of autophagy is also under-
scored by the results of a comprehensive screen using a chemical 
compound library in order to identify new pharmacologic induc-
ers of autophagy, in which proautophagic activity of candidate 
molecules was always associated with decreased phosphorylation 
of mTOR targets (53). Extensive studies will be required to dissect 
the primary signalling events triggered by the combination of oba-
toclax and dexamethasone, as they may provide important clues 
about the mechanisms of drug resistance in ALL.
GC resistance does not appear to be associated with genetic or 
functional defects of the GC receptor in ALL (54, 55). Dexametha-
sone was proposed to induce apoptosis by increasing the levels of 
the BH3-only proapoptotic protein BIM, which were markedly 
reduced in selected cases of GC-resistant ALL (32). However, in most 
cases tested, we could not detect induction of BIM by dexametha-
sone in GC-sensitive cell lines and primary ALL cells. Furthermore, 
we did not detect increased levels of BIM, decreased MCL-1 pro-
tein levels, or increased MCL-1 protein turnover associated with 
steroid sensitization. Instead, we found, by immunoprecipitation 
of endogenous proteins, subcytoxic concentrations of obatoclax 
to result in the disruption of MCL-1 with beclin-1 in ALL cells. 
This suggests the possibility that MCL-1 could control induc-
tion of autophagy via beclin-1, as it was proposed for other BCL-2 
family members recently (14, 15). Interestingly, this effect was not 
seen in cells treated with rapamycin, again pointing out that the 
target mechanism of obatoclax is different. We recognize the fact 
that this effect could also result from indirect mechanisms on the 
protein complex, including MCL-1 and beclin-1. Furthermore, 
functional experiments modulating MCL-1 expression levels were 
not conclusive. Knockdown of MCL-1 resulted in moderate activa-
tion of apoptosis and partial sensitization to dexamethasone that 
was caspase dependent but prevented complete resensitization to 
dexamethasone by obatoclax and autophagic cell death. Activation 
of apoptosis is possibly overriding induction of autophagy in this 
context. In support of this hypothesis, we detected activation of 
caspase-9 after downregulation of MCL-1, with caspase-9–depen-
dent cleavage of beclin-1. This provides a possible mechanism to 
prevent autophagy induction when apoptosis is activated. Taken 
together, steroid modulation with low-dose obatoclax did not 
involve release of proapoptotic BCL-2 family proteins from MCL-1 
but triggered autophagy-dependent cell death by a mechanism 
that required the presence of MCL-1.
In this context, activation of autophagy is required to induce 
necroptosis, a form of programmed necrosis that has been 
described to occur when apoptosis is abortive due to caspase 
inhibition (16, 56). Execution of necroptosis is dependent on the 
RIP-1 kinase (17). Our data demonstrate that RIP-1 activity is 
absolutely required for steroid sensitization by obatoclax and by 
rapamycin. The cell death morphology that was documented by 
electron microscopy is consistent with the morphology reported 
for necroptosis (12, 56). Furthermore, the deubiquitinase cyl-
indromatosis (CYLD), which has been shown to regulate RIP-1 
(38), was functionally required for execution of necroptosis. This 
is consistent with experiments showing that RIP-1 kinase activ-
ity was required to trigger cell death and that ubiquitination of 
RIP-1 prevents cell death signalling (16, 19). RIP-1 and CYLD were 
included among the core genes that were identified in a functional 
siRNA screen for genes that were essential for necroptosis (18). To 
the best of our knowledge, we provide the first clinically relevant 
model with consistent validation in primary leukemia cells from 
patients with very high risk disease, in which the necroptotic path-
way can be exploited to restore response to therapy. As such, this 
will constitute a very relevant experimental model to study the 
mechanisms of necroptosis in depth. Our results clearly imply a 
direct link between the autophagic pathway and RIP-1–mediated 
signalling events leading to necroptosis. Autophagy is triggered 
early and independent of RIP-1 kinase activity, indicating that it 
acts upstream of necroptotic signals. A number of studies identify 
RIP functionally as part of a complex with proteins of the death 
receptor pathway, such as FADD and caspase-8 (35). Experiments 
using mouse models indicate that autophagy and necroptosis 
could be linked via recruitment of components of the death recep-
tor pathway to the membrane of autophagosomes (41). It is tempt-
ing to speculate that a similar mechanism is triggered in ALL cells 
upon costimulation with dexamethasone and obatoclax. Our find-
ings warrant extensive biochemical follow-up studies to under-
stand how RIP-1 is activated and how the autophagic machinery 
is connected to the necroptotic pathway.
Based on promising studies by others (32), we have established 
a leukemia xenograft model of de novo highly resistant ALL. The 
power of this approach resides in the possibility to select cases 
from relevant patient groups, starting from cryopreserved left-
over diagnostic samples, from one of the largest cooperative trials 
for the treatment of childhood ALL. By focusing on cases with 
VHR-ALL by MRD, we also selected for patients that are most 
significantly resistant to prednisone in vivo, as defined by the 
reduction of leukemia cells in the peripheral blood after 1 week 
of prednisone monotherapy. Accordingly, ALL cells from these 
patients were completely resistant to dexamethasone and other 
chemotherapeutic agents in vitro. Low-dose obatoclax restored 
the response to dexamethasone, both in precursor B cell and T cell 
ALL cases. The durable remissions observed with 1 year follow-up, 
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using the leukemia xenograft model, are indicative of strong 
antileukemic activity. Furthermore, the broad chemosensitizing 
effect of low-dose obatoclax in combination with daunorubicin, 
vincristine, and cytarabine in multidrug-resistant primary ALL 
cells provides a strong basis for further evaluation of obatoclax in 
combination with a multidrug regimen. The xenograft approach 
will be essential to validate this approach for heavily pretreated 
relapse and refractory patients. Our observation that isolated 
clones can emerge in clonogenic assays after treatment of a cell 
line with obatoclax and dexamethasone indicates that resistance 
to this approach may occur. Our established xenograft system will 
enable us to screen a larger number of ALL cases to verify whether 
resistance to this approach has to be expected. The identification 
of resistant cases would provide a model to establish markers 
that correlate with response or resistance. Based on current data, 
dynamic changes of mTOR activity with treatment represent a 
good candidate marker. Such knowledge will serve to optimize 
patient selection for clinical trials.
Taken together, our data support a model in which the apop-
totic blockade in GC-resistant ALL cells can be overcome by acti-
vating an autophagy-dependent necroptotic cell death pathway. 
The characteristic necroptotic features by electron microscopy 
and the changes in the phosphorylation profile of S6 protein pro-
vide tools to assess the biological response to combination treat-
ment with obatoclax and dexamethasone in patients in refractory 
ALL. Given the acceptable toxicity profile of obatoclax in clini-
cal studies in adults with hematologic malignancies (9, 10), our 
study provides a compelling rationale for the evaluation of this 
new pharmacological strategy for the treatment of children with 
refractory and relapsed ALL.
.FUIPET
Cell culture, reagents, and standard procedures. CEM-C7-14 and CEM-C1-15 
cells (referred to CEM-C7 and CEM-C1 in the text) were provided by E.B. 
Thompson (University of Texas Medical Branch, Galveston, Texas), human 
hTERT-immortalized primary bone marrow MSCs (57) were provided by 
D. Campana (St Jude Children’s Research Hospital, Memphis, Tennessee), 
caspase-9–deficient and retransfected Jurkat cells (58) as well as Bax/Bak-
deficient Jurkat cells (59) were provided by K. Schulze-Osthoff (Univer-
sity of Tübingen, Germany), and parental and Bax/Bak-deficient MEFs 
(26) were provided by J.-C. Martinou (University of Geneva, Switzerland). 
Rip1–/– cells were provided by B. Seed (Harvard Medical School, Boston, 
Massachusetts). Obatoclax was provided by J. Viallet and G. Shore (Gemin 
X, Malvern, Pennsylvania) and ABT-737 was provided by S. Elmore and S. 
Rosenberg (Abbott Laboratories, Chicago, Illinois).
Detailed procedures are described in Supplemental Methods. For RNA 
silencing experiments, 30 nM beclin-1 (sc-29797, Santa Cruz Biotechnology 
Inc.) was used. pEGFP-LC3 was provided by M. Jäättelä (Danish Cancer Soci-
ety, Copenhagen) and the FLAG-tagged beclin-1 construct by B. Levine (Uni-
versity of Texas Southwestern Medical School, Dallas). All constructs were 
transfected by nucleofection (Amaxa) using solution V and Amaxa program 
T-016 for CEM-C1, A-024 for CEM-C7 cells, and U-020 for MEFs. Transfec-
tion efficiency was controlled using the pEGFP plasmid (Clontech).
Patient samples. ALL cells were recovered from cryopreserved anonymized 
samples from patients who were enrolled in the ongoing ALL-BFM 2000 
protocol and had given informed consent in accordance with the Decla-
ration of Helsinki. Approval was obtained from the Institutional Review 
Board (IRB) of the Medical School Hannover and the local IRB for all par-
ticipating centers in the trial ALL-BFM 2000. This approval extends to the 
use of leftover diagnostic material for add-on research projects, including 
those addressing basic biological questions.
In vitro drug response. In vitro drug response curves in cell lines were 
established with the MTT assay and were normalized to vehicle con-
trol. Primary patient samples were cocultured on hTERT-immortalized 
human MSCs, and drug response curves were analyzed with flow cytom-
etry using propidium iodide.
Xenograft model. Xenograft experiments were approved by the veterinary 
office of the Canton of Zurich. In brief, primary ALL cells were recovered 
from cryopreserved samples and transplanted intrafemorally to NSG mice. 
Leukemia progression was monitored by flow cytometry with human 
CD45 and CD19 antibodies (AbD Serotec). ALL cells recovered from 
spleens of NSG mice after the first xenotransplantation were used for in 
vivo therapeutic trials. Randomized cohorts were treated with vehicle intra-
muscularly (i.m.): 3 mg/kg/d obatoclax i.m., 5 mg/g/d dexamethasone i.p., 
or the combination of dexamethasone i.p. and obatoclax i.m. for 5 days per 
week for 3 consecutive weeks.
Statistics. All experiments were performed 4 times, unless stated otherwise 
in the figure legends. Data are represented as mean ± SD. For in vitro experi-
ments, Student’s t test (2-tailed) was used on triplicates. P values of less than 
0.05 were considered significant. Event-free survival (EFS) was defined as 
the time from the start of treatment until 10% of human leukemia cells were 
detectable in the mouse peripheral blood and was assessed by Kaplan-Meier 
analysis. Survival curves were analyzed with the log-rank test (GraphPad 
prism). P values of less than 0.05 were considered significant.
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Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in
which aberrant expression of CRLF2 is associated with mutated JAK2: a report
from the International BFM Study Group
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We report gene expression and other analy-
ses to elucidate the molecular characteris-
tics of acute lymphoblastic leukemia (ALL)
in children with Down syndrome (DS). We
find that by gene expression DS-ALL is a
highly heterogeneous disease not definable
as a unique entity. Nevertheless, 62% (33/53)
of the DS-ALL samples analyzed were char-
acterized by high expression of the type I
cytokine receptor CRLF2 caused by either
immunoglobulin heavy locus (IgH@) translo-
cations or by interstitial deletions creating
chimeric transcripts P2RY8-CRLF2. In 3 of
these 33 patients, a novel activating somatic
mutation, F232C in CRLF2, was identified.
Consistent with our previous research, mu-
tations in R683 of JAK2 were identified in
10 specimens (19% of the patients) and,
interestingly, all 10 had high CRLF2 expres-
sion. Cytokine receptor-like factor 2 (CRLF2)
and mutated Janus kinase 2 (Jak2) cooper-
ated in conferring cytokine-independent
growth to BaF3 pro-B cells. Intriguingly, the
gene expression signature of DS-ALL is
enriched with DNA damage and BCL6 re-
sponsive genes, suggesting the possibility
of B-cell lymphocytic genomic instability.
Thus, DS confers increased risk for geneti-
cally highly diverseALLs with frequent over-
expression of CRLF2, associated with acti-
vating mutations in the receptor itself or in
JAK2. Our data also suggest that the major-
ity of DS children with ALL may benefit from
therapy blocking the CRLF2/JAK2 path-
ways. (Blood. 2010;115:1006-1017)
Introduction
Children with Down syndrome (DS) have a higher rate of acute
lymphoblastic leukemia (DS-ALL). DS-ALLs are mostly of B-cell
precursor (BCP) origin and similar in the age of diagnosis and
immunophenotype to high hyperdiploid (HD) or TEL-AML1 ALLs,1
the 2 most common genetic subtypes of childhood ALL. Given that
these cytogenetic abnormalities are less frequent in DS-ALL,2 the
existence of unique collaborating somatic genetic events in DS-
ALL, similar to the GATA1 mutation in DS-acute megakaryoblastic
leukemia,3 has been postulated.
We and others reported the presence of somatic activating mutations
in JAK2 in approximately 20% of DS-ALLs.4-6 Similar mutations are
present in approximately 10% of high-risk ALLs in non-DS children,
corresponding to approximately 3% of unselected childhoodALLs.7 We
hypothesized that the mutated Janus kinase 2 (JAK2) may cooperate
with a type I cytokine receptor that is aberrantly expressed in DS-ALL.4
To characterize additional molecular abnormalities in DS-ALL,
we performed genomic analysis of a large group of DS-ALLs. This
analysis reveals, next to a striking heterogeneity of these leuke-
mias, an aberrant expression of the cytokine receptor CRLF2 in
62% of the patients, associated with somatic activating mutations
in JAK2 or in the receptor itself.
Methods
Patient samples
RNA and DNA were derived from diagnostic bone marrow samples of
children with DS and BCP-ALL enrolled on treatment protocols with an
informed consent and approval of the ethics committees of all participating
institutions in accordance with the Declaration of Helsinki. Samples were
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anonymized for the study. Patients’ clinical data are described in supple-
mental Tables 1 and 2 (available on the Blood website; see the Supple-
mental Materials link at the top of the online article). Seventy-six of these
patients were included in our previous publication describing the JAK2
mutations in DS-ALL.4 The study was approved by the Israeli Health
Ministry Ethic committee (approval no. 920070771).
Genomic studies
RNA processing and hybridization to Affymetrix arrays were performed
according to the manufacturer’s instructions and as previously published.8,9
Only specimens containing more than 70% blasts were included. There
were 4 datasets obtained by different teams as summarized in Table 1.
Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) is the
main dataset used for gene expression analysis, comprising 97 diagnostic
ALL samples: 25 DS-ALL, and 72 non–DS-ALL samples, described in
Table 1. The additional 3 datasets were used for validations. The primary
gene expression data files have been deposited in National Center for
Biotechnology Information’s Gene Expression Omnibus (GEO; http://
www.ncbi.nlm.nih.gov/geo/)11 (GEO series accession no. GSE17459).
Genomic DNA from 42 diagnostic bone marrow ALLs and 34 paired
remission samples were genotyped with Affymetrix GeneChip Human
Mapping 100K set (Affymetrix) according to the manufacturer’s directions.
See supplemental data for details.
Mutation analysis
Mutation analysis was performed as we previously described.4,12 CRLF2
(NM_022148.2) primers are described in supplemental Table 3.
Quantitative real-time PCR
Quantitative real-time polymerase chain reaction (qRT-PCR) was per-
formed using Applied Biosystems TaqMan Gene-Expression Assays (CRLF2
Hs_00845692, GAPDH Hs_99999905) according to the manufacturer’s
instructions. Each sample was run in triplicate. The endogenous control
gene was GAPDH.
FISH
Fluorescence in situ hybridization (FISH) for detection of IGH@-CRLF2
translocation or the presence of a microdeletion upstream to CRLF2 was
performed as described.13
Flow cytometric analysis
Flow cytometric analysis (FACSCanto II [Becton Dickinson]; FlowJo
software [TreeStar]) was performed on primary cryopreserved ALL cells
after the first xenotransplantation in Nod/LtSzScid interleukin-2 (IL2)–
null mice. Antibodies used were anti–cytokine receptor-like factor 2
(CRLF2; clone 1D3, ab48482; Abcam), goat anti–mouse Alexa Fluor 488
(Invitrogen), anti-IL7RA Alexa 647 (CD127, clone HIL-7R-M21; BD),
anti-CD19 phycoerythrin (clone LT19, MCA1940; AbD Serotec), and
7-amino-actinomycin D (AbD Serotec). All samples were gated on the
viable (7-amino-actinomycin D–negative) and leukemic (CD19) popula-
tion before analysis of CRLF2 and IL7RA. For the calculation of delta
mean fluorescence intensity (MFI), background nonspecific staining was
evaluated in populations gated by CD19, comparing tubes with or without
anti-CRLF2 antibodies. This background MFI was similar to the MFI of
CRLF2-negative populations in normal human blood.
Plasmid construction
The FLAG-mJak2 wild-type and R683S were cloned into the pHRSINCSGW
lentivirus,12 which carries spleen focus-forming virus (SFFV) promoter and an
emerald green fluorescent protein reporter. pMX-Puro-hCRLF2 was used as a
template for the generation of CRLF2 mutations by site-directed mutagenesis
(QuikChange-II-XL; Stratagene).
Cell lines
BaF3 cells were cultured in RPMI-1640 containing 10% fetal calf serum
and 10% WHEI-3B conditioned media as a source of interleukin-3.
Parental BaF3 cells were transduced with pMX-Puro-hCRLF2,14 and
hCRLF2-expressing cells were selected with puromycin (2 g/mL). Paren-
tal BaF3 and BaF3-CRLF2 cells were transduced with the appropriate
Jak2-expressing vector and green fluorescent protein–positive cells were
sorted by flow cytometry 3 to 4 days later.
BaF3 proliferation assays and Western blotting
BaF3 proliferation assays and Western blotting were performed as de-
scribed before.4 Antibodies used were anti-JAK2 (C-20; Santa Cruz
Biotechnology), anti–signal transducer and activator of transcription 5
(STAT5), anti–phospho-JAK2 Tyr1007 (Cell Signaling Technology), anti–
phospho-STAT5 Tyr694 (Epitomics), anti–human thymic stromal lympho-
poietin (hTSLPR; AF981; R&D Systems), anti–FLAG-M2, and anti–-
tubulin (Sigma-Aldrich).
Pharmacologic inhibition of JAK2
BaF3 cells expressing Jak2 R683S and BaF3/CRLF2 cells expressing
wild-type (wt) or R683S Jak2 were cultured without cytokines in different
concentrations of JAK inhibitor I (Calbiochem). Controls were BaF3/EpoR
cells expressing BCR-ABL. Viable cells were counted after 72 hours. Data
from 3 independent experiments were combined for analysis. We calculated
the normalized viability by dividing the cell number at each inhibitor
concentration by the cell number with vehicle alone.
Bioinformatics
Gene expression preprocessing is described in supplemental Methods.
Combining probe sets of the same gene. For those genes that were
represented by more than one probe set, we used, when needed, a
combination procedure to create a single representation of a gene’s
expression (supplemental Methods).
GSEA. The first ingredient of Gene Set Enrichment Analysis (GSEA)15
is a list of genes (L), ranked by some attribute (A), ordered from low to high
values of A. The second ingredient is a set of genes (S) that is a subset of L.
GSEA aims at answering whether the members of S are randomly
distributed along the ranked list L, or whether they are skewed toward one
of the sides. For details see supplemental Methods and Subramanian et al.15
Refining DS-ALL profile genes. The preliminary DS-ALL profile
gene list, which was constructed using the AIEOP dataset, was narrowed
down using GSEA15 to select genes that show consistent expression pattern
in at least 2 of the other 3 datasets (Table 1). We used the up-regulated members
Table 1. Description of the gene expression datasets analyzed
Dataset symbol
No. samples
PlatformTotal DS-ALL HD TEL-AML1 Other
AIEOP* 97 25 26 29 4 E2A-PBX1, 6 MLL, 7 BCR-ABL Affymetrix HG-U133 Plus 2.0
ICH 15 6 5 4 Affymetrix HG-U133 Plus 2.0
BFM8*  St Jude10† 36 7 12 17 Affymetrix HG-U133A
IL† 27 11 10 6 Affymetrix Exon 1.0 ST
AIEOP indicates Associazione Italiana Ematologia Oncologia Pediatrica; ICH, Institute Child Health; BFM, Berlin-Frankfurt-Munster; and IL, Israel.
*IL is partially overlapping with AIEOP (5 DS-ALLs) and BFM (4 different DS-ALLs).
†We used a subgroup of HD and TEL-AML1 samples from St Jude dataset.
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of the preliminary DS-ALL genes as our set S (see “Bioinformatics”) and the
genes of 1 of the other 3 experiments constituted L. The genes of L were ordered
according to their differential expression in DS versus the rest of the samples (see
Refining DS-ALL profile genes in supplemental Methods). The process was
repeated for each of the 3 datasets and for the down-regulated genes, yielding for
each case genes that were identified as consistently up-regulated (or down-
regulated) in the AIEOP dataset and the other dataset tested (Figure 2A).
Results
Marked heterogeneity of DS-ALLs revealed by unsupervised
gene expression analysis
We first explored the extent of similarity between DS-ALLs and
other defined BCP-ALL genetic subtypes using in the analysis the
1500 probe sets with the highest standard deviation among the
AIEOP samples. Two unsupervised analysis algorithms were used:
Sorting Points Into Neighborhoods (SPIN),16 which places samples
with similar expression profiles near each other (Figure 1A), and
Principal Component Analysis (PCA; MATLAB 7.4 software
[Mathworks]; Figure 1B). Both gave similar results.
In agreement with previous studies,10 unsupervised analysis of
gene expression tends to group the pediatric ALL samples accord-
ing to their genetic subtypes. As can be seen in the Euclidian
distance matrix in Figure 1A, the ALL subgroups that are the most
homogenous (exhibiting high similarity of samples of the same
subtype) are E2A-PBX1–positive ALL and MLL-AF4–positive
ALL, followed by TEL-AML1–positive ALL. HD-ALL samples are
also grouped together, but are relatively more distant from each
other than the E2A-PBX1, MLL-AF4, and TEL-AML1 samples.
Although BCR-ABL ALLs are clustered together, they are less
homogeneous, consistent with previous reports.10
In contrast, DS-ALLs are very heterogeneous (Figure 1A-B).
Approximately half are grouped together, relatively close to both
BCR-ABL and HD-ALL. However even here, individual DS
samples are further separated from each other than a typical pair of
samples within the other ALL subtypes (Figure 1A-B). The other
half are grouped with other ALL subtypes: 6 with TEL-AML1,
6 with HD, 2 with BCR-ABL, and 1 with E2A-PBX1. Of these
15 DS-ALLs, only 3 carried the chromosomal translocation of the
subtype of ALL to which they are most similar (1 E2A-PBX1,
2 TEL-AML1) and only 1 DS-ALL sample was found to be also
HD. Even the 5 DS-ALL samples with somatic mutations in JAK2
(blue boxes below Figure 1A and black circles at Figure 1B) are not
clustered together.
This unsupervised gene expression analysis reveals that DS-
ALLs are markedly less homogenous than the other ALL genetic
subtypes. It suggests that DS is a predisposing condition to several
genetic subtypes of B-cell precursor ALLs, and that unlike the
myeloid leukemia of DS should not be considered as a unique
molecular entity.
Genomic analysis of DS-ALL
We performed 100-K single nucleotide polymorphism array analy-
sis of 34 paired diagnosis and remission samples (15 DS-, 9 HD-,
and 10 TEL-AML ALLs, supplemental Methods). Copy number
and loss-of-heterozygosity analyses (supplemental Figure 3; supple-
mental Table 10) generally confirm previous reports5,17 that dele-
tions are more common in DS and TEL-AML1 compared with
HD-ALLs. The frequency of deletions in genes regulating normal
B-lymphoid development (supplemental Table 9) in DS-ALL was
53%, slightly higher than the 40% reported for of BCP-ALL.18
Recently, deletions in the IKZF1 gene were reported in the majority
of patients with BCR/ABL and “BCR/ABL-like” ALL.19,20 Because
most of these deletions involve only a subset of exons (most
commonly exons 4-7), the 100-K single nucleotide polymorphism
platform is inadequate to detect these abnormalities. Therefore,
38 additional diagnostic DS-ALL specimens were screened for
IKZF1 deletions by PCR analysis as previously reported.21 Monoal-
lelic IKZF1 deletions were identified in 9 patients (24%; supplemen-
tal Table 8 and supplemental Figure 3). Thus the frequency of
deletions in B-cell differentiation genes, including IKZF1, in
DS-ALL is similar to other non–BCR-ABL subtypes of BCP-ALL.
DS-ALL gene expression profile
We hypothesized that, despite their heterogeneity, DS-ALLs share
a common gene expression signature. We reasoned that by
comparing the gene expression in DS-ALL to the relatively similar
groups, HD and TEL-AML1, we could potentially isolate the
“DS-ALL” characteristics from the other ALL characteristics that
might be similar between these groups. In addition, the analysis
was done in a way that only genes that differentiate DS from
TEL-AML1 and from HD-ALLs are depicted. The fact that
TEL-AML1 and HD-ALLs have dissimilar expression profiles
(denoted by dark red entries in Figure 1A) helps to identify genes
that characterize DS-ALL, and not one of the groups to which it
is compared.
We first identified probe sets that had significant differential
expression in DS-ALL samples, compared with both HD and
TEL-AML1 ALLs in the AIEOP dataset (supplemental Methods).
Figure 1. Unsupervised analysis of the AIEOP dataset.
(A) Samples’ Euclidian distance matrix. The color in each entry
(y,x), where x,y  1, . . . , 97 (the number of samples), represents
the Euclidian distance between the expression profiles of samples
x and y. It was measured after centering and normalization of each
sample’s expression, using 1500 probe sets with highest standard
deviation. The samples are ordered by SPIN along both the x-axis
and y-axis. The color bars next to both axes represent the different
ALL subtypes, listed on the right of the figure. The blue marks at
bottom specify DS-ALL samples with mutant JAK2 (J2m), and the
red marks specify samples with high CRLF2 expression levels
(CRLF2) (see “Aberrant expression of the cytokine receptor
CRLF2 in DS-ALLs” section on CRLF2). (B) Projection of all
samples onto the first 3 principle components of the expression.
DS indicates Down syndrome ALL; J2m, Down syndrome ALL
with mutated JAK2 R683; HD, high hyperdiploid; TEL, TEL-AML1;
BCR, BCR-ABL; E2A, E2A-PBX1; and MLL, MLL-AF4.
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This “preliminary DS-ALL profile” consisted of 792 genes up-
regulated and 535 genes down-regulated in DS-ALL. To check
consistency with each of the other 3 gene expression datasets
(“BFM,” “ICH,” and “IL”), we performed GSEA22 separately on
each of the 3. A representative enrichment analysis is shown in
Figure 2A; here the genes are ordered according to their DS-ALL
differential expression in the ICH dataset (used as the list L;
“Bioinformatics”), and the 535 genes down-regulated in DS-ALL
are used as the set S, tested for enrichment. Six such analyses
showed significant enrichment of the preliminary gene lists (both
up- and down-regulated) obtained from AIEOP, in the other
3 datasets (Table 2). We refined our AIEOP-based lists by including
only genes that showed consistent expression patterns in at least
2 of the 3 other datasets. The “refined DS-ALL profile genes”
(Figure 2B) consists of 152 up-regulated and 199 down-regulated
genes (supplemental Tables 4-5).
Pathway analysis and BCL6 signature
To identify molecular pathways that showed differential expression
in the refined DS-ALL profile, we interrogated the DAVID
database23 of Gene Ontology functional categories.24 Constituent
genes of 8 pathways were significantly (false discovery rate [FDR]
 10%) overrepresented in the DS-ALL expression profile (Table
3 and supplemental Table 6). The most enriched pathway (P  .001)
is “Response to DNA damage stimulus”: 10 of the 341 genes
assigned by DAVID to this pathway are down-regulated and 6 are
up-regulated in DS-ALL. One of the up-regulated genes is BCL6,
with a mean fold change of 1.46 in DS-ALL compared with non
DS-ALL (supplemental Table 4). BCL6 is a transcription factor
expressed primarily in mature B cells at the germinal centers,
where it facilitates immunoglobulin (Ig) affinity maturation by
repressing the DNA damage response. It is also a known oncogene
in diffuse large B-cell lymphomas.25,26
To search for evidence for BCL6 activity in the DS-ALL gene
expression profile, we used the Oncomine (http://www.oncomine.
org)27,28 database, in which cancer gene expression signatures
derived from different expression analyses are stored as molecular
concept maps. These are lists of differentially expressed genes
between 2 logical groupings of normal or malignant human tissue
or cell lines. We tested BCL6 direct targets and each of the
24 Oncomine molecular concept maps that involve BCL6 (supple-
mental Table 7) for enrichment in DS-ALL up- and down-regulated
genes, and 8 of these 25 gene groups passed at false discovery rate
(FDR)29 of 15% (Table 4). These include the target genes of
BCL6,32 genes modified by ectopic expression of BCL6 in
lymphoblastoid B cells,30 and the gene expression signature of
B-cell lymphomas with oncogenic activation of BCL6.31 Hence the
targets and pathways downstream to BCL6 in lymphomas and
mature B cells are modified in the DS-ALL expression profile.
Aberrant expression of the cytokine receptor CRLF2 in
DS-ALLs
We have previously hypothesized that a cytokine receptor may be
aberrantly expressed in DS-ALL and cooperate with JAK2 carrying
Figure 2. DS-ALL gene expression profile. (A) GSEA analysis on ICH dataset. Genes are ranked (bottom of panel, gray) according to their expression in DS-ALL samples
versus the rest of the samples, by GSEA, using the default parameters. The members of a gene set S (here, the set of 535 genes down-regulated in DS-ALL, AIEOP data) are
tested: are they randomly distributed in the ranked gene list, or primarily found at the top or bottom? Occurrences of members of the gene set S in the ranked gene list are
shown as vertical black lines above the ranked signature. The green curve and upper y-axis represent the enrichment score (ES) as a function of the number of ranked genes
tested for enrichment of gene set S. See supplemental Methods for full details. (B) Expression levels of the genes from the refined DS-ALL lists, measured on the AIEOP
dataset. Four hundred twenty-three probe sets that belong to the refined DS-ALL profile gene lists are centered and normalized. Values for each individual case are
represented by a color, with red representing deviation above the mean and blue representing deviation below the mean. The colors along the x-axis represent the different ALL
subtypes, listed on the right of the plot. DS indicates Down syndrome ALL; HD, high hyperdiploid; TEL, TEL-AML1; BCR, BCR-ABL; E2A, E2A-PBX1; and MLL, MLL-AF4.
Table 2. GSEA for genes of the DS-ALL expression signature,
identified from the AIEOP dataset, in 3 other datasets
Enrichment
score Nominal P FDR q-value
DS-ALL up-regulated genes
ICH dataset 0.437993 .010 0.008979
IL dataset 0.361621 .035 0.022851
BFM dataset 0.344479 .002 0.009101
DS-ALL down-regulated genes
ICH dataset 0.50601554 .006 0.012959
IL dataset 0.5008136 .012 0.006397
BFM dataset 0.55240697 .002 0.001131
Table 3. Gene ontology pathways overrepresented in the differential
DS-ALL signature
Gene ontology group Size P FDR, %
GO:0006974 response to DNA
damage stimulus
16  .001 0.77
GO:0006397 mRNA processing 13 .002 2.80
GO:0015031 protein transport 24 .002 3.30
GO:0008104 protein localization 26 .002 3.70
GO:0046907 intracellular transport 24 .003 4.40
GO:0065003 macromolecular
complex assembly
20 .004 5.80
GO:0051649 establishment of
cellular localization
27 .005 7.60
GO:0043067 regulation of
programmed cell death
19 .006 9.10
For details, see supplemental Table 6.
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the “lymphoid” mutation in R683.4 Examination of the DS-ALL
expression signature (supplemental Table 4) reveals that the third
most differentially expressed gene is CRLF2 (cytokine receptor-
like factor 2, TSLPR) located at the pseudoautosomal region of the
sex chromosomes. As depicted in Figure 3A, increased expression
of CRLF2 was noted in 23 (62.1%) DS-ALLs of 37 samples that
were hybridized to U133 family of arrays (CRLF2 is not repre-
sented on the exon arrays used in the IL dataset), compared with
other ALL subtypes (see supplemental Methods). CRLF2 expres-
sion along DS-ALL versus all other ALL subtypes yielded t test
P values less than .001 for AIEOP, BFM, and ICH datasets.
CRLF2 is known to dimerize with IL7RA to form the het-
erodimeric receptor for thymic stromal lymphopoietin (TSLP).33
Whereas CRLF2 is aberrantly expressed in DS-ALLs (Figure 3A),
expression of IL7RA is similar in the different ALL subtypes
(Figure 3B).
To validate the findings of the expression arrays and to analyze
additional DS-ALL samples, we measured the expression of
CRLF2 by qRT-PCR in 32 patients (Figure 3C). Microarray data
were available for 16 of these cases. The qRT-PCR confirms the
CRLF2 expression levels seen in the arrays (Pearson correla-
tion  0.85, P  .001). In 2 patients’ CRLF2 expression was
analyzed in RNA derived from diagnostic and remission bone
marrows and was seen only in the diagnostic sample. In one
patient, similar CRLF2 expression levels were seen in bone marrow
samples from diagnosis and relapse (supplemental Figure 2).
Altogether, 33 (62.3%) of 53 DS-ALL patients analyzed by either
qRT-PCR or microarrays overexpressed CRLF2. The surface
expression of the CRLF2 protein was also verified on 4 samples by
flow cytometry (Figure 3D). IL7RA is also expressed on the
leukemic blasts independent of CRLF2 expression.
Recently, Russell et al13 reported aberrant expression of CRLF2
caused by either chromosomal translocations to the IGH@ locus or
interstitial deletions upstream to CRLF2 juxtaposing CRLF2 with
the P2RY8 regulatory elements in approximately 5% of childhood
ALLs. To examine whether the increased CRLF2 expression in
our specimens was caused by the same genomic aberrations,
12 available diagnostic DS-ALL samples overexpressing CRLF2
were analyzed by FISH (Figure 4A). IGH@ translocations were
seen in 4 specimens and interstitial deletions in 7. In the remaining
sample (no. DS-32; supplemental Table 2), in which the CRLF2
expression level was just above the threshold, the FISH pattern of
CRLF2 appeared normal. Further evidence supporting the presence
of the deletions is provided by a statistically significant inverse
correlation between CRLF2 and P2RY8 expression (P  .02,
Figure 4B).
To test whether the deletion caused a fusion between the P2RY8
and CRLF2, we performed RT-PCR with primers derived from both
genes (supplemental Table 3). A transcript fusing the first noncod-
ing exon of P2RY8 and the first exon of CRLF2 prior to the ATG
was detected in the 2 DS patients with the deletion detected by
FISH but not in the patient with the IgH@ translocation (Figure
4C). A similar chimeric transcript was described in a single patient
with splenic lymphoma, fusing P2RY8 to SOX5 resulting in
overexpression of SOX5.34 We extended the analysis and identified
the chimeric transcript in 7 of 10 patients with overexpression of
CRLF2 and in none of 8 samples with no expression of CRLF2
(supplemental Table 2). Thus, consistent with the FISH findings,13
the interstitial deletion is more common than the IgH@ translocation.
To explore the effect of CRLF2 on gene expression, we
compared the 30% of DS-ALLs with the highest CRLF2 expres-
sion and the 30% of DS-ALLs with the lowest CRLF2 expression
in the AIEOP database. Only 5 probe sets passed FDR of 30%, with
CRLF2 being 1 of the 5 (Table 5). This is consistent with the
finding that samples that overexpress CRLF2 (red marks in Figure
1A) do not cluster separately from DS-ALLs that do not express
CRLF2. Interestingly, the IGJ gene that differentiates these 2 groups
(fold change, 36.4; Table 5) is also the most differentiating gene
between DS-ALL and non–DS-ALL in our datasets (supplemental
Table 4).
Clinical significance of CRLF2 expression in DS-ALL
Clinically, children with high/medium expression of CRLF2 were
diagnosed younger (Table 6) than children with no/low expression
of CRLF2 (5.56 vs 9.87 years, P  .004).
No significant differences between the 2 groups regarding their
sex or white blood cell count at diagnosis were found. Patients
expressing CRLF2 tended to have a lower probability for event-
free survival (supplemental Figure 4, P  .12 log-rank test).
Cooperation between JAK2 R683 mutations and CRLF2
aberrant expression
Among the 53 DS-ALL samples for which CRLF2 expression was
available, 10 had somatic mutations in JAK2 R683. We identified
chimeric P2RY8-CRLF2 transcripts in 3 additional patients with
JAK2 R683 mutations (supplemental Table 2). Thus all mutations
occurred in specimens with aberrant expression of CRLF2, support-
ing our initial hypothesis that CRLF2 may act as type I cytokine
receptor for mutated JAK2.
To examine whether CRLF2 and mutated JAK2 cooperate, we
generated BaF3 cells that express hCRLF2 (BaF3-CRLF2) and
transduced both BaF3 and BaF3-CRLF2 cells with wild-type
mJak2-FLAG, R683S mJak2-FLAG, and empty vector. As de-
picted in Figure 5A, there was synergism between CRLF2 and both
wt Jak2 and R683S mutated Jak2, with the best cytokine-
independent growth observed in cells expressing CRLF2 and the
mutated Jak2. These functional effects on cell growth are reflected
Table 4. Enrichment of BCL6-related gene expression signatures
and direct targets in DS-ALL profile genes (FDR < 15%)
Size P Q-value
Oncomine “Molecular Concepts” enriched in
DS-ALL up-regulated genes
EREB lymphoblastoid cell line BCL6
transfection top 10% overexpressed30
17 .004 0.093
Ramos Burkitt lymphoma cell line BCL6 pest
mutant top 5% underexpressed in anti-IgM30
11 .011 0.138
Lymphoma BCL6 break top 5%
overexpressed31
11 .019 0.138
Lymphoma BCL6 break top 10%
overexpressed31
17 .022 0.138
BCL6 direct targets32 11 .030 0.147
Oncomine “Molecular Concepts” enriched in
DS-ALL down-regulated genes
Lymphoma BCL6 break top 10%
underexpressed31
36  .001 0.001
EREB lymphoblastoid cell line BCL6
transfection top 10% underexpressed30
26  .001 0.001
Lymphoma BCL6 break top 5%
underexpressed31
20 .001 0.008
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Figure 3. CRLF2 expression in DS-ALL. (A) CRLF2 expression in the AIEOP (i), BFM (ii), and ICH (iii) datasets. The y-axis represents CRLF2 log basis 2 expression. The
x-axis represents the different ALL subtypes. Each point corresponds to a sample. The black line in each ALL subtype is the CRLF2 mean (log basis 2) expression in this
subtype. The height of the blue rectangle in each ALL subtype is the measured standard deviation of CRLF2 (log basis 2) expression. DS-ALL versus all other ALL yielded t test
P values of less than .001 for AIEOP (i), BFM (ii), and ICH (iii). DS indicates Down syndrome ALL; HD, high hyperdiploid; TEL, TEL-AML1; BCR, BCR-ABL; E2A, E2A-PBX1;
and MLL, MLL-AF4. (B) IL7RA expression in the AIEOP (i), BFM (ii), and ICH (iii) datasets. There are no statistically significant differences between DS-ALLs and
non–DS-ALLs. (C) Verification of CRLF2 expression levels by qRT-PCR. Bars represent qRT-PCR CRLF2 expression levels (left, y-axis: fold change relative to patient DS-12,
the lowest CRLF2 expressor). Rhombuses represent gene expression array CRLF2 expression levels (right, y-axis: log basis 2). Red bars represent patients with JAK2 R683
mutation; blue bars, patients with CRLF2 F232C mutation (Figure 6). Rem indicates CRLF2 levels of available remission samples (patients DS-19 and DS-20); CONT, control
CRLF2 expression levels in peripheral white blood cells of healthy donors. (D) CRLF2 and IL7RA protein expression on the surface of DS-ALL leukemic blasts. (Left panel)
Delta mean fluorescence intensity of the signal detected by flow cytometry using specific anti-CRLF2 antibodies compared with background unspecific staining (“Flow
cytometric analysis”), indicating an apparent association between the JAK2 mutational status and the level of expression of CRLF2 on DS-ALL blasts. (Right panel) Dot plot of
2 representative CRLF2 and IL7RA costainings. IL7RA is highly expressed on leukemic blasts independent of JAK2 mutational status and level of CRLF2 expression in all
cases examined. wt indicates wild-type; mut, mutant; het, heterozygous; and hom, homozygous.
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in protein analysis of the JAK/STAT pathway (Figure 5B).
Interestingly, despite identical levels of CRLF2 at the time of
transduction, the levels of CRLF2 were consistently higher in cells
transduced with Jak2 compared with empty vector or parental cells.
Examination of Stat5 and Jak2 phosphorylation 5 hours after
cytokine withdrawal reveals that when CRLF2 was expressed,
phosphorylation levels in cells transduced with wt Jak2 were
increased, whereas no change was observed in the already high
ba
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Figure 4. Genomic analysis of CRLF2 aberrations. (A) FISH analysis of DS-ALL expressing CRLF2 (i-ii) IGH@ CRLF2 translocation, patient DS-85: (i) Metaphase showing
a positive result with the LSI IGH@ break-apart rearrangement probe (Abbott Molecular): normal chromosome 14 (yellow arrow) derived chromosome 14 (red arrow), derived X
chromosome (green arrow). (ii) Interphase nucleus from the same patient hybridized with the homegrown CRLF2 probe showing a split signal pattern, 1R1G1F, confirming its
involvement in the translocation (1 fusion signal [yellow arrow], 1 red signal [red arrow], and 1 green signal [green arrow]). (iii-iv) CRLF2 microdeletion, patient DS-82.
(iii) Interphase nucleus hybridized with the IGH@ probe showing the normal 0R0G2F signal pattern confirming the presence of 2 normal copies of IGH@. (iv) Interphase
nucleus from the same patient hybridized with the homegrown CRLF2 probe showing the deletion of the green portion of the probe (1 red signal [red arrow] and 1 fusion signal
[yellow arrow]) denoting the presence of a centromeric interstitial deletion. (B) CRLF2 and P2RY8 expression in DS-ALL samples. Centered and normalized log basis
2 expression of CRLF2 and P2RY8 along DS-ALL samples in AIEOP dataset. Values for each individual case are represented by a color, with red representing deviation above
the mean and blue representing deviation below the mean. The samples are sorted using SPIN. Pearson correlation between CRLF2 and P2RY8: 0.45 (P  .02).
(C) Detection of the P2RY8-CRLF2 fusion transcript. (i) Schematic representation of the deletion breakpoint region at the telomeric end of chromosome X/Y with gene
locations. The dashed lines represent the genomic deletion leading to the fusion of the first noncoding exon of P2RY8 and to the first (coding) exon of CRLF2. (iii) RT-PCR
experiments on cDNA of DS patients. (Lanes 1-3) DS diagnostic ALL samples (DS93 and DS82 with FISH determined deletion and DS92 with FISH determined IgH@
translocation). (Lane 4) Blank. The 3 patient samples were positive for ABL amplification (not shown). Primer sets used are (A) P2RY8 F01/CRLF2 R01; (B) P2RY8 F01/
CRLF2 R02; (C) P2RY8 F01/CRLF2 R03 shown on the sequence on the left (ii). Chimeric transcripts are present in the first 2 lanes of each set. (ii) Nucleotide sequencing of the
largest PCR fragment confirming the fusion transcript; vertical lines indicate exon boundaries; the arrowhead indicates the P2RY8/CRLF2 transcript junction. As seen, the
fusion is just upstream to the ATG of CRLF2. Reference sequences are P2RY8-001 (ENST00000381297) and CRLF2-001 (ENST00000400841). Boxed sequence around the
transcript junction is represented in the electropherogram on the right lower side (iv).
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phosphorylation levels in cells expressing the mutated Jak2. The
marked advantage in cytokine-independent growth rate of cells
coexpressing CRLF2 and R683S Jak2 despite similar Stat5
phosphorylation may indicate the involvement of additional
signaling pathways.
To test whether the cells expressing CRLF2 and/or either wt or R683
mutated Jak2 depend on activated JAK signaling, we incubated BaF3
cells transduced with the different vectors cultured without IL3 in the
presence of different concentrations of JAK inhibitor l (Figure 5C).
Although BaF3 cells transduced with CRLF2/Jak were more sensitive
to the inhibitor compared with the control cells expressing BCR-ABL
(P  .04, analysis of variance), the cells expressing CRLF2 and mutated
Jak2 were the least sensitive.
Activating mutations of CRLF2 in DS-ALL
To identify additional events leading to CRLF2 activation, we
screened 87 diagnostic DS-ALL samples for mutations in CRLF2
(Figure 6). In addition to polymorphisms V136M and V244M that
were present also in remission samples and in healthy controls, we
identified in 3 patients a somatic mutation replacing phenylalanine
232, located at the juxtamembranous domain, with cysteine
(F232C). Genomic data were available for one of the patients
(DS-97) who displayed the P2YR8-CRLF2 transcript. Although
F232C induced constitutive Stat5 phosphorylation in cytokine-
deprived BaF3 cells (Figure 6E), it did not provide a consistent
survival advantage. Whereas during the first few days after
cytokine withdrawal more cells expressing F232C CRLF2 were
alive compared with cells expressing wt CRLF2, at day 7 almost all
BaF3 cells were dead (not shown). To examine the collaboration
with wt Jak2, BaF3 cells stably expressing wt Jak2 were transduced
with retroviral vectors expressing either wt CRLF or F232C
CRLF2 (Figure 6D-E). In the presence of exogenous wt Jak2, there
was an approximately 15-fold increase in the growth rate of cells
expressing the mutant CRLF2 compared with those expressing wt
CRLF2 (P  .02, paired t test). Together these observations
demonstrate that the F232C CRLF2 activates Jak/Stat signaling
and cooperates with Jak2 to provide significant growth advantage
in a cytokine-deprived environment.
Discussion
Here we report the results of a genome-wide study of DS-ALL
based on a dataset of unprecedented size. Unexpectedly, the
molecular phenotype obtained by gene expression profiling is
strikingly less homogeneous in DS-ALL than any of the common
genetic subtypes of childhood BCP-ALLs. However, despite this
heterogeneity, we describe a major feature that is shared by up to
two-thirds of the patients—the aberrant expression of the wt or
mutated cytokine receptor CRLF2 and its association with muta-
tions in JAK2.
That DS-ALL is less uniform than the specific DS-associated
myeloid leukemia has been suggested by a large cytogenetic study
performed by the International BFM Study Group.2 However,
neither that study nor the genomic analysis reported here or
previously5,17 explains the level of inhomogeneity in gene expres-
sion. Even those DS-ALLs that clustered together were not similar
to each other. Such heterogeneity suggests that unlike the common
aberrations of childhood ALL (TEL-AML1, hyperdiploidy, E2A-
PBX1, etc), constitutional trisomy 21 is not a typical initiating
event. Rather, DS is a predisposing condition to multiple genetic
subtypes of BCP-ALLs.
To identify genes and pathways common to DS-ALLs, we have
generated a DS-ALL gene expression signature, exploiting the
Table 6. Clinical and diagnostic characteristics of patients with DS-ALL with high/medium expression of CRLF2 versus low/no expression
of CRLF2
No/low CRLF2 expression (n  20) High/medium CRLF2 expression (n  33) P
Sex 	 .999*
Male 11 17
Female 9 16
Age, y .004†
Mean (SE) 9.87 (1.21) 5.56 (0.67)
Median (range) 11.62 (1.74-18.7) 4.06 (1.99-20.22)
White blood cell count at diagnosis, cells/L .392†
Mean (SE) 41.6  109 (8.7  109) 39.8  (9.7  109)
Median (range) 23.9  109 (2.4-130  109) 18 930 (1.5-259  109)
JAK2 R683 mutations .008*
Yes 0 10
No 20 22
*According to Fisher exact test.
†According to Mann-Whitney U test.
Table 5. CRLF2 differentiating genes
Probe set ID Gene symbol Description Band Fold change
212592_at IGJ Immunoglobulin J chain 4q13.3 36.4
208303_s_at CRLF2 Cytokine receptor-like factor 2 isoform 1 Xp22.33 8.47
244871_s_at USP32 Ubiquitin specific protease 32 17q23.2 2.77
221523_s_at RRAGD Ras-related GTP binding D 6q15 0.551
208765_s_at HNRNPR 1p36.12 0.716
List of statistically significant differentiating genes (FDR 30%) between 8 DS-ALL samples with highest CRLF2 expression and 8 DS-ALL samples with lowest CRLF2
expression in AIEOP dataset. The fold change value is between the mean expression in the 2 groups.
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advantage of having several datasets. CRLF2 is 1 of the 3 genes
that most differentiates between DS-ALLs and non–DS-ALLs.
Confirming the expression of CRLF2 RNA and protein in DS-
ALLs and extending these observations to patients for whom array
data were not available, we observed increased expression of
CRLF2 in 62% of 53 patients with DS-ALL. These data are
corroborated by the recent report describing IGH@ translocations
or interstitial deletions upstream of CRLF2 in 5% of nonselected
childhood ALL, and in 35 (52%) of 68 DS-ALLs consecutively
enrolled in United Kingdom treatment protocols.13
We report that the interstitial deletion results in fusion transcript
in which the first noncoding exon of P2YR8 fuses to the coding
region of CRLF2, thereby driving CRLF2 expression by the P2YR8
promoter. A similar mechanism was reported in a single patient
with splenic lymphoma and P2YR8-SOX5 fusion34 and is reminis-
cent of the common SIL-SCL (STIL-TAL1) rearrangement in
T-ALL.35 Cloning of the genomic breakpoints is required to
determine whether, like SIL-SCL, the deletion is caused by aberrant
V(D)J activity.
Although we do not have genomic data for all CRLF2-
expressing samples, the FISH and RT-PCR results of 17 of
33 specimens overexpressing CRLF2, the inverse correlation
between CRLF2 and P2YRY8 expression, and the similar frequency
of CRLF2 overexpression in our and Russell et al’s13 2 independent
cohorts suggest that most, if not all, aberrant CRLF2 expression is
caused by genomic rearrangements.
CRLF2 dimerizes with IL7RA to form the receptor to thymic
stromal-derived lymphopoietin (TSLP), an epithelial-derived cyto-
kine that plays a role in inflammation and lymphoid develop-
ment.14,36-38 The expression of IL7RA on the leukemic blasts
suggests that some of the aberrantly expressed CRLF2 may interact
with IL7RA and form a TSLP receptor on the leukemic cells.
However, we also demonstrate that CRLF2 cooperates with Jak2 to
transform BaF3 cells lacking expression of IL7RA (Figure 5A and
supplemental Figure 5). This suggests that CRLF2 may act
independently of IL7RA, possibly through homodimerization
similar to other type I cytokine receptors.
We report an unusual cooperation between CRLF2 and ectopi-
cally expressed wt Jak2 in BaF3 cells, a phenomenon not observed
with other type I cytokine receptors such as erythropoietin receptor
(EPOR) or thrombopoietin receptor (TPOR). CRLF2 is an atypical
type I cytokine receptor that contains only one of the 2 “boxes” that
mediate binding of JAK enzymes and only one tyrosine in its
C-terminal domain. Hence it is a weak activator of JAK2.39 This
may explain the requirements for higher levels of Jak2 for
activation of the Jak/Stat pathway. Interestingly, the levels of
CRLF2 were higher in the presence of ectopically expressed wt or
mutated Jak2. Positive regulation of the expression of a type I
cytokine receptor by JAK2 and Tyk2 was previously reported.40-42
Thus one mechanism by which Jak2 may cooperate with CRLF2 is
by increasing the expression of the latter.
We observed 2 acquired events associated with the increased
expression of CRLF2. The most common event is activating “lym-
phoid” somatic mutation in JAK2. All DS-ALLs specimens with JAK2
mutations in our series and in the cohort reported by Russell et al13 had
aberrant expression of CRLF2, strongly implying that CRLF2 is the
cytokine receptor cooperating with R683 mutated JAK2. Indeed, in
BaF3 cytokine weaning assays, only the combination of CRLF2 and
mutated Jak2 led to a robust cytokine-independent growth, demonstrat-
ing for the first time that these 2 proteins cooperate in providing growth
and survival advantage.
Figure 5. Functional significance of CRLF2 expression. (A) Cytokine withdrawal assay of BaF3 and BaF3-CRLF2 cells infected with either empty vector (EV), mouse
FLAG-Jak2 wild-type (wt), or mouse FLAG-Jak2 R683S. Error bars represent SE. (B) Constitutive activation of the Jak/Stat5 pathway in BaF3 and BaF3-CRLF2 cells
expressing mouse FLAG-Jak2 wild-type (wt) or R683S, after 5 hours of cytokine deprivation. IL3 indicates cells harvested after 5 hours of interleukin-3 deprivation followed
by 15 minutes of interleukin-3 stimulation. (C) Effect of JAK inhibitor I on growth of BaF3 cells expressing Jak2 R683S and BaF3-CRLF2 cells expressing either wt Jak2 or
Jak2 R683S.
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The second less common event is an activating mutation in CRLF2.
Yoda et al43 reported an E40G activating somatic mutation in CRLF2 in
a single patient with adult BCP-ALL. We now found that 3 of the
33 patients with DS-ALL overexpressing CRLF2 have a somatic
mutation replacing phenylalanine in the juxtamembrane position 232 by
cysteine. This mutation caused constitutive phosphorylation of Stat5
associated with robust cytokine-independent growth of BaF3 cells
ectopically transduced with wt Jak2. Introduction of cysteines in this
region in the erythropoietin receptor, another type I cytokine receptor
signaling through JAK2, caused its constitutive activation by enhancing
ligand-independent dimerization.44
Although several scenarios may be possible, a reasonable model
(Figure 7) is that the overexpression of CRLF2 is the first event
occurring in approximately 60% of DS-ALL patients. The ex-
panded preleukemic clone then acquires additional genetic aberra-
tions, among them an activating mutation in JAK2 or CRLF2 or
thus far unidentified events that may involve the JAK/STAT
pathway. This model explains 3 key observations: (1) All samples
with mutated JAK2 and the only evaluable patient with mutated
CRLF2 also had aberrant CRLF2 expression. (2) Many CRLF2-
overexpressing samples do not have mutation in JAK2. (3) In one
reported patient,13 an aberrant CRLF2 genomic rearrangement was
present at diagnosis whereas mutant JAK2 was present only in the
relapse sample.
The most intriguing question is why there is a dramatic 10-fold
increase in genomic lesions causing CRLF2 overexpression in DS
(60% in DS-ALL compared with 5% in sporadic ALL) and how
this relates to trisomy 21. Only a single Hsa21 gene, SON, was
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Figure 6. Mutations of CRLF2 in patients with Down syndrome–associated acute lymphoblastic leukemia. (A) Example of sequences depicting the F232C in CRLF2.
The F232C (arrowed) is present at diagnosis but not in remission. The wild-type sequence denotes positions of both nucleotides and amino acids. (B) Expression of
CRLF2 F232C mutation. Examples of 2 patients: in one (i) both alleles, wild-type and mutated, are expressed, whereas in the other (ii) only the mutated allele is
expressed. (C) Schematic presentation of CRLF2. SP indicates signal peptide; EC, extracellular region; TM, transmembrane region; and Cy, cytoplasmic region. Numbers
indicate amino acid position. (D) Cytokine withdrawal assay of BaF3 cells stably expressing wild-type mouse FLAG-Jak2 that were transduced with either wild-type human
CRLF2 or human CRLF2 F232C. Error bars represent SE. (E) Constitutive activation of the Jak/Stat5 pathway in BaF3 cells expressing wild-type mouse FLAG-Jak2 and either
wild-type human CRLF2 (wt) or human CRLF2 F232C (F232C), after 5 hours of cytokine deprivation.
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included in the DS-ALL signature and it was only slightly (1.3)
up-regulated (supplemental Table 4). Indeed, we found no major
difference in the gene expression from the trisomic chromosome 21
between DS-ALL and HD-ALL (data not shown). Yet our data
suggest that DS-ALL and HD-ALL are to a great extent different
leukemias. There are obvious fundamental differences between
constitutional and acquired trisomy,45 such as the developmental
stage in which the trisomy occurs and the fact that a constitutional
trisomy is present both in the leukemia cells and in their
microenvironment.
Regardless of the role of the constitutional trisomy, our data
generate an intriguing hypothesis. We observe a significant enrich-
ment in DNA damage and repair genes in DS-ALL and identify
increased expression and clear “footprint” of BCL6 in these
leukemias. BCL6 regulates the germinal center B-cell maturation,
through its effects on the DNA damage response. Recent studies by
Duy et al46 suggest for the first time a role for BCL6 in BCP-ALL.
We speculate that DS may predispose to ALL through B-cell
lymphocytic specific genomic instability involving BCL6. The
signatures of BCL6 and the DNA damage response pathway may
be related to previous reports on impaired cellular response to DNA
damage in DS47 and to the increased prevalence of IgH@
chromosomal translocation in DS-ALL.13,48 At present, however, it
is impossible to determine whether the BCL6 signature precedes or
follows the CRLF2 rearrangements. As high expression of CRLF2
blocks B-cell differentiation,13 one cannot exclude the possibility
that it causes a developmental arrest of the preleukemic cell in
a stage in which BCL6 is active. Distinguishing between these
2 hypotheses will require the identification and study of preleuke-
mic cells in children with DS.
Finally, our data imply that therapeutics targeting JAK/STAT
signaling may be of potential benefit to the majority of DS-ALLs not
limited only to those with mutated JAK2.Although we demonstrate that
BaF3 cells coexpressing CRLF2 and mutated Jak2 are more susceptible
to JAK inhibitor l than cells transformed with BCR-ABL, they were
relatively resistant in comparison with cells transformed only with
mutated Jak2. This preliminary observation requires further testing in
primary leukemic cells. It may indicate that targeting other pathways
activated by CRLF2 or the use of anti–CRLF2-specific antibodies will
synergize with JAK2 inhibitors in treatment of DS-ALL and non–DS-
ALL with aberrant CRLF2 expression.
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Figure 7. CRLF2 in DS-ALL: a model. Increased
CRLF2 expression caused by genomic aberration is
followed by progression event consisting of activating
mutations in CRLF2, in JAK2, or other alterations in yet
unidentified kinases. The percentages in the figure are
approximations based on combination of the data in our
paper and in the paper by Russell et al.13
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